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ABSTRACT 
 
The past recent years have seen a surge of evidence demonstrating the regulation of 
microRNAs (miRNAs) in a myriad of vascular biology events such as cardiogenesis. 
Nevertheless, the missing miRNA-link in controlling pluripotent human embryonic stem 
cell (hESC) fate in differentiation towards the endothelial lineage is currently undiscovered. 
Main objectives in this project are determining which miRNAs are involved in endothelial 
lineage differentiation from hESCs and the further delineation in their underlying 
mechanisms.  
 
Firstly, undifferentiated hESCs were cultured in differentiating conditions to derive 
endothelial (ECs) and smooth muscle cells (SMCs). hESC-derived ECs express specific EC 
markers such as PECAM/CD31, eNOS, and vWF, while hESC-derived SMCs express 
specific SMC markers such as SMA and SMMHC II. Both hESC-derived cells also 
displayed functional characteristics upon functional analyses.  
 
Next, five potential miRNAs involved in embryonic EC development were determined and 
selected from the miRNA array expression profile in differentiating hESCs. Using loss- and 
gain-of-function gene experiments, it was demonstrated that both miR-150 and miR-200c 
played an important role in EC differentiation from hESCs. However, miR-1915, 141 and 
205 did not display such functions. In addition, epithelial-to-mesenchymal transition 
(EMT)-activator ZEB1/TCF8 was further identified as an important mRNA target for miR-
150* and 200c. Importantly, it was also demonstrated that miR-150* and miR-200c were 
both involved in the vasculogenesis of in vivo chick embryos.  
 
These findings may suggest that during hESCs differentiation, an increase of miR-200c 
expression contribute to the decline or repression of EMT process. Meanwhile, mir-150* 
also contributes to the differentiation of hESCs, resulting in the formation of more 
 iii 
differentiated, senescence and less proliferative cells or in this case, mature vascular ECs. 
These findings illustrate that miR-150* and 200c can regulate the development of ECs from 
hESCs, providing new targets for modulating vascular formation and creating novel clinical 
therapies in future cardiovascular disease applications.   
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CHAPTER 1 
Introduction 
 
 
 
1.1 The Vascular system 
 
1.1.1 The physiology and anatomy of the blood vessels  
 
The human vascular system carries out vital transport of nutrients and oxygen to tissues as 
well as the removal of metabolic waste products. The vascular system comprises of an 
arterial, a venous, a capillary and a lymphatic compartment that maintains an immune 
barrier against foreign pathogens.  
 
In the human body, the circulatory system is divided into the pulmonary  and systemic 
circulation. The pulmonary circulation carries deoxygenated blood from the heart to the 
lungs via the pulmonary arteries and returns oxygenated blood back to the heart through the 
pulmonary veins. Meanwhile, the systemic circulation carries oxygenated blood away from 
the heart to the whole body. There are two subtypes of systemic arteries which can be 
grouped into the muscular and elastic category. The elastic arteries generally have a large 
lumen with thin walls while the muscular arteries have a smaller lumen and thicker wall. 
Systemic arteries deliver blood to the arterioles which help regulate blood pressure by 
contracting their smooth muscle walls. Following which, oxygen-rich blood flows into the 
capillaries where a fast exchange of nutrients and gases ensues. The thin walls and large 
surface area of the single endothelial-celled capillaries is a perfect environment for 
diffusion to occur. Blood returns from the body back to the heart through the low-pressured 
veins (Fig.1A).  
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Fig. 1. Blood circulation in the veins and arteries 
(A) In the systemic circulation, oxygenated blood is pumped through the heart’s aorta 
which then branches into many smaller arterioles which run throughout the body. Gaseous 
and metabolic exchange occurs in the capillaries which gather to form small venules. 
Deoxygenated blood is pumped back into the right atrium of the heart through the vena 
cava veins 
1
. (B) A cross-section of an artery showing the three main layers consisting of 
the innermost tunica intima, the thick tunica media, and the outermost adventitia 
2
.  
 
 
 
A 
 
B 
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There are three layers in the structure of arteries which are namely the tunica intima, tunica 
media and tunica adventitia (Fig.1B). The intima is the innermost layer coating the lumen 
layer and consists of two further layers; the endothelium and a subendothelial layer. 
Endothelium is a single layer of endothelial cells (ECs) that line the inner lumen of the 
vessel. As these cells are constantly in need of replacement, the basal lamina that the cells 
are supported on has a high turn-over rate of 1% daily 
3
. Coating the endothelium is the 
subendothelial layer that contains delicate loose connective tissues with some smooth 
muscle cells. Separating the subendothelial from the media layer, is an internal elastic 
lamina made of elastin and fibrous tissue. Concentric layers of vascular smooth muscle 
cells that synthesize extracellular matrix are arranged helically in the tunica media together 
with fibrous and elastic tissues. The external elastic lamina separates the media from the 
outermost adventitia layer which contains elastic and Collagen Type I fibers that form loose 
connective tissue. 
 
Arteries have thicker walls as compared to veins which are generally thin-walled, contain 
less elastins and have low distending pressures. Thus veins are stiffer than arteries. There 
are several different types of arteries depending on their sizes and the extent of the medial 
layer (Fig.2). In order of descending artery size are the large elastic arteries, smaller 
muscular arteries, and arterioles. Larger elastic arteries, such as the aorta, help to cushion 
stroke volume, decrease ventricular work and maintain pressure during diastole 
3
. The 
smaller and more muscular arteries aid in regulating peripheral resistance and blood flow 
by changing their vascular smooth muscle tone which leads to a change in lumen size. 
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Fig. 2. The different composition and relative sizes of endothelium, elastic, smooth 
muscle and fibrous tissues in each type of vessel 
Larger arteries contain more elastic and fibrous connective tissue, whereas smaller arteries 
have more smooth muscle in the tunica media. Smooth muscle content in the arteries is 
more than that of veins. Note that capillaries are the smallest vessel of the system which 
lack smooth muscle cells 
4
. 
 
 
1.1.2 The major building blocks of the blood vessel 
1.1.2.1     Endothelial physiology 
 
The endothelium comprises of a thin monolayer of ECs lining the inside of blood vessels in 
the entire circulatory and organ systems. While the subendothelium that coats the 
endothelium provides elasticity and support to the structural integrity of the vessels, ECs 
are the building blocks of blood vessels and a vital inferface between the circulating blood 
stream and the body tissues. In an adult human body, approximately 10
12
 ECs constitute the 
inside of the blood vessel lining and cover a total surface area of  roughly (5000 m
2
) 
5(Ref 
number 5)
. 
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1.1.2.1a Synthesis of Subendothelial Components     
ECs are situated on the underlying subendothelium that contains an array of different 
matrix proteins such as collagen, laminin, thrombospondin, fibronectin, elastin, glycoso-
aminoglycans and von Willebrand Factor (vWF) 
6, 7
 . Collagen is a major constituent of the 
subendothelium and is capable of either promoting or inhibiting endothelial cell growth. In-
vitro culture assays have shown that most of these collagens are secreted by the ECs into 
the culture medium or into their underlying extracellular matrix 
8, 9
. Moreover, ECs express 
Very late activation antigen 2 (VLA-2) and Very late activation antigen 3 (VLA-3) 
integrins which act as attachment sites for binding collagen and other matrix molecules.  In 
addition, the glycoprotein laminin which is secreted by ECs into the subendothelium, 
interacts with both integrins VLA-2 and VLA-3. Tissue culture studies have shown that 
laminin promotes endothelial cell adhesion, growth and tubulogenesis 
10
. Also involved in 
the adhesion function of ECs are fibronectin and thrombospondin. However, both can 
induce detachment of ECs and facilitate cell movement. Both proteins are produced by ECs 
and exist as fibrillar meshworks in low amounts in the subendothelium 
11, 12
.  
 
Elastin is another matrix protein found in the subendothelium and synthesised initially as a 
single chain soluble protein, the tropoelastin. After secretion, multiple tropoelastin 
molecules covalently bind together with crosslinking amino acids, desmosine and 
isodesmosine to form elastin 
13
. Last but not least, glycosoaminoglycans can be found in 
both ECs and subendothelium. The EC membrane contains predominantly heparan sulfate 
whereas the subendothelium contains members of the glycosoaminoglycans such as 
heparan sulfate, dermatan sulpfate and chondroitin sulpfate 
14, 15
. Heparan sulfate binds to 
collagen and is involved in EC attachment initiation. It also plays a role in the anticoagulant 
property of ECs with the activation of anti-thrombin III. Providing a non-thrombogenic 
surface which inhibits platelet adhesion, blood clot and facilitates blood flow, is a vital 
physiological role of the endothelium.  
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Nevertheless, when an injury agitates the endothelium and hence exposing the 
subendothelial, a cascade of coagulation activity follows to stop bleeding. Between these 
two anticoagulant and procoagulant states, a dynamic equilibrium exists that enables the 
injured endothelium to return back to its normal quiescent state once the procoagulant 
stimulant disperse 
16
. During the activation of the coagulation cascade, platelets are 
attracted to the site of injury and soon degranulate. Platelets aggregate in the presence of 
the exposed subendothelium’s collagen types IV, V and microfibrils 17. It is believed that 
platelets adhere to the subendothelium via their membrane receptors specific for vWF 
18
. 
ECs synthesise and secrete functionally active large molecular weight vWF multimers 
which actually consist of an aggregation of smaller 220 kDa vWF subunits 
19
. Functional 
vWF is released from Weibel-Palade bodies of the ECs by thrombin during injury. It can be 
bound to collagens in the extracellular matrix of the subendothelium or by receptors on the 
ECs. 
 
Apart from this hemostasis role, ECs also contribute to numerous metabolic functions 
including thrombolysis, vasomotor property, antigen presentation and synthesis of growth 
factors and adhesion molecules.  
 
1.1.2.1b Endothelial Derived Growth Factors     
Not only do ECs produce a variety of extracellular matrix proteins, they also secrete several 
regulatory factors such as platelet derived growth factor (PDGF), insulin-like growth factor 
1 (IGF-1) and fibroblast growth factor (FGF) which promote cell growth 
20, 21
. Other than 
endothelial cells, smooth muscle cells also secrete PDGF which acts as a major mitogen 
and chemoattractant 
22, 23
. PDGF is a well characterised growth factor which plays a 
significant role in angiogenesis 
24
. It is a dimeric glycoprotein containing four polypeptide 
chains A, B, C and D which results in the formation of five different dimeric isoforms, the 
homodimers (AA, BB, CC, DD) and heterodimers (AB). PDGF produced from ECs could 
stimulate the proliferation of underlying smooth muscle cells 
21, 25
. In addition, there seems 
to be a synergistic relationship between PDGF and IGF-1 whereby PDGF can induce the 
mitogen IGF-1 expression in ECs which in turn promotes smooth muscle cell growth 
26
. 
Other endothelium derived factors such as endothelin, angiotensin II, nitric oxide, and 
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oxygen free radicals have also shown to be mitogenic for both endothelial and smooth 
muscle cells. 
 
1.1.2.1c Adhesion Molecules on Endothelial Cells      
ECs express adhesion molecules on their surfaces that aid in cell-cell interactions and 
adhesion for vessel formation. EC-cell interactions are vital for the maintenance of vascular 
integrity. Platelet endothelial cell adhesion molecule-1 (PECAM-1) or known as Cluster of 
Differentiation molecule 31 (CD31), is expressed by all ECs in the adult, whereby its 
expression is largely concentrated at junctions between adjacent cells 
27
. Belonging to the 
immunoglobulin (Ig) gene superfamily, PECAM-1 is composed of 6 extracellular Ig folds, 
a transmembrane and a cytoplasmic domain. It has a molecular weight of 130 kDa and is 
differentially glycosylated involving N-linked and O-linked sites. PECAM-1 promotes cell-
cell adhesion at lateral junctions between adjacent ECs 
28
 by homophilic binding of its 
ligand 
29, 30
. The adhesion of PECAM-1 has been associated with the maintenance of a 
vascular permeability barrier and migration of endothelial cells, monocytes or neutrophils 
31, 
32
. Moreover, it was demonstrated that PECAM-1 is involved in the formation of new blood 
vessels in angiogenesis. Using polyclonal and monoclonal antibodies directed to PECAM-1, 
resulted in the inhibition of in-vitro tube formation 
33
. Another EC adhesion molecule, 
Vascular Endothelial Cadherin (VE-cadherin; also known as cadherin 5) is of dominant 
importance as an adhesive component of endothelial-specific adherent junctions (AJs). 
Blocking the adhesive function of VE-cadherin with antibodies has shown to dissociate EC 
layers 
34
.  
 
Collectively, EC junctions are a complex network of adhesion proteins that are linked to 
intracellular cytoskeletal and signalling molecules. Moreover, modulation of the matrix in 
the subendothelium allows the endothelium to control the activity of the vessel wall 
structure. This builds a direct relationship between the endothelium and rest of the 
vasculature system including the underlying vascular smooth muscle cells.  
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1.1.2.2     Smooth muscle physiology 
 
Smooth muscle is an involuntary non-striated muscle which can be found in different 
locations of the human body such as the tunica media layer of large and small arteries and 
veins, the bladder and uterus. In this context, smooth muscle cells residing in the blood 
vessels are of interest and will be termed vascular smooth muscle cells (VSMCs).  
 
Depending on the type of vascular bed, VSMCs or pericytes cover the outside of the 
endothelium lined blood vessels, protecting the fragile channels from rupture. VSMCs also 
contribute to the contraction and relaxation of the vessels, thus altering the luminal 
diameter to maintain an appropriate blood pressure and control blood flow. VSMCs exhibit 
an extraordinary capacity to undergo rather profound and reversible phenotypic plasticity or 
otherwise known as phenotypic modulation at different developmental stages 
35
. Unlike 
other muscle cells, VSMCs are not terminally differentiated in adult organisms 
36
. VMSCs 
can perform both contractile and synthetic functions which represent the two ends of a 
spectrum of VSMCs with clearly different morphologies, proliferation and migration rates 
as well as the expression of different protein markers. Generally, contractile VSMCs have 
an elongated, spindle-shaped morphology whereas synthetic VSMCs have a less elongated 
and cobblestone morphology which is also referred to as epithelioid 
37, 38
. Moreover, 
synthetic VSMCs contain a large quantity of organelles involved in protein synthesis, 
whereas these are largely superseded by contractile filaments in contractile VSMCs. 
Furthermore, synthetic VSMCs exhibit higher growth and migratory activities than 
contractile VSMCs.  
 
During normal vascular development, dedifferentiated VSMCs are exceedingly 
proliferative and migratory. Being highly synthetic, they also tend to produce extracellular 
matrix components of the blood vessel wall such as collagen, elastin, and proteoglycans, 
while concurrently acquiring contractile capabilities. However, once fully developed, 
VSMCs differentiate into a contractile phenotype to assume the functions required of the 
mature arterial wall. A point to note is that apart from the norm, VSMCs can also 
dedifferentiate and re-enter the cell cycle in response to injury such as atherosclerosis, after 
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angioplasty, stenting, or bypass surgery. During dedifferentiation, there is a decrease in 
VSMCs contractile markers expression and are highly proliferative 
39, 40
.  
 
Many of the smooth muscle cell (SMC) markers commonly used to define SMC 
phenotypes are involved in SMC contractile ability either as a structural component or as a 
regulator of contraction. Smooth muscle alpha-Actin (SMA) is the first SMC contractile 
protein isoform identified 
41
. In addition, both smooth muscle-myosin heavy chain (SM-
MHC) and smoothelin are currently the best markers to define the phenotype of mature 
contractile SMC. In embryonic mouse studies, SM-MHC expression is SMC-specific and 
has never been detected in non-SMCs 
42
. Smoothelin expression is more sensitive and 
complements SM-MHC as a contractile SMC marker.  As depicted in a cultured porcine 
VSMCs study, smoothelin was expressed more uniformly and more rapidly downregulated 
during phenotypic modulation towards a synthetic state 
43
.  Other contractile associated 
protein markers currently used to define the phenotype of VSMCs are calmodulin, h-
caldesmon, and calponin, a thin filament-associated protein implicated in the regulation of 
SMC contraction 
35
.   
1.2 Stem cells  
 
Despite its crucial and essential capability, the vascular system is sometimes fraught with 
numerous pathologies. Cardiovascular diseases such as coronary heart disease (heart attack) 
and cerebrovascular disease (stroke) are the number one cause of global morbidity and 
mortality. These diseases share common features such as the loss or impairment of tissue-
specific cells resulting in damaged blood vessels, endothelial dysfunction and ischemic 
tissues. Furthermore, minimally invasive surgery and organ transplantation that have been 
carried out increasingly over the years can lead to the loss and dysfunction of the 
endothelium in cases such as angioplasty-induced restenosis, transplant arteriosclerosis and 
vein bypass graft atherosclerosis. In seek of therapeutic treatments, the use of stem cells in 
vascular regeneration has gained immense momentum over the years.  
 
Stem cells have the ability to self renew and the capacity to differentiate into different types 
of specialized cells. There are currently different sources of stem cells and these are mainly 
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categorised into adult stem cells, embryonic stem cells and induced pluripotent stem cells 
(iPSC). Adult stem cells are multipotent and partially lineage-commited. These cells are 
capable of giving rise to only cells of a given germ layer. Although adult stem cells are 
autologous, as these cells are harvested from the patient themselves for stem cell therapy, 
and hence there is an absence of an immunologic barrier, these cells are however limited in 
quantity, replicative capacity and are lineage restricted.   
 
Unlike adult stem cell, embryonic stem cells can differentiate into any cell type or any 
organ from the three germ layers. Mouse embryonic stem cells (mESCs) were isolated in 
1981 from the inner cell mass of the blastocyst by Sir Martin J. Evans and Matthew 
Kaufman 
44
 and independently by Gail R. Martin 
45
. Their discoveries have contributed 
immensely to the study and understanding of pluripotency and differentiation of stem cells. 
At almost more than a decade later, James Thomson et al. reported the first derivation of 
human embryonic stem cell lines 
46
. The availability of human embryonic stem cells 
(hESCs) has revolutionized science by providing the opportunity to develop stem cell-
based therapies for human diseases.  
 
More recently in 2006, Yamanaka et al. reprogrammed mouse fibroblasts (somatic cells) 
into iPSCs by overexpressing four transcription factors Oct3/4, Sox2, c-Myc, and Klf4 
47
. 
In this case, differentiated adult cells were simply ‘transformed’ into cells with traits similar 
to pluripotent embryonic stem cells. Not only do these cells display pluripotent markers, 
other studies have also demonstrated that iPSCs were capable of forming the three germ 
layers and subsequently differentiating into adult stem cells 
48-51
. Since the first discovery 
of iPSCs, many advances were made to streamline the reprogramming process such as 
removing the use of c-Myc and Klf4 during reprogramming 
51-53
 and the addition of small 
molecules to enhance the reprogramming progress  
54, 55
.  
 
The advent of iPSCs has made the availability of patient-specific stem cells possible and 
besides, these cells are easily obtainable as the patient’s skin or hair tissues can be used. 
Furthermore, iPSCs do not have the immunological barrier that exists in cells derived from 
embryonic stem cells. In addition, human iPSCs (hiPSC) can be derived from patients with 
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genetic diseases, and the derived disease-specific cell lines can aid in understanding 
heritable disorders and thus search for new cures  
56, 57
.  Despite these advantages, there are 
a number of concerns regarding the use of iPSCs in clinical application. The use of gene 
manipulation via retroviruses or lentiviruses in deriving iPSCs, increases the risk of 
inducing oncogenesis 
58, 59
. Another cause of concern is that a significant number of hiPSC 
lines were found with an abnormal expression of imprinted genes 
60
  and gene expression 
profiles 
48, 61
, which were otherwise found to be stable in hESCs. It also seems that there are 
functional differences observed between differentiated cells derived from hESCs and iPSC. 
Cells derived from iPSC had a signiﬁcantly increased apoptosis, severely limited growth, 
expansion capability and an early cellular senescence 
62
. Although there may be one day 
that hiPSCs will provide the same theurapeutic potential as hESCs, but until solutions or 
explainations to these problems are found, the use of iPSC is currently not ideal for clinical 
applications.  
 
Herein, ‘naturally occurring’ and genetically unmodified hESCs, still hold the greatest 
potential in therapeutic applications and the ‘gold standard’ in terms of pluripotency 59, 63.  
 
 
1.2.1 Human embryonic stem cells as a therapeutic source for vascular 
regeneration 
 
Current cell transplantation therapies to treat vascular diseases are hampered by the lack of 
donor cells and the ability to acquire a vast number of harvested cells. Besides, fully 
matured ECs isolated from patient’s blood vessels have limited proliferation and expansion 
capabilities. On the other hand, hESCs, which have an unlimited self-renewal capability 
46
, 
can offer a plentiful source of ECs for therapeutic revascularization. Hence, human 
embryonic stem cells (hESCs) are increasingly sought after as the cellular therapy for 
regenerating damaged areas. 
 
hESCs were initially derived in 1998 by isolating the inner cell mass of pre-implanted 5-6 
days old blastocysts via immunosurgery 
46
. These cells have an indefinite lifespan and are 
pluripotent, which refers to their ability to differentiate into the three embryonic germ 
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layers – the ectoderm, mesoderm and endoderm 64. In addition, their capability in prolonged 
self-renewal has sparked enormous interest for their therapeutic applications. These 
applications include the engineering of artificial blood vessels, repair of damaged vessels 
and cell transplantation for the replacement of ischemic tissues 
65-69
. Another beneficial 
area of hESCs cells is the creation of a valuable source of human disease model for drug 
discovery and toxicology in-vitro screening studies 
70, 71
. Moreover, the availability of 
hESCs enables the study of the earliest events in human embryogenesis and developmental 
biology as well as the formation of functional blood vessels during development. This will 
certainly dismiss the need for using ethically complicated early stage human embryos for 
in-vivo research.  
 
In order to fulfill the potential of hESCs as a platform for treating cardiovascular diseases, 
the understanding of its roles and functional biology in vasculogenesis is pivotal. As such, 
the following sections will discuss current vasculogenesis studies focusing hESCs as a 
model system and the relevant mechanisms that occur during the process.  
 
1.3 Mechanisms of embryonic vasculogenesis and vascular cell 
differentiation 
 
Both vasculogenesis and angiogenesis take place in the early developing embryo, enabling 
the establishment of the vascular system. In fact, the cardiovascular system is the first organ 
formed during early embryogenesis 
72
. Moreover, during the early stages of embryogenesis, 
the endothelium is the first tissue to differentiate. Formation of a functional de novo 
vascular network from embryonic mesoderm via the process of vasculogenesis is crucial for 
embryonic survival and organogenesis 
73
.  
 
1.3.1 Formation of the hemangioblast in embryos and embryonic stem cells 
 
Vasculogenesis is driven by the invagination of epiblastic cells through the primitive streak 
to form the mesoderm during gastrulation. De novo mesodermal cells gradually organize 
into different segments such as the axial (notochord), paraxial (somites), intermediate 
mesoderm (kidney), lateral and extra-embryonic mesoderm (Fig.3) 
74
. After the formation 
of the coelome, the lateral mesoderm divides into two layers attributing to a dorsal sheet 
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(somatopleural mesoderm) and a ventral sheet (splanchnopleural mesoderm). The 
extraembryonic mesoderm is situated at the posterior part of the mesoderm. Both lateral 
and posterior mesoderm which comprises the posterior two thirds of the embryo, were 
shown by Murray in 1932 to give rise to endothelial as well as hematopoietic cells 
75
. 
Formation of endothelial and hematopoietic cells occurs after migration of the newly 
formed lateral and posterior mesodermal cells toward the yolk sac where the cells 
differentiate. Florence Sabin was the first who observed under light microscope that 
migration leads to the appearance of mesdoderm cell clusters or known as hemangioblastic 
aggregates during the incubation period in living chick blastoderms 
76
. From the second day 
of incubation, she observed that hemangioblastic aggregates were present at the border of 
the embryonic and extraembryonic areas, which subsequently matured to blood islands. 
Cells present at the periphery of these aggregates flatten and differentiate into ECs, while 
cells in the core of the cluster differentiate into hematopoietic cells (Fig.3). Embryonic ECs 
aggregate and coalesce to form de novo vascular networks via the process of 
vasculogenesis. Ultimately, both the intra and extra embryonic vessels will form a vascular 
plexus. 
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Fig. 3. The origins of the hemangioblast 
(A) A schematic map depicting the 
prospective mesodermal territories of a 
gastrulating chick embryo 
74
. (B) A Schematic 
drawing of the yolk sac blood island 
development according to Sabin 
76
. 
 
 
 
 
 
 
1.3.1.1     Derivation of hemangioblasts from hESCs  
 
Since both ECs and hematopoietic cells originate in close proximity during embryonic 
development, the hypothesis of a common vascular precursor or a hemangioblast was 
postulated (Fig.4) 
75, 76
. The hemangioblast concept was proven initially from studies in 
differentiating mouse embryonic stem cells (mESCs) 
77-79
 and later in early developing 
mouse embryos 
80
.  These early studies carried out in mouse, have paved the progress for 
the identification of hemangioblasts in hESCs.  
 
 - 35 - 
Previously, before the advent of the hESCs model system, the study of early hematopoietic 
and endothelial precursors during human embryonic development has been impeded. 
Reasons are due to the scarcity of early human embryos, its associated ethics and the lack 
of in-vitro experimental conditions which can mirror the early-stage human embryonic 
development. The limited and exclusive number of studies using human embryos showed 
that hematopoietic cells first arise in the third week of human ontogeny inside yolk sac 
developing blood vessels and subsequently found one week later from independent origins, 
within the wall of the embryonic aorta and vitelline artery. Flow cytometry analysis of 
sorted CD31+/ CD45-  or CD34+/CD45- early ECs from the yolk sac and aorta resulted in 
a yield of blood-forming hemogenic ECs 
81
. However, whether these precursor cells display 
hemangioblast properties remains elusive.  
 
Using hESCs as a culture model system and ultilising a similar technical approach to 
generate mouse hemangioblasts, Zambidis et al achieved both primitive and definitive 
human hematopoiesis from the formation of human embryoid bodies (hEBs) 
82
. The 
formation of spontaneous hEBs, mimics the early events of human yolk sac blood 
development, from the differentiation of mesodermal-hemangioblast followed by primitive 
erythromyeloid hematopoiesis. Without supplemental growth factors or xenogeneic stromal 
cocultures, hEBs were differentiated in serum-free colony-forming cells assay conditions. 
After 6-9 days, semi-adherent mesodermal hematoendothelial (MHE) cluster colonies 
emerged, which contained both adherent and nonadherent cells. The nonadherent cells 
expressed CD45 and gave rise to hematopoietic colonies whereas the adherent cells from 
MHE colonies resulted in cells with endothelial morphology, expression of endothelial 
markers, CD31, VE-cad, vWF, and were capable of Dil-labeled acetylated low density 
lipoprotein (Dil-Ac-LDL) uptake. To further support the hemangioblast concept, MHE 
colony derived primitive hematopoietic blasts were also located close to adherent 
CD31+VE-cadherin+ ECs. However, it is unclear whether MHE colonies are generated 
from single hESCs as the formation of hEBs in this study were generated from dispase 
induced hESCs cell clumps. This raised an uncertainty in the relationship between MHE 
colonies and bipotential hemangioblast.  
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Fig. 4. The origins of ECs and hematopoietic cells  
In the developing embryo, both angioblasts and hematopoietic stem cells share a common 
precursor, the hemangioblast. Angioblasts further differentiate into ECs which line the 
inside of blood vessels, whereas hematopoietic stem cells can give rise to blood cells 
83
.  
 
 
In addition, several in-vitro hESCs studies have also shown to support the hypothesis that 
both hematopoietic and endothelial cells develop from a common precursor, the 
hemangioblast or from primitive hemogenic endothelial cells 
62, 84
. Using serum free 
medium containing a cocktail of cytokines BMP-4, FGF-2 and VEGF, Kennedy et al. have 
derived hemangioblasts from in-vitro hESCs differentiation 
85
. These hemangioblasts were 
identified by the ability to generate blast colonies with hematopoietic and endothelial 
potential as previously reported in mESCs differentiation studies 
77
. However the kinetics 
of hematopoietic colony formation is different from previous studies  
84, 86
 which could be 
because of the different hESC differentiation conditions, growth factors or different hESC 
lines used. Due to the employment of a variety of different differentiation protocols 
82, 84, 85
, 
it is unclear whether the same or different populations of potential bipotent precursors were 
examined.  
 
Presently there is no standard protocol in generating hESCs-derived hemangioblasts, thus 
resulting in varying kinetics of hEBs differentiation and expression of hemangioblast-
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related markers. An imminent reason is the use of different mixtures of cytokines and 
batches of fetal bovine serum and hence, contributing to variation between different 
research groups. The discovery of more specific markers expressing exclusively only on 
hemangioblast’s cell surface and concurrently emerging at specific differentiation time-
points as well as function assessments may aid in solving these discrepancies.  
 
 
1.3.2 hESCs derived endothelial cells 
 
The isolation and establishment of EC lines in 1973 was an early achievement in the 
vascular biology field 
87
. However, these cultures do not provide a three-dimensional 
interaction that comprise of the cultured ECs, the underlying matrix and the adjacent 
supporting cells, which are crucial in the regulation of vascular processes.  In comparison, 
pluripotent embryonic stem cells are capable of forming EBs wherein vascular 
development occurs in a myriad of interactions with adjacent non-ECs. Since the first in-
vivo observation of differentiating ESCs into ECs and subsequent vascular morphogenesis 
by Doetschman et al. 
88
,  a series of ECs differentiation studies were carried out extensively 
in murine embryogenesis, including maturation steps, molecular events, and growth factor 
involvement 
89-92
. The combinations of assessing multiple endothelial specific markers and 
functional assays such as Dil-Ac-LDL uptake and vasculogenesis using matrigel assays are 
classic hallmarks in identifying and characterizing ESC-derived ECs. Microscope 
examinations determined that ESC-derived ECs also acquire a cobblestone morphology 
93
. 
Expression of PECAM-1, VEGFR2, VE-cad, endothelial nitric oxide synthase (eNOS) and 
vWF were detected in a time-dependent manner from the early stages of ESCs 
differentiation to mature vessels via immunofluorescence staining and gene expression 
analysis in mouse EBs 
89
. Vittel et al. reported that Fetal Liver Kinase-1 (Flk-1; 
alternatively known as Vascular endothelial growth factor receptor 2 (VEGFR2) or Kinase-
inserted domain containing receptor (Kdr)) mRNA occurred at differentiation day 3 
whereas later stage markers such as VE-cad and Tie1 mRNAs were detected at day 5. Flk1 
has been regarded as one of the earliest markers to appear during endothelial linage 
development and has also been reported to appear around day 3-4 of differentiation 
91
. On 
the other hand, expression of VE-cad and vWF are known as late or mature EC markers.  
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The belief that ESCs must undergo through the EB route to proceed with differentiation 
was overturned by Nishikawa et al 
79
. mESCs grown on collagen type IV coated dishes as a  
monolayer, further differentiated into Flk1+ cells and eventually gave rise to ECs. Using 
similar methods of differentiation, Yamashita et al. showed that isolated Flk1+ cells, which 
under the influence of VEGF165 application, resulted in the formation of ECs 
90
. Moreover, 
treatment of Flk1+ cells with PDGF-BB also formed mural cells, which further 
demonstrated that Flk1+ cells could give rise to vascular cells. In-vivo, these Flk1+ cells 
could incorporate as endothelial and mural cells and contribute to the developing 
vasculature in chick embryos 
90
. Since then, isolating Flk1+ cells and the inclusion of 
VEGF into culture systems in differentiating towards EC has been widely utilised in many 
groups 
91, 92
.  In an alternative to obtain ECs and VSMCs from differentiating mESCs, Xiao 
et al. isolated stem cell antigen-1 positive (Sca-1+) vascular progenitor cells from mESCs 
and further differentiated  these cells on collagen type IV in the presence of VEGF165 and 
PDGF-BB to derive ECs 
94
 and VSMCs 
95
. Using this method, we achieved a large quantity 
of functional ECs with flow cytometry analysis depicting that 99% of differentiated cells 
were positive for CD31/PECAM and 75% were vWF positive. In-vivo, these ECs showed 
the capacity to regenerate the endothelium of denuded vessels and reduced neointimal 
lesion formation after arterial injury in mice. Moreover, histone deacetylase 3 (HDAC3) 
which reportedly regulates the structure and function of chromatin 
96
, was found to play a 
role in the differentiation process of Sca-1
+
 progenitor cells towards the endothelial lineage 
94
.  
 
Advances and findings in early mESCs derived ECs studies have aided in hESCs studies, 
with the endothelial potential of hESCs being increasingly apparent during the past recent 
years. Several groups have successfully derived ECs from hESCs, mainly via two 
approaches, the spontaneous differentiation of EBs, also known as three-dimensional 
differentiation (3D) 
66, 67, 93, 97-100
 or two-dimensional differentiation (2D) as monolayers 
101-
106
. In 2002, a breakthrough in differentiating hESCs to derive ECs was reported by 
Levenberg et al. 
67
. During differentiation, endothelial-specific genes were characterized 
from Ebs to assess their vasculogenic potential. CD31/PECAM-1, CD34 and VE-Cad 
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mRNA expressions peaked at days 13-15. Subsequently, CD31/PECAM-1+ cells were cell-
sorted from day 13 EBs. A yield of 2% CD31/PECAM-1
+
 cells was obtained and these 
cells were expanded in endothelial growth medium. These cells were characterised by 
analyzing the expression of endothelial-specific genes and proteins. Cells were positive for 
markers such as CD34, VE-Cad and vWF and capable of Dil-Ac-LDL uptake. In- vivo 
study was carried out by transplanting PECAM-1/CD31
+
 cells into severe combined 
immunodeficient (SCID) mice. Further histological examinations on transplanted implants 
were immunoreactive with human CD31 and CD34. The presence of mouse blood cells in 
the human positive lumens was indicative of the formation of functional microvessels. 
However, some questions remain unanswered as blood carrying function of the vessels was 
not investigated further in-vivo and the integration of the implant into the host vasculature 
was not well defined. Later, some research groups concluded that a population of primitive 
precursors (CD31
+
Flk1
+
CD45
-
) or CD34
+
 vascular progenitor cells could be obtained from 
day 10 EBs which upon further selection and differentiation, could give rise to mature and 
functional ECs 
66, 84, 107
. These studies confirmed that the EB is a true event of early human 
development wherein EC progenitor cells exist and whereby adult ECs could be derived.   
 
In another study using EBs to derive endothelial cells, Kim et al. isolated the center region 
of attached EBs which expressed higher endothelial markers compared to the outgrowth 
region of the EBs 
98
. To obtain cells from the center region of the EB, the group used a two-
step enzyme treatment comprised of trypsin-Ethylenediaminetetraacetic acid (EDTA) and 
cell dissociation buffer. Flow cytometry analysis of cells from the center region revealed a 
higher level of PECAM/CD31+ cells at 7.39% as compared to Levenberg et al 
67
. As these 
cells were further differentiated, they expressed endothelial markers and were capable of 
tube formation in matrigel assay as well as Dil-Ac-LDL uptake. However, these cells were 
not conducted in-vivo and hence the behavioral function of these hESCs-derived ECs was 
not fully evaluated. Cho et al. took a step further with the cells isolated from the central 
region of the EBs 
93
. After mechanical isolation of the PECAM-1/CD31
+
 cells in the middle 
of the EB and further expansion, vWF positive cells were sorted out via FACS. In-vivo 
evaluation was carried out by transplanting the vWF positive cells into the hindlimb of a 
mouse ischemia model. In the transplanted mice, perfusion blood flow was improved with 
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enhanced angiogenesis as observed by the increased formation of capillaries and arterioles. 
There was also an improvement of limb salvage as these cells facilitate postnatal 
neovascularisation. Moreover, reverse transcription polymerase chain reaction analysis 
showed that human angiogenic factors such as VEGF, bFGF and Ang1 were expressed 
only in the transplanted ischemic mouse limbs. Taken together, this study has shown that 
transplanted hESC-ECs could serve as an alternative cell source for therapeutic 
angiogenesis to treat peripheral ischemia or other ischemic diseases. Also, improvements 
during cell transplantation in this study could be made by using a matrix which might 
enhance the efficacy of cell therapy by facilitating optimal cell transfer and distribution into 
ischemic sites. However as Cho et al. retrieved 41.81% vWF positive cells, it seems that 
mechanical isolation is a less efficient method compared to the two step enzyme treatment 
carried out by Kim et al who obtained 52.04% of vWF positive cells 
98
. Interestingly, both 
groups used the same hESC line, CHA-3 hESC in their studies. Another probable reason in 
the differences is the different length of days taken to culture and attach the Ebs prior to 
isolation (Table 1). 
 
Table 1. Differences in the culture and subsequent attachment of Ebs. 
Probable reasons in explaining the different percentages obtained in the derivation of vWF 
positive hESC-derived ECs from studies carried out by Kim et al. and Cho et al. 
Determination and optimisation of the most efficient method will greatly aid in retrieving 
high numbers of potentially pure hESC-derived ECs for therapeutic therapies. 
  
 
% of  
hESCs-
derived 
vWF 
+cells 
isolated 
Medium in which EBs 
was cultured in 
No. of 
days for 
EB 
formation 
Medium in 
which 
attached 
EBs were 
cultured 
No. of days 
EBs was 
attached 
prior to 
isolation of 
cells in the 
middle region 
Kim et al  
98
 
52.04% 
bFGF-free  + 
DMEM/F12 medium 
supplemented with 20% 
serum replacement, 
1 mM l-glutamine, 1% 
nonessential amino acids, 
100 mM β-
mercaptoethanol 
5 days 
Not 
mentioned 
10 days 
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Cho et al 
93
  
41.81% Same as Kim et al 9 days 
DMEM + 
10% Fetal 
Bovine 
Serum 
7-9 days 
 
 
The formation of EBs is believed to be an inefficient method to gain large quantities of pure 
hESCs-derived ECs as usually an entire colony of hESCs is required for generation of a 
EB. Hence, the differentiation of hESCs towards the endothelial lineage was achieved in a 
2-dimensional (2D) model bypassing the need for EB formation 
101, 103
. Gerecht-Nir et al. 
reported the differentiation of hESCs into vascular cells by seeding undifferentiated 
aggregates of hESCs on collagen-IV coated surface 
103
. After 6 days, the cell population 
was filtered through a 40μm strainer, resulting in a population of filtered cells expressing 
endothelial progenitor markers such as CD31, CD34 and GATA binding protein 2 
(GATA2). Further differentiation of these filtered cells in human VEGF165 resulted in the 
growth of vWF expressing mature ECs, which are capable of Dil-Ac-LDL uptake. 
Vasculogenesis was observed when the differentiated cells were seeded in 3D collagen 
type-1 and matrigel culture systems. Nevertheless, the method of isolating vascular 
progenitor cells using a 40μm filtration may compromise the purity of these isolated cells 
and is not as specific as to FACS and magnetic activated cell sorting (MACS). The lack of 
in-vivo study also questioned the long-term durability and integration of these differentiated 
cells in animal models.  
 
Zack et al. also used the 2D method to generate hESCs-ECs, by seeding undifferentiated 
hESCs on mouse embryonic fibroblasts in the presence of FBS but without additional 
growth factors for 10 days 
101
. They obtained ~10% CD34+CD45- cell population and 60-
90% CD31+ cells. After two rounds of magnetic bead selection, 80-95% purity of CD34+ 
cells was achieved and these progenitor cells were further differentiated in endothelial 
growth medium with VEGF and bFGF. The resultant hESCs-derived ECs contributed to 
arborized blood vessels after transplantation into SCID mice. The implants successfully 
formed functional vessels and integrated into the recipient’s circulatory system which 
lasted more than 150 days. Oyamada et al. also demonstrated the therapeutic potential of 
transplanted hESCs-derived hECs. In this study, transplanted hESCs-derived ECs and 
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mural cells improved vascular regeneration and reduced the infarct area after stroke in mice 
104
.  
 
There are several reported 2D differentiation studies which also used various feeder layers 
such as OP9 bone marrow derived mouse stromal cells or methylcellulose to induce the 
formation of hESCs-derived ECs 
82, 104, 108
. However instead of differentiating hESCs using 
the conventional 3D or 2D method, one particular study utilized genetic manipulation of 
hESCs to drive the production of ECs. Rufaihah et al., made day 7 hESCs EBs, trypsinised 
them into single cells and transduced with an adenoviral vector expressing the human 
VEGF165 gene (Ad-hVEGF165). For more than 30 days post-transduction, Ad-hVEGF165-
transduced cells continued secreting high levels of hVEGF165 into the culture medium as 
compared to non-transduced and Ad-null-transduced cells. Immunostaining for hVEGF 
revealed 90% transduction efficiency. They also assessed the biological activity of the 
secreted VEGF165 by Ad-hVEGF165-transduced cells which stimulated an extensive 
proliferation of human umbilical cord vascular endothelial cells (HUVEC). Real-time PCR 
showed an upregulation of VEGF, Ang-1, Flt-1, Tie-2, CD34, CD31, CD133 and Flk-1 
gene expression in the Ad-hVEGF165-transduced cells. Although flow cytometry analysis 
revealed an approximately 5-fold increase in CD133 marker expression in Ad-hVEGF165-
transduced cells as compared to control, other specific endothelial markers such as 
PECAM-1/CD31 and vWF were not qualitatively assessed. Moreover the function of these 
derived Ad-hVEGF165-transduced cells was not determined in matrigel or Dil-Ac-LDL 
assays. Hence the vasculogenesis of the derived Ad-hVEGF165-transduced cells is 
questionable as well as its behavior in-vivo. 
 
Although ECs present a common set of markers and features, they exhibit certain 
heterogeneity. For example in structural heterogeneity, ECs from aorta are larger and 
thicker than those found in capillaries and veins 
109
. This heterogeneity also comprises of 
diversity in different expression of cell surface markers, proteins and mRNA 
110, 111
. Hence, 
challenges still remain to delineate, refine, control, monitor and quantify the kinetics of 
vascular differentiation, maturation and tissue organization so as to mimic the complex 
microenvironment where vasculogenesis occurs during embryogenesis.  
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1.4 MicroRNA and its role in vasculogenesis 
 
The past recent years have seen a surge of evidence illustrating that microRNAs (miRNAs) 
are involved in various biological processes, such as cardiogenesis and the differentiation 
of skeletal muscle and hematopoietic lineages 
112-114
. Its importance has also been 
highlighted in the human genome, which has been estimated to encode up to 1000 miRNAs 
that are predicted to regulate a third of all genes 
115
. miRNA was initially studied in model 
organism such as Caenorhabditis elegans where the founding members of miRNAs, lin-4 
and let-7 were discovered to regulate crucial roles in its development 
116, 117
. With the ever 
expanding investigations into its function and regulation, the concept of miRNA 
manipulation to regulate disease-related processes is fast becoming a feasible future 
therapeutic approach. 
 
1.4.1 microRNA biogenesis 
 
miRNAs are highly conserved, short non-coding RNA molecules of about 22 nucleotides in 
length. They regulate gene expression at the post-transcriptional level by either repressing 
target mRNAs through an antisense mechanism or by enhancing the degradation of mRNA, 
thereby silencing gene expression.  
 
Originally, miRNAs reside in the nucleus as RNA polymerase II primary miRNA (pri-
miRNAs) transcripts, which are transcribed from independent miRNA genes (intergenic), 
polycistronic transcripts that often encode multiple related miRNAs (polycistronic), or 
introns of protein-coding genes (intronic) (Fig.5) 
118
. Once the stem-loop pri-miRNAs are 
expressed, they are matured and processed in two steps, catalyzed by the ribonuclease III 
(RNase III) type endonucleases Dicer and Drosha. Within the nucleus, pimary miRNA 
transcript (pri-miRNAs) are processed by Drosha which form complexes with a double-
stranded RNA-binding domain protein, DiGeorge syndrome critical region gene 8 
(DGCR8)/Pasha 
119, 120
. Eventually the pri-miRNAs are processed into approximately 70-
100 nucleotide hairpin-shaped precursors known as pre-miRNAs. The majority of 
mammalian miRNAs encoded in introns are processed before splicing. But there is a subset 
of very short intronic miRNAs (miRtrons) that bypass the Drosha pathway 
121
 and gets 
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processed into pre-miRNAs by the spliceosome and the debranching enzyme. Both pre-
miRNAs and miRtrons are transported to the cytoplasm via an Exportin-5 and Ran-GTP–
dependent mechanism 
122
.  
 
Once in the cytoplasm, the doubled-stranded ribonuclease Dicer, forms a complex with 
protein (human immunodeficiency virus transactivating response RNA-binding protein) 
TRBP and cleaves the pre-miRNAs to yield ~20-22 base pair mature miRNA duplexes 
123
. 
After cleavage, one strand of the RNA duplex is incorporated into an Argonaute family 
protein (AGO) to form the core component of the effector ribonucleic acid induced 
silencing complex (RISC).  Mammals express multiple AGO homologues, which are 
namely AGO1–AGO4. During loading into the RISC, the RNA duplex is unwound to form 
a mature single-stranded miRNA (guide strand) and its complementary strand (passenger 
strand or miRNA*) which is typically degraded 
124
. On the other hand, there are instances 
when the miRNA* strand can also be loaded into the RISC to function as active miRNAs 
and involve in gene regulation 
125-127
. Generally, selection of the active mature strand that 
associates with the RISC seems to depend on the stability of both ends of the double-
stranded RNA 
128, 129
. It appears that there is a preference for the strand with lower stability 
base pairing of the 2–4 nucleotides at the 5' end of the double-stranded RNA duplex 128.  
 
1.4.2 microRNA mode of operation  
 
Mature miRNAs guide the RISC to target mRNAs and binds with Watson–Crick base 
pairing to the 3’untranslated region (UTR) of specific target mRNAs. Unlike in plants, few 
mammal miRNAs are highly complementary to their target mRNAs and thus most binds 
with near-perfect complementary match 
130-132
. The 7-8-nucleotide seed sequence spanning 
from nucleotides 2 to 8 in the 5′ end of the mature miRNA strand is critical for the majority 
of 3’UTR mRNA target recognition 133, 134. However, in some rare cases, there are also 
reports that demonstrated the ability of mature miRNAs which target regions outside the 
mRNA 3’UTR, such as the amino acid coding sequence and regions in 5’UTR of mRNA 
targets 
135, 136
. Moreover, each miRNA might have up to several hundred mRNA targets, 
which may be part of a related pathway or process 
137
. 
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After recognization by miRNA, this leads to endonucleolytic cleavage and degradation of 
the target mRNAs and this mechanism applies to small interfering RNAs (siRNAs) and 
many plant miRNAs. However, since animal miRNAs pair imperfectly with their target 
mRNAs, this leads to translational repression or deadenylation and decay of mRNAs 
138
. 
Finally, mRNAs which are repressed by deadenylation or during the translation–initiation 
step, are transported to P-bodies for either degradation or storage 
139
.  
 
1.4.3 Nomenclature for miRNAs 
 
A standard miRNA nomenclature scheme has been applied since the initial large-scale 
miRNA discoveries 
140-142
. Names are assigned after a submitted manuscript has 
experimentally confirmed the discovery of the miRNA and before the publication of article 
143
. In the nomenclature system, the prefix "mir" is followed by a dash and sequential 
numerical identiﬁers that often indicate order of naming (e.g. mir-123 was named and 
likely discovered prior to mir-456) 
144
.  Identical miRNAs have the same number, 
regardless of organism (e.g. hsa-miR-101 in human and mmu-miR-101 in mouse are 
orthologous). Abbreviated 3-letter prefix is designated to species of origin (e.g. hsa-miR-
101 belonged to Homo sapiens). The capitalized "miR-" refers to the mature form of 
miRNA whereas the uncapitalized "mir-" refers to the pre-miRNA precursors. Mature 
miRNAs that differ at only one or two nucleotide positions are annotated with an additional 
lower case letter (e.g.  miR-123a would be closely related to miR-123b) 
144
. Pre-miRNAs 
that are located at different loci in the genome but leading to completely identical mature 
miRNAs have an additional dash-number suffix (e.g. hsa-mir-194-1 and hsa-mir-194-2 are 
both located in different loci of the genome but lead to an identical mature miRNA hsa-
miR-194) 
143
. In the instance whereby two different mature miRNAs sequences originate 
from opposite arms of the same hairpin pre-miRNA precursor, they are assigned with a -3p 
(3’arm) or -5p (5’arm) suffix. In terms of the levels of miRNA relative expression, an 
asterisk following the name indicates a miRNA expressed at low levels relative to the 
miRNA in the opposite arm of a hairpin (e.g. although both miR-123 and miR-123* share a 
pre-miRNA hairpin, higher levels of miR-123 would be found in the cell) 
144
. 
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Fig. 5. Process of the formation of miRNAs and their functions 
miRNAs are generated in a two step processing pathway (nuclear and cytoplasmic) 
mediated by enzymes, Dicer and Drosha. Mature miRNAs are incorporated into a RISC 
complex, which contains components of the Argonaute family (Ago1 to -4). Targeted 
mRNA is either translational repressed or degraded 
145
. 
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1.4.4 microRNA and its regulation in vascular biology 
 
Vascular biology applies to processes affecting blood vessels. It has been increasingly well 
established that miRNAs play important roles in vascular biology. The first few 
experiments demonstrating the significance of miRNAs in mammalian vascular biology 
regulation, involved depleting levels of miRNAs in vascular cells by arresting miRNA 
biogenesis 
146-148
. In an in-vivo study involving transgenic mouse lacking the first two 
exons essential for the function of dicer, homozygous dicer 
ex1/2 
mutant mouse did not 
survive. Majority of E11.5 dicer 
ex1/2 
embryos have impaired growth and development and 
those which survived had a severely compromised blood vasculature formation. Hence this 
indicates that dicer or miRNAs plays a crucial role in mouse development and its 
angiogenesis  
146
. Moreover, the knockdown of dicer in ECs as shown in-vitro, reduced its 
proliferation and cord formation. In this study, there was an increased expression of 
FLT/VEGFR and KDR/VEGFR2 suggesting that the VEGF signaling pathway was 
upregulated to compensate for failed angiogenesis and remodeling 
147
. In addition, the 
silencing of both Dicer and Drosha significantly abated capillary sprouting of ECs and tube 
formation 
147, 148
.  
 
Other members of miRNAs were also reported in the regulation of vascular biology and 
angiogenesis. The activation of angiogenic program in ECs is crucial for normal embryonic 
development and regenerative therapy such as tissue healing or transplantation. However, 
uncontrolled and excessive angiogenesis can also lead to pathological discorders such as 
cancer. In one of the studies that looked into the role of miRNAs in angiogenesis, it was 
discovered that both miR-221 and miR-222 regulated the expression of c-Kit and its ligand; 
the stem cell factor. Interaction between miR-221/2 and c-Kit, forms part of a complex, 
which inhibits endothelial cell migration, proliferation, and angiogenesis in vitro 
149
. In 
another study, Bonauer et al. has identified the miR-17-92 cluster as a negative regulator of 
angiogenesis. miR-92a, a member of this cluster, inhibits angiogenesis both in vitro and in 
vivo 
150
. More recently, Sabatel et al. discovered that in ECs, miR-21 acts as a negative 
modulator of angiogenesis by targeting RhoB 
151
.  
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Another miRNA integral to angiogenesis and blood vessel formation is miR-126. miR-126 
is an endothelial specific miRNA and one of the most abundantly expressed miRNAs in 
endothelial cells 
148, 152
 . It is found prominently in the heart and other highly vascularized 
murine tissues 
153-155
. Located in chromosome 9q34.3 within the host gene encoding for 
epidermal growth factor like-7 (Egfl-7), miR-126 regulates many aspects of endothelial cell 
biology in vitro, including organization of the cytoskeleton and cell migration 
155, 156
. Its 
expression also appears crucial during embryonic development as knockdown studies in 
zebrafish resulted in hemorrhage and loss of vascular integrity 
152
. Moreover, in a mice 
study, targeted deletion of miR-126 leads to partial embryonic lethality with hemorrhagic 
defects during development 
155
. Nevertheless, those surviving mice in this study exhibit 
impaired neovascularization and thus show increased mortality after myocardial infarction 
and inadequate wound healing 
155
.  
Besides, miR-126 was found enriched in ECs derived from mESCs 
152
. Fish et al. further 
discovered that miR-126 targets the Sprouty-related protein (SPRED1) and 
phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2/p85-beta) which are negative 
regulators of the VEGF pathway 
152
. These findings were further ratified by Spred1 
overexpression and VEGF signaling inhibition in zebrafish studies whereby defects similar 
to miR-126 knockdown were observed 
152
. Following reports stating that effects in miR-
126 appear to regulate vascular integrity and angiogenesis in mouse and zebrafish models, a 
recent report has also demonstrated levels of miR-126 being induced in day 10 
differentiated hESCs grown in EC differentiaiting conditions 
106
. However, no further 
studies have if miR-126 play a role in hESCs differentiation towards the EC lineage. 
Moreover, Fish et al. were unable to promote differentiation of miR-126 overexpressing 
pluripotent stem cells towards the EC lineage 
152
. This indicates that although miR-126 is 
found enriched in vascular progenitors, it does not control early EC lineage commitment. 
To date, present studies have demonstrated the regulation of miRNAs in a myriad of 
vascular biology events, nevertheless there are still insufficient evidence demonstrating 
their involvement in early human development of vascular cells, how they control EC fate 
commitment and their mechanisms involved in these differentiation processes. Hence this 
project aims to determine and identify miRNAs which are crucial in regulating the 
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differentiation of hESCs into ECs. Delineation of the mechanisms and signaling pathways 
involved by these particular vascular-specific miRNAs will greatly aid in understanding the 
molecular regulation of human vasculogenesis. These findings will also serve to benefit 
future clinical therapies in cardiovascular disease applications.   
1.5 Project objectives 
 
 
1. Design and develop a differentiation culture model to derive endothelial and smooth  
muscle cells from undifferentiated hESCs.  
 
2. Isolate pure population of hESC-derived ECs that display EC markers using FACS. 
Function tests will be assessed on these hESC-derived cells to ensure that these cells 
display functional characteristics of vascular EC cells. 
 
3. Determine and identify which selected enriched miRNAs are crucial in regulating the 
differentiation of hESCs into ECs, microRNA array analysis will be carried out.  
 
4. Determine if selected miRNAs also play a role in vivo developing chick embryos   
 
5. Delineate the underlying mechanisms of EC differentiation from hESCs mediated by 
the selected miRNAs. Target mRNA will be determined using gain-of-function and 
loss-of-function tests. Luciferase assay will then be used to verify the miRNA target 
sites. 
 
 
Hypothesis 
miRNA may play a role in early human endothelial cell development.  
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CHAPTER 2 
Materials and Methods 
 
 
2.1 Maintaining the human embryonic stem cells 
 
2.1.1 Making stocks of 25ug/ml Mitomycin C  
  
Two milligram of Mitomycin C (Sigma-Aldrich) was dissolved in 1ml of Mouse 
Embryonic Fibroblast (MEF) medium containing Dulbecco's Modified Eagle Medium 
(DMEM; Gibco, Invitrogen) with 15%v/v Foetal Bovine Serum (FBS; ATCC, Manassas, 
VA), vortexed and spun down. The dissolved Mitomycin C was topped up with MEF 
medium to make a concentration of 25µg/ml and sterile filtered through a 0.2µm filter 
(Whatman). The prepared 25µg/ml Mitomycin C stocks were aliquoted and stored at -
20ºC. A final concentration of 8µg/ml of Mitomycin C was used to inactivate MEFs.  
 
2.1.2 Making stocks of 100 mg/ml Collagenase type IV  
 
Reconstitiute 1g of the lyophilized enzyme Collagenase type IV (CIV; Gibco, Invitrogen) 
with 10ml of DMEM / F-12 1:1, (1X) containing 15 mM HEPES (Stem Cell technology). 
The solution was mixed well and filtered using a 0.2µm filter (Whatman). Aliquots of the 
100mg/ml CIV stock solution were stored at -20ºC. CIV was further diluted with 
DMEM/F12 to a concentration of 0.5mg/ml prior to use. 
 
2.1.3 Making stocks of human basic Fibroblast Growth Factor-2 
 
Fifty microgram of human basic Fibroblast Growth Factor-2 (hbFGF; Miltenyi Biotec Inc, 
Auburn, USA) was reconstituted with 1ml of 0.1%v/v Bovine Serum Albumin (Sigma-
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Aldrich). 50µg/ml of the prepared hbFGF was further diluted to 10µg/ml and aliquoted into 
smaller volumes of 100-200 µl for long-term storage at -20ºC. 4ng/ml of hbFGF was used 
in maintaining hESCs.   
 
2.1.4 Inactivating MEFs and preparing feeders for hESCs passaging 
 
MEFs (CF-1 strain, ATCC, Manassas, VA) were grown to approximately 80% confluency 
prior to inactivation. Spent medium was aspirated and cells were washed once with 
Dulbecco’s Phosphate Buffered Saline (D-PBS; Sigma-Aldich). 8µg/ml of Mitomycin C 
was added to the flask and incubated for 2 hours in a 37ºC incubator. After which, 
Mitomycin C was removed and cells were washed once with D-PBS before incubating 
with trypsin (Gibco, Invitrogen) for 3 minutes at 37ºC. An equal volume of MEF medium 
was added to neutralise the trypsin. Cells were collected into a 15ml tube and centrifuged 
at 270g for 5 minutes. The cells were resuspended in 2ml of MEF medium, counted using 
the hematocytometer and plated at 350,000 cells per 25cm
2
 gelatinised flasks. The MEFs 
were allowed to settle overnight at 37ºC before plating hESCs. For the optimal 
maintenance of hESCs, MEFS were only used from passages 3 to 5.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
2.1.5 Preparation of soda lime 3mm glass beads  
 
hESCs were passaged using either Pasteur pipettes (Scientific Laboratory Supplies Limited, 
Nottingham, UK) or soda lime glass beads (Sigma-Aldrich) after treatment with 0.5mg/ml 
CIV. The glass beads were prepared and sterilised before use. Firstly, the beads were 
incubated with concentrated 3.8M Hydrochloric acid (HCL) overnight.  The next day, 
equal amounts of 3.8M Sodium hydroxide (NaOH) was added and incubated for 10 
minutes to neutralise the HCL. The mixture was discarded and tap water was allowed to 
run into the beaker containing the glass beads for a couple of hours. After rinsing, the glass 
beads were washed 4 times with distilled water (dH20). dH20 was left with the glass beads 
to soak overnight. The following day, the glass beads were washed twice with dH20, 
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autoclaved and dried. Approximately 15-20 glass beads were filled into capped cryovials 
(Greiner Bio-One) and subsequently autoclaved and dried for use in hESCs passaging.  
 
2.1.6 Thawing vitrified hESCs onto feeders 
 
Inactivated MEFs were prepared and seeded onto gelatinised In-vitro fertilisation (IVF) 
dishes (Corning, NY) at a cell density of 50,000/dish prior to thawing hESCs. On the day 
of thawing, MEF medium in which the MEFs were seeded in was replaced with hESC 
medium after washing once with D-PBS and placed in the 37ºC incubator for at least half 
an hour.  hESC medium contained knockout DMEM and supplemented with 20%v/v 
Knockout Serum Replacement (KoSR), 1% v/v Non-essential amino acid, 1mM Glutamax, 
0.1mM β-mercaptoethanol (Gibco, Invitrogen) and 4ng/ml hbFGF. Warm hESC medium 
was also aliquoted onto 1-2 wells of a 24-well plate where vitrified hESCs were thawed 
into and left in the incubator for 5 minutes. The thawed pieces of hESCs in the 24-well 
plate were immediately transferred onto the previously prepared MEF feeders in IVF 
dishes. The freshly thawed cells were allowed to settle overnight in the 37ºC incubator and 
medium was changed the day after next. During the routine maintenance of hESCs, 
medium was changed daily and cells were passaged onto new MEF feeders every 3-4 days. 
hbFGF was added to the medium fresh daily. 
 
2.1.7 Passaging hESCs onto fresh MEFs 
 
The Shef-3 human embryonic stem cell line was obtained from the United Kingdom Stem 
Cell Bank (UKSCB, Hertfordshire, UK). Prior to passaging hESCs, the MEF medium in 
the freshly prepared 25cm
2
 MEFs flask was replaced with hESC medium after washing 
once with D-PBS and kept in the 37ºC incubator. hESCs were treated with 0.5mg/ml CIV 
after the removal of spent medium and incubated for 5 minutes at 37ºC. CIV was removed 
and hESC medium was added to the flask. hESCs were then either mechanically passaged 
at a ratio of 1:2 using pasteur pipettes under the dissection microscope (Nikon, Japan) or 
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glass beads and transferred to the freshly prepared MEFs. The cells were allowed to settle 
and attach overnight in the 37ºC incubator and the hESC medium was only changed the 
day after next.  
 
2.1.8 Freezing stocks of hESCs with 10% Dimethyl sulfoxide  
 
Spent medium was removed from flask and hESCs were incubated with CIV for 30 
minutes until the edges of hESCs colonies start to curl. After the replacement of CIV with 
hESC medium, undifferentiated hESC colonies were passaged into larger than usual sized 
clumps using the pasteur pipette.  The passaged cells were collected and spun at 50g for 5 
minutes. The cell pellet was washed once with D-PBS and centrifuged again. The 
supernatant was removed and the cell pellet was resuspended in cold freezing medium 
consisting of 10% v/v Dimethyl sulfoxide (DMSO; BDH) and FBS. The hESCs suspension 
was split into cryovials at a ratio of 1:3, placed into a freezing container (NUNC) and 
stored at -80
o
C freezer overnight. Next day, the cryovials were transferred into liquid 
nitrogen for long-term storage.  
 
2.1.9 Thawing hESCs from frozen cryovials onto MEFs 
 
Upon immediate retrieval of the frozen cryovials from liquid nitrogen, hESCs in the vials 
were thawed in a 37 ºC water bath. The thawed hESCs suspension was added slowly to 
pre-warmed MEF medium. The thawed cell mixture was centrifuged at 50g for 5 minutes 
and the supernatant was subsequently removed. The cell pellet was gently resuspended in 
pre-warmed hESC medium and seeded onto freshly prepared MEF flasks. Medium was 
changed only the day after next. Freshly thawed hESCs might take 1 week for colonies to 
surface.  
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2.2 Differentiating hESCs into vascular cells   
 
2.2.1 Differentiation of hESCs towards the endothelial lineage 
 
Matrigel
TM
 Basement Membrane Matrix (BD Biosciences, Bedford, MA) was diluted at 
1:50 and coated on 75cm
2
 flasks for 3 hours at 37ºC. Meanwhile, undifferentiated hESCs 
were passaged as previously mentioned using pasteur pipettes except that each of the 
pieces were cut smaller than usual at approximately 200-300 cells. The passaged hESCs 
were collected and centrifuged at 50g for 5 minutes. The supernatant was removed and the 
cell pellet was resuspended in complete Endothelial Growth Medium-2 (EGM-2; Lonza, 
Walkersville, MD). hESCs were counted using the hematocytometer and seeded onto the 
prepared Matrigel
TM
 coated flasks containing EGM-2. Cells were seeded at densities of 1.3 
x 10
6
, 1.0 x 10
6
, 8 x 10
5
, 8 x 10
5
 and 6 x 10
5
 per 75 cm
2
 for differentiation days 3, 5, 6, 7, 9 
respectively. During differentiation, the medium was changed every other day 
 
2.2.2 Differentiation of hESCs towards the smooth muscle lineage 
 
75cm
2
 flasks were coated with 10µg/ml of Collagen type IV (BD Biosciences, Bedford, 
MA) for 3 hours. Undifferentiated hESCs were collected via mechanical scraping using 
pasteur pipettes after 5 minutes incubation with Collagenase IV. hESCs were passged to 
obtain small colonies of 200-300 cells each. Before seeding, cells were collected and 
centrifuged at 50g for 5 minutes. Supernatant was removed and cells were resuspended in 
differentiation medium containing α-Minimum Essential medium (Gibco, Invitrogen), 
0.05mM β-mercaptoethanol (Gibco, Invitrogen) and 10%v/v Fetal Bovine Serum (Gibco, 
Invitrogen). hESCs were counted using the hematocytometer and were seeded at densities 
of 1.3 x 10
6
, 1.0 x 10
6
, 8 x 10
5
, 8 x 10
5
 and 6 x 10
5
 per 75 cm
2
 for differentiation days 3, 5, 
6, 7, 9 respectively. During differentiation, the medium was changed every other day.  
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2.3 Real-time quantitative-Polymerase Chain Reaction (RT-qPCR) 
analysis  
2.3.1 Extraction of Ribonucleic acid from samples 
 
Cell scrappers were sterilised in 70% Ethanol for a few minutes and rinsed in cold 1X PBS. 
Medium from 75cm
2
 flasks where cells were grown in were discarded and the flask was 
washed once with 1X PBS to remove any remaining dead cells. Cells were scrapped in 
cold PBS as most enzymes were active at room temperature. The cells were collected into 
15ml tubes and centrifuged at 1000 rpm for 5 minutes. Supernatant was discarded and the 
cell pellet was either stored at -80 ºC or followed with RNA extraction.  
 
All work involved with Ribonucleic acid (RNA) was carried out in a sterile or RNase free 
manner. Prior to carrying out RNA extraction, the work area was first disinfected using 
70% Ethanol. Sterile and autoclaved pipette tips and eppendorf tubes were used to prevent 
RNA degradation. RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA). 
The cell pellet was loosened by vortexing. 500μl of Buffer RLT was added to lyse the cells 
and vortexed to mix. Each sample was transferred into a QIAshredder spin column placed 
in a 2 ml collection tube, and centrifuge for 1.5 minutes at 13.2 revolutions per minute 
(rpm), room temperature. 500μl of 70% Ethanol was added to the collected supernatant to 
precipitate the RNA. The mixture was pipetted for at least 25-27 times and precipitation 
was observed. 700μl of each sample was transferred into RNeasy Spin Column and 
centrifuged for 0.5 minute for 13.2 rpm. This step was repeated until all remaining 
individual samples were centrifuged through the column. 700μl of wash Buffer RW1 was 
added to each RNeasy spin column and spun at 13.2 rpm for 30 seconds. A new collection 
tube was changed for each column. 500μl of Buffer RPE was added to each RNeasy spin 
column and centrifuged for 0.5 minutes at 13.2 rpm. The flow-through was discarded. 
Another 500μl of Buffer RPE was added into each column and spun for 2 minutes at 13.2 
rpm. Flow-through was discarded and each RNeasy spin column was transferred to a new 
2ml collection tube. 45μl of RNase-free water was aliquoted to the center of the column 
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and left to incubate for 1 minute. The tubes were spun for 2 minutes for 13.2 rpm and the 
RNA samples were stored -80 ºC 
2.3.2 Reverse Transcription-Polymerase Chain Reaction  
 
RNA samples were thawed in ice after retrieval from -80 ºC and mixed by vortexing. Prior 
to measuring the RNA concentration, 5μl of RNA sample was diluted to 500μl with 
RNase-free water (1:100 dilution). The RNA concentration was determined using the 
spectrometer (Bio-rad). 2.5μg of RNA was diluted with RNase-free water to make a total 
volume of 8μl before adding 2μl of Random Primers (50ng/l, Promega, Madison, WI, 
USA). The mixture was vortexed to mix and incubated for 5 minutes at 70ºC in a heating 
block (Techne, Staffordshire, UK) which destabilised mRNA secondary structures and 
enhanced primer binding to mRNA. After heating, the mixture was quickly placed on ice 
for 5 minutes. Meanwhile, the master mix for the reverse transcription reaction was 
prepared. The master mix of one reaction contained 19μl of RNase-free water, 2μl of 
25mM 2'-deoxynucleoside 5'-triphosphate (dNTPs; Invitrogen), 10μl of 5X Reaction 
Buffer, 6μl of 25mM Magnesium Chloride (MgCl2), 2μl of ImProm-II reverse transcriptase 
and 1μl of RNasin Plus RNase Inhibitor (Promega, Madison, WI, USA). The master mix 
was mixed and aliquoted at 40μl into each tube of the prepared RNA sample. The samples 
were placed into the thermal block of a Thermal Cycler (Techne, Staffordshire, UK) which 
has a programme set at 25ºC for 5 minutes for annealing to occur and followed by an 
extension at 42 ºC for 90 minutes. The reaction was stopped by denaturing the enzyme at 
70ºC for 15 minutes. The final concentration of each synthesised complementary 
Deoxyribonucleic acid (cDNA) samples was 50ng/μl. Samples were stored at -20 ºC.
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2.3.3 Real-time Polymerase Chain Reaction (qPCR)   
 
Real-time PCR also known as quantitative-PCR, was carried out on ice at all times. The 
work area was disinfected with 70% Ethanol and autoclaved pipette tips and eppendorf 
tubes were used. cDNA samples were thawed from -20ºC and diluted with RNase-free 
water to a working concentration of 10ng/μl. The master mix for one reaction of a real-time 
PCR was made using 7.5μl RNase-free water, 12.5μl SYBR® Green PCR Master mix 
(Applied Biosystems), 1.5μl of 2mol forward primer and 1.5μl of 2mol reverse primer 
(Primer sequences are listed below in Table 2). The master mix was mixed by vortexing 
and aliquoted at 23μl for each reaction in a well of a MicroAmp® Optical 96-well Reaction 
Plate (Applied Biosystems). Each sample was carried out in duplicates. 2μl of 10ng/μl 
sample cDNA was added last to its respective wells. The 96-well plate was sealed with a 
cover film and centrifuged at 700g for 1 minute to collect all reaction mixtures at the 
bottom of the plate. ABI Prism 7000 (Applied Biosystems) was used to run the PCR 
reaction with one cycle programmed to run at at 50ºC for 2 minutes, 95ºC for 10 minutes 
and  40 cycles each of 95ºC for 15 seconds and 60ºC for 1 minute. The real-time PCR 
programme was run after the 96-well plate was inserted into the plate holding area. After 
the reaction has completed, the real-time PCR result was analysed with the ABI Prism 
7000 SDS software. Housekeeping gene 18S was used as normalisation control.  
Table 2. Primer sequences used in real-time PCR.  
human CD144 Forward: ATGAGAATGACAATGCCCCG 
 Reverse: TGTCTATTGCGGAGATCTGCAG 
  
human CD146 Forward: TTCCACTGCCAGTCCTCATACC 
 Reverse: CACACAATCACAGCCACGATG 
  
human vWF Forward: TGCGAAGTACCTTGGTTACCCA 
 Reverse: TAATCGTCAGTACATGCCCCG 
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human Kdr Forward: TGCGAAGTACCTTGGTTACCCA 
 Reverse: TAATCGTCAGTACATGCCCCG 
  
hu Nanog Forward: AAGGTCCCGGTCAAGAAACAG 
 Reverse:  GCTGGAGGCTGAGGTATTTCTG 
  
human SMA Forward: TGAGCGTGGCTATTCCTTCGT 
 Reverse: GCAGTGGCCATCTCATTTTCAA 
  
human SM 
Calponin 
Forward: ATTTTTGAGGCCAACGACCTG 
 Reverse: CCCACGTTCACCTTGTTTCCT 
  
human MYH11-
SM2  
Forward: AACTTCGCAGTGATGCACCAG 
 Reverse: CCATTGAAGTCTGCGTCTCGA 
  
human PDGFR-
beta 
Forward: GCAATGTGACGGAGAGTGTGAA 
 Reverse: AGCAAATTGTAGTGTGCCCACC 
  
human 18S Forward: CCCAGTAAGTGCGGGTCATAA 
 Reverse: CCGAGGGCCTCACTAAACC 
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2.4 Protein expression analysis 
 
2.4.1 Staining hESCs to determine their pluripotent or differentiated states 
  2.4.1.1     Immunofluorescence staining for pluripotency markers in 
undifferentiated  hESCs 
 
For staining undifferentiated colonies of hESCs were cultured for 4-5 days on mouse 
feeders grown in 8-wells chamber slides (NUNC, Rochester, NY, USA). Spent medium 
was aspirated and hESCs were fixed in 4%v/v paraformaldehyde (Sigma-Aldrich) for 15 
minutes at room temperature. After fixing, cells were washed twice for 5 minutes with 1X 
PBS. 0.1%v/v Triton X-100 in 1× PBS (Sigma-Aldrich) was used to permeabilise hESCs 
for 10 minutes at room temperature. Cells were washed twice for 5 minutes with 1X PBS 
and blocked with either 4% normal rabbit or swine serum (Dako, Denmark). After blocking 
for 30 minutes at room temperature, cells were incubated with primary antibodies diluted in 
blocking solution. The primary antibodies used were directed against Stage-specific 
embryonic antigen-4 (SSEA4; 1:50), TRA-1-60 (1:50), TRA-1-81 (1:50), SRY-box 
containing gene 2 (Sox 2; 1:800), Stage-specific embryonic antigen-1 (SSEA1; 1:100; all 
five antibodies were from Chemicon), Octamer 3/4 (Oct3/4; 1:50; Santa Cruz 
Biotechnology, CA), VEGFR1 (1:50) and VEGFR2 (1:50), both from Abcam, Cambridge, 
UK) for an hour. Following incubation with primary antibodies at room temperature, cells 
were washed thrice for 5 minutes. Cells were later incubated for another hour at room 
temperature with secondary antibodies diluted in 1X PBS. The secondary antibodies used 
were Polyclonal Rabbit Anti-Mouse Immunoglobulins Tetramethyl Rhodamine Iso-
Thiocyanate (TRITC), Polyclonal Swine Anti-Rabbit Immunoglobulins TRITC and 
Polyclonal Swine Anti-Rabbit Immunoglobulins Fluorescein isothiocyanate (FITC; all 
secondary antibodies used were from Dako, Denmark). These isotype IgG antibodies were 
substituted as primary antibodies for negative controls. Cells were washed thrice for 5 
minutes with 1X PBS and stained with 4,6-diamidino-2-phenylindole (DAPI; 1:1000; 
Sigma-Aldrich) for 3 minutes.  After two further washes with 1X PBS, cells were mounted 
using Fluorescence Mounting Medium (Dako, Denmark). Fluorescence images were 
viewed using fluorescent microscope (Axioplan 2 imaging; Zeiss).  
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  2.4.1.2     Determining alkaline phosphatase activity in undifferentiated hESCs 
 
hESCs were fixed with a 4%v/v paraformaldehyde for 1-2 minutes, aspirated and rinsed 
once with PBS. Alkaline phosphatase reagents (Chemicon) were prepared by mixing Fast 
Red Violet with Naphthol phosphate solution and water in a 2:1:1 ratio. This staining 
solution was incubated with hESCs in the dark at room temperature for 15 minutes. 
Staining solution was removed, rinsed with PBS and cells were covered with PBS to 
prevent drying. Alkaline phosphatase (AP) activity in hESCs was observed under a 
microscope. 
 
  2.4.1.3     Immunofluorescence staining to detect vascular markers in 
differentiated hESCs 
 
For derivation of endothelial cell lineage, undifferentiated hESCs were seeded in 8-wells 
chamber slides (NUNC, Rochester, NY, USA) and differentiated for 9 days while cultured 
in their differentiation medium as mentioned previously. The immunostaining procedure 
was carried out as previously mentioned in section 2.4.1.1. Most of the staining was carried 
out via the indirect method whereby 0.1%v/v Triton X-100 was used to permeabilise cells. 
Only cells to be stained with markers CD31/PECAM (1:20; Santa Cruz Biotechnology, 
CA), CD146 (1:300), CD144/VE-cad (1:20) and VEGFR2/Kdr (1:50; all three were from 
Abcam, Cambridge, UK), do not require the permeabilisation step (Direct method). The 
remaining endothelial markers used were vWF (1:60; Abcam, Cambridge, UK) and 
endothelial Nitric Oxide Synthase (eNOS; 1:200; Sigma-Aldrich). Markers used to stain 
for smooth muscle cells were Smooth Muscle α-Actin (1:100; Sigma-Aldrich), Smooth 
Muscle Myosin Heavy Chain II (SM MHC; 1:100; AbD Serotec, Oxford, UK) and 
Calponin (1:600; Abcam, Cambridge, UK).  
2.4.2 Western blot and immunodetection 
 
Prior to carrying out western blot, proteins were extracted from cell samples on ice. Cell 
pellets were collected from scrapping cells grown in 75cm
2
 flasks using cell scrapers. The 
cell pellets were either stored at -80
o
C or continued with protein extraction. The cell pellet 
 - 62 - 
was mixed with 100μl of lysis buffer and sonicated at 4oC to disrupt cell membranes which 
resulted in the release of protein contents. After which, the lysates were left on a rotator 
and incubated for 40 minutes at 4
o
C to lyse. Samples were centrifugated at 4
0
C, 13.2rpm 
for 9 minutes to remove cell debris and 100μl of protein supernatant was collected into pre-
cooled microtubes. Concentrations of proteins were measured in duplicates using the 
BIORAD Protean assay solution (Bio-rad, Herts, UK) diluted at 1:5. 2μl of each protein 
sample was added to 998μl of the diluted BIORAD Protean assay solution (1:500 dilution). 
The mixtures were vortexed and incubated for 10 minutes. Protein contents were measured 
using the spectrophotometer (Bio-rad, Herts, UK) which has a Bradford standard protein 
curve readings already stored in the machine. Lysis buffer and 5X sodium dodecyl dulfate 
(SDS) loading dye were then added into each sample.  
 
Protein samples were either stored at -80ºC or continued with electrophoresis. Prior to 
loading wells of a 4-12% NuPAGE
®
 Novex Bis-Tris Mini Gel (Invitrogen), samples were 
denatured at 96
 O
C for 7 minutes, vortexed and centrifuged. After setting up the XCell 
SureLock™ Mini-Cell (Invitrogen) electrophoresis apparatus and gel, 40μg of each protein 
sample as well as a Precision Plus Protein
TM
 Protein Standard marker (Bio-rad) was loaded 
into the wells of the gel. The distance migrated through the gel is strictly dependent upon 
the molecular weight of the protein. The gel was run at 160V for 2 hours in running buffer. 
After which, the proteins were transferred from the gel onto nitrocellulose membranes (GE 
Healthcare) using the XCell II
TM 
Blot Module (Invitrogen) blotting apparatus. Blotting 
pads, filter papers and membranes were pre-soaked in transfer buffer and assembled as 
shown in Fig.6. The surface of the gel was also wetted with transfer buffer and all trapped 
air bubbles in the setup were removed by rolling over the surface with a roller. The proteins 
were electrotransferred in transfer buffer for 3 hours at 25V, 400mA.  
 
 
 
 
 - 63 - 
 
Fig. 6. A pictorial representation of setting 
up a western blot transfer assembly 
The negatively charged molecules will 
migrate out from the gel and move towards 
the positive electrode which gets deposited 
on the nitrocellulose membrane. 
XCell II
TM
 Blot Module Manual, 
Invitrogen 
 
 
After electrotransfer, the nitrocellulose membrane was blocked with the proteins facing 
upwards, in 5%w/v milk (Marvel) in PBST on a three-dimensional rocker. After 1 hour, 
the membrane was incubated with the respective primary antibodies on the slow rocker 
overnight at 4ºC. Endothelial markers and their respective concentration used were 
CD31/PECAM (1:200), CD144/VE-cad (1:200; both from Santa Cruz Biotechnology, CA), 
eNOS (1:2000; Sigma-Aldrich) and CD146 (1:1000), vWF (1:1000), Kdr (1:500; all three 
were from Abcam, Cambridge, UK). Markers used for detecting smooth muscle cell 
proteins were Smooth Muscle α-Actin (1:2000; Sigma-Aldrich), Smooth Muscle Myosin 
Heavy Chain II (1: 150; AbD Serotec, Oxford, UK). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a housekeeping protein (1:500; Santa Cruz 
Biotechnology, CA). The next day, the membrane was washed 3 times with PBST for 10 
minutes each wash. Secondary horseradish peroxide conjugated antibodies were incubated 
with the membrane at room temperature on the rocker. After 1 hour, the membrane was 
washed again 3 times with PBST for 10 minutes each wash. Finally, the membranes were 
exposed for 2 minutes with ECL-Plus reagents (Amersham Biosciences, Stockholm, 
Sweden) which aid in detecting proteins in the presence of the secondary horseradish 
peroxide conjugated antibodies. The excess reagent was removed from the membrane, 
wrapped in plastic film and secured in an autoradiographic cassette. In the dark room, 
membranes were exposed to Hyperfilm ECL (GE Healthcare) for normally 2-10 minutes 
 - 64 - 
(depending on signal strength) and the protein bands were developed using the developer 
machine (Xograph healthcare, UK).  
 
2.4.3 Flow cytometry 
 
Flow cytometry was carried out either using the direct or indirect method depending on the 
antibody of interest. For both methods, cells were detached by incubating with Collagenase 
IV for 10 minutes followed by trypsin-EDTA (Gibco, Invitrogen) for another 10 minutes. 
The number of cells was counted and centrifuged at 1000 rpm for 5 minutes. Cell pellet 
was washed once with cold PBS and spun again to remove supernatant. 5ml of cold 4% 
Paraformaldehyde was added and incubated on ice for 20 minutes. The mixture was 
centrifuged at 1000 rpm for 5 minutes to remove supernatant. Only for intracellular markers 
detection, 5ml of cold permeabilisation buffer containing 0.1% Triton X-100 in PBS was 
added to the cell pellet, vortexed and incubated for 15 minutes on ice. Removal of 
permeabilisation buffer was carried out by centrifugation at 1500 rpm for 5 minutes. Cells 
were resuspended in 10% FBS to adjust the cell concentration to 1x 10
7
 per ml and 
incubated on ice for 20 minutes to block non-specific antibody binding. Cell suspension 
was aliquoted into individual glass tubes with each to stain for a different fluorochrome-
conjugated antibody. Endothelial markers used were CD146 (1:1000), VEGFR2/Kdr 
(1:250), vWF (1:400; all three obtained from Abcam, Cambridge, UK), and CD31/PECAM 
(1:40), CD144/VE-cad (1:40) (both from Santa Cruz Biotechnology, CA). Markers used to 
stain for smooth muscle cells were Smooth Muscle α-Actin (1:50; Sigma-Aldrich) and SM 
MHC (1:50; AbD Serotec, Oxford, UK). Isotype IgG negative controls and/or additional 
negative control which do not require any addition of primary antibodies were also 
included. The cells and antibody mix were vortexed and incubated at room temperature in 
the dark. After 1 hour, 2ml of cold PBS was added to the mixture, vortexed and 
centrifudged at 1500 rpm for 5 minutes. Supernatant was aspirated and removal of any 
residual liquid from the cell pellet was achieved by dabbing glass tubes onto paper napkins. 
Appropriate secondary antibodies (1:50~100; Sigma-Aldrich and DAKO) resuspended in 
100 µl of cold 10%v/v FBS were added into respective cell pellets and incubated for 30 
minutes at room temperature in the dark. 1.5ml of cold PBS was added to each tube, mixed 
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and centrifudged at 1500 rpm for 5 minutes. Cell pellet was resuspended in 500µl of 1% 
Paraformaldehyde and analyzed with a flow cytometer (Becton Dickinson 
Immunocytometry
 
Systems, Mountain View, CA). Flow cytometry analysis was carried out 
using the CellQuest software (Becton Dickinson Immunocytometry
 
Systems, Mountain 
View, CA). 
 
2.5 Fluorescence-activated cell sorter analysis (FACS)  
 
Cells that had been differentiated for 12 days were detached by incubating with 
Collagenase IV for 5 minutes followed by trypsin-EDTA (Gibco, Invitrogen) for another 5 
minutes. The number of cells was counted using haematocytometer and centrifudged at 50g 
for 5 minutes. Cell pellet was washed once with cold PBS and spun again to remove 
supernatant. Each staining reaction contain 1 x 10
6
 cells which were resuspended in 100μl 
of PBS contaning 10% FBS and 0.1mM EDTA and incubated on ice for 20 minutes to 
block non-specific antibody binding. 1-1.5μg of the respective fluorochrome-conjugated 
antibody was added to each glass tube containing cells. Endothelial markers used were 
CD146 and vWF (Abcam, Cambridge, UK). Isotype IgG negative controls and additional 
negative control which do not require any addition of primary antibodies were also 
included. The mixture was vortexed and incubated on ice in the dark. After an hour, 500μl 
of cold PBS was added to each staining reaction and vortexed. The supernatant was 
removed after centrifudging each staining reaction at 50g for 5minutes. Next, the cell pellet 
was resuspended in 100μl of PBS contaning 10% FBS and 0.1mM EDTA. 2µl of secondary 
antibodies (1:50; Sigma-Aldrich) were added into each tube and incubateed for 30 minutes 
on ice in the dark. After which, cells were washed with 1xPBS and centrifuged to obtain 
cell pellet. The stained cell pellets were resuspended in PBS, filtered using 40μm cell 
strainers (BD Biosciences, Bedford, MA) and centrifuged again. The cells were 
resuspended in 500μl of PBS contaning 1% FBS and 0.1mM EDTA prior to using the cell 
sorter (Becton Dickinson Immunocytometry
 
Systems, Mountain View, CA).  Cells which 
were sorted using FACS were resuspended in EGM-2 medium containing an additional 
12% FBS and seeded onto Collagen I coated wells to settle overnight.
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2.6 Endothelial function tests 
 
2.6.1  In-vitro EC function test 
  2.6.1.1    Formation of vascular structures using MatrigelTM 
 
Pre-chilled 24-well plates were coated with 100µl of Matrigel
TM
 Basement Membrane 
Matrix (BD Biosciences, Bedford, MA) per well and incubated for 30 minutes at 37
o
C 
94
. 3 
x 10
5
 CD146+ sorted cells were counted and plated into each well. These cells were 
allowed to settle for another 30 minutes in the incubator at 37
o
C. Thereafter, 400µl of 
EGM-2 medium (Walkersville, MD) were added to the settled cells and the formation of 
tubes was observed 24 hours later under a conventional microscope (Nikon, Japan).  
 
  2.6.1.2    Dil-labeled acetylated low density lipoprotein uptake and lectin staining 
 
One day prior to staining, 8 x 10
4
 CD146+ cells were seeded into each well of a collagen-I 
coated, 8-well glass-bottomed chamber slide (NUNC, Rochester, NY, USA) and allowed to 
settle overnight 
94
. On the day of staining, culture medium was aspirated and the cells were 
washed once with D-PBS. 2.4μg of Dil-Ac-LDL (AbD Serotec, Oxford, UK) was dissolved 
in serum-free DMEM and added to the cells for an hour incubation at 37
o
C. The mixture 
was aspirated, and the cells were washed with D-PBS twice to remove any remaining Dil-
Ac-LDL. The cells were fixed with 4%v/v formalin for 10 minutes and followed by one 
wash with D-PBS. Next, the cells were further incubated with 10 μg/ml of FITC conjugated 
Lectin from Ulex europaeus (Sigma-Aldrich) at 37
o
C. After an hour, the mixture was 
removed and the cells were washed with D-PBS. The cells were subsequently stained with 
DAPI (1:1000) and the slide was mounted. The stained cells were observed under a 
fluorescent microscope (Axioplan 2 imaging; Zeiss) and images were taken.  
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2.6.2  In-vivo EC function test 
 2.6.2.1    Labelling cells with PKH26 red fluorescent cell linker 
 
Adherent CD146 cells were washed with D-PBS and trypsinised. After 4-5 minutes, the 
cells were washed once with DMEM (Gibco, Invitrogen), collected into a 50-ml tube and 
the total number of cells was determined using a haematocytometer.  A DMEM mixture 
containing 3.5 x 10
6
 cells was aliquoted into a seperate tube and centrifuged at 400x g for 5 
minutes. In the meantime, 4 x 10
-3
mM of PKH26 dye (Sigma, U.S.A) was prepared using 
Diluent C (PKH26 Red Fluorescent Cell Linker Kit; Sigma, U.S.A). PKH26 is a stable 
fluorescent dye with long aliphatic tails which incoroporates into the lipid regions of cell 
membrane 
157
. Diluent C is an iso-osomotic aqueous solution designed to maintain cell 
viability while maximizing dye solubility and staining efficiency. The supernatant was 
aspirated and the cells were resuspended with 175μl of Diluent C. 175μl of the prepared 
PKH24 dye was immediately added to the resuspended CD146 cells, mixed by pipetting 
and incubated at 25 
o
C for 5 minutes. The staining reaction was stopped by adding an equal 
volume (350μl) of FBS (ATCC, Manassas, VA) and incubated for 1 minute. Next, the 
serum-stopped mixture was diluted with another equal volume (700μl) of complete 
medium containing DMEM with 15% FBS. The cells were centrifuged at 400x g for 10 
minutes to remove staining solution. Supernatant was removed and the cell pellet was 
transferred to a new tube for three more washes. In each washing step, 10ml of complete 
medium was used to wash the cell pellet and centrifuged. Finally, the cell pellet was 
resuspended with 50μl of EGM-2 medium .  
 
2.6.2.2 In vivo angiogenesis 
 
PKH26 labeled cells (10
6
 in 50µl) were mixed with 50µl of Matrigel (Becton Dickinson 
Labware) at 4°C, and subcutaneously injected into SCID mice. After 7 days, mice were 
sacrificed and the implants (Matrigel plugs) were harvested, frozen in liquid nitrogen and 
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prepared for H&E staining or used for detection of cell markers by immunofluorescent 
staining.  All animal experiments were performed according to protocols approved by the 
Institutional Committee for Use and Care of Laboratory Animals. Project licence number 
7016458. 
 
2.7 microRNA analysis 
2.7.1  microRNAs (miRNAs) isolation from samples 
Adherent cells were scraped and the collected pellet was snap-frozen in liquid nitrogen for 
storage at -80ºC prior to miRNA isolation. The extraction of miRNA was achieved using 
mirVana™ Protein and RNA Isolation System™ Kit (Applied Biosystems, Ambion Inc). As 
miRNA is susceptible to degradation, the work area was disinfected with 70% Ethanol and 
RNase-free pipette tips and eppendorf tubes were used. Cell pellets were thawed and 625μl 
of ice-cold cell disruption buffer was added. Samples were vortexed to lyse the cells 
completely and to obtain a homogenous lysate. An equal volume of 2X denaturing solution 
at room temperature was immediately added to the lysate to prevent RNA degradation. 
After mixing, 1250μl of Acid-Phenol:Chloroform was added to the mixture and vortexed 
for 1 minute to mix. To separate the mixture into aqueous (upper) and organic (lower) 
phases, the mixture was centrifuged for 5 minutes at 13,000 rpm at room temperature. The 
upper aqueous phase was carefully removed and transferred into a fresh centrifuge tube. 
The volume of 100% ethanol (room temperature) to add to the aqueous phase was 1.25 
times the volume of recovered aqueous phase. Each lysate/ethanol sample was mixed 
thoroughly and aliquoted onto a filter cartridge placed into one of the collection tubes. The 
mixture was centrifuged at 13,000 rpm for 30 seconds. The flow through was discarded and 
centrifugation was repeated until all of the lysate/ethanol samples had filtered through the 
cartridge. 700μl of miRNA Wash Solution 1 was added to the filter cartridge and 
centrifuged for 30 seconds. The flow through was discarded and the filter cartridge was 
washed with 500 μl Wash Solution 2/3. A repeat wash with 500μl Wash Solution 2/3 was 
carried out and flow through was discarded. Residual fluid was removed from the filter 
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cartridge by centrifuging the assembly for 1 minute. The filter cartridge was transferred into 
a fresh collection tube and 100μl of 95ºC preheated Elution Solution was aliquoted to the 
center of the filter. The miRNA eluate was recovered by centrifugation for 30 seconds and 
the concentration of miRNA in each sample was determined using the spectrophotometer. 
The samples were either stored at -80ºC or further processed. 
 
2.7.2 cDNA synthesis and qPCR analysis of miRNAs 
 
The NCode™ VILO™ miRNA cDNA Synthesis Kit (Invitrogen) was used to synthesise poly 
(A) tails of all the miRNAs followed by cDNA synthesis from the tailed population in a 
single reaction. Each single reaction contained 8μl of 5X Reaction Mix, 4μl of 10X 
SuperScript
® 
Enzyme Mix, 2µg of microRNA and topped up to 40μl with DEPC-treated 
water.  The contents were vortexed to mix and centrifuged briefly. The samples were 
placed into a PCR Thermal Cycler which has a programme set at 37ºC for 60 minutes, 
followed by termination of reaction at 95ºC for 5 minutes and  the reaction was held at 4ºC 
until further use. The 50ng/μl cDNA was diluted to a working concentration of 10ng/μl and 
stored at -20ºC.  
 
Quantitative real-time PCR was carried out as mentioned previously, except that each 
master mix reaction contained 10μl EXPRESS SYBR® GreenER ™  qPCR SuperMix 
Universal, 1.5μl of 2μM/L miRNA-specific forward primer, 1.5μl of 2 μM/L Universal 
qPCR Primer (Primer sequences are listed in Table 3), 0.4μl of 25μM ROX Reference Dye 
and 4.6μl DEPC-treated water. The master mix was mixed by vortexing and aliquoted at 
18μl for each reaction in a well of a MicroAmp® Optical 96-well Reaction Plate (Applied 
Biosystems). Each sample was carried out in duplicates. 2μl of 10ng/μl sample cDNA was 
added last to its respective wells. The 96-well plate was sealed with a cover film and 
briefly centrifuged. ABI Prism 7000 (Applied Biosystems) was used to run the PCR 
reaction with one cycle programmed to run at 50ºC for 2 minutes, 95ºC for 10 minutes and  
40 cycles each of 95ºC for 15 seconds and 60ºC for 1 minute. After the reaction has 
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completed, the real-time PCR result was analysed with the ABI Prism 7000 SDS software. 
Housekeeping gene 5.8S was used as normalisation control.  
 
Table 3. Primer sequences used in miRNA qPCR.  
human 5.8s Forward: AGGACACATTGATCATCGACACTTCGA 
 
 
has-mir-141 Forward: GCTAACACTGTCTGGTAAAGATGG 
 
 
has-mir-205 Forward: CTTCATTCCACCGGAGTCTG 
 
 
has-mir-150* Forward: AGGCCTGGGGGACAGAA 
  
has-mir-200c Forward: CTGCCGGGTAATGATGGA 
  
has-mir-1915 Forward: CGACGCGGCGGGAAA 
  
pmiR-Luc-hZEB1 Forward: GACGACACGCGTGACTCAGAGAGCAACAATAC 
 Rerverse: CTCCACAAGCTTGTTAGCACGGGTTGGAACTAC 
 
2.7.3 Transfection of miRNA precursors or inhibitors into hESCs derived ECs  
 
Transfection is the introduction of foreign DNA into a eukaryotic cell and an important tool 
for studying the regulation of gene and protein expression as well as function. Before the 
preparation of transfection complexes, day-6 of differentiating hESCs were trypsinised, 
filtered and counted. Cells were centrifuged, resuspended in EGM-2 medium and separated 
into three tubes, one to be prepared for 24 hours post transfection, 48 hours post 
transfection and the other for 72 hours post transfection. The cell density required per well 
of a 6-well plate was 2x10
5
 cells for 24 and 48 hours and 1.5 x10
5
 cells for 72 hours. The 
prepared cell suspension was placed in 37 ºC incubator while preparing the transfection 
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complexes. Either miRNAs inhibitors or precursors and miRNA negative controls were 
transfected into differentiating hESCs using siPORT
TM
 NeoFX
TM
 transfection agent 
(Ambion, Applied Biosystems). For each reaction, 95μl of warm Opti-MEM (Gibco, 
Invitrogen) was mixed with 5μl of warm siPORTTM NeoFXTM agent by pipetting and 
incubated for 10 minutes at room temperature. While incubating, each miRNA inhibitors or 
precursors and miRNA negative controls (10µM/L, Ambion, Applied Biosystems) were 
diluted by adding 92.5μl Opti-MEM to 7.5μl 10µM miRNA inhibitors, precursors or 
negative controls per reaction. After incubating for 10 minutes, an equal volume of diluted 
siPORT
TM
 NeoFX
TM
 Transfection Agent was combined with an equal volume of the 
diluted miRNA. The mixtures were mixed by pipetting and incubated for 10 minutes at 
room temperature to allow transfection complexes to form. 200μl of transfection complexes 
were added in each well, followed by the addition of 2.3ml of prepared cells. The plates 
were gently tilted back and forth to evenly distribute the complexes and cells in the wells. 
Analysis of miRNAs inhibition or overexpression was carried out in 24, 48 and 72 hours 
post transfection and the collected samples were subjected to cDNA synthesis and real-time 
PCR detection as described previously.  
 
2.7.4  Human ZEB1/TCF8 3’UTR vector  
 
Reporter vector harboring sequences of the human Zinc finger E-box-binding homeobox 1 
(ZEB1), or alternatively known as transcription factor 8 (TCF8), were created using human 
genomic DNA from 6-day pre-differentiated hESCs. The 3’-flanking untranslation region 
(3731bp/3993bp) of human ZEB1 gene was amplified by PCR with primers shown in Table 
3 and cloned into the pmiR-reporter-basic vector (Ambion, Applied Biosystems), 
designated as pmiR-Luc-hZEB1. The vector was verified by DNA sequencing.  
 
2.7.5  Luciferase activity assay 
 
hESC-derived CD146-positive cells (40,000 cells per well of a 24-well plate) were co-
transfected with pRenilla (25ng/well), pmiR-Luc-hZEB1 (150ng/well), and negative 
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control miR precursor, miR-200c precursor or miR-150* precursor (20nM), by using 
siPORT
TM
 NeoFX
TM
 transfection agent (Ambion, Applied Biosystems) according to the 
manufacturer's instructions. The cells were then cultured on collagen-I-coated
 
24-well plate 
for 48 and 72 hours.
 
Luciferase and Renilla activities were
 
detected after transfection using 
a standard protocol.
 
Relative luciferase unit (RLU) was defined as the ratio of Firefly
 
versus 
Renilla with that of the control set as 1.0. At least, three independent transfections were 
performed in triplicates.
 
 
 
2.7.6 In vivo transfection of miRNA inhibitors into developing chick embryos using 
Chorioallantoic membrane assay 
 
Fertilized chick eggs were obtained from Joyce and Hill Farm and incubated at 38.5°C in a 
humidiﬁed incubator. Hamburger and Hamilton (HH) staging was applied throughout the 
experiment 
158
. 
Before the start of the experiment, the eggs were incubated until around HH10. After 
sterilising the surface of the egg shell with 70% ethanol, a window was opened at the side 
of the egg with a blade. As described previously (in section 2.7.3), transfection complexes 
containing siPORT NeoFX Transfection Agent and miRNA miR200c inhibitor or control 
were made prior to the administration of the complexes. Using a microinjector, 100µl of 
miR200c inhibitor or control was injected beneath the the right hand side of the 
choroallantoic membrane (CM). The eggs were then sealed tight with tape and placed back 
into the 38.5°C incubator slowly, window side up. The eggs were incubated for the next 
few days until HH20. Photos were taken using Nikon stereomicroscope SMZ800 after 
exposing the CM. Then the left hemisphere of CM and right hemisphere of CM (the 
anterior/posterior omphalomesenteric vein is regarded as the middle line) were harvested 
separately for total RNA extraction for miRNA and mRNA identification. Using a 
grayscale program in Adobe Photoshop, the area of observed blood vessels at both 
sides of the chick embryo were analysed.  
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2.8 Contractililty assay for assessing smooth muscle cell function 
 
Day 9 hESCs derived SMCs were cultured on collagen type IV coated 48-well plate and 
washed once with PBS prior to stimulation with the agonist. Potassium Chloride (KCl; 
BDH, AnalaR, Poole, England) was used as an agonist to assess the contractility ability of 
SMCs. A serial dilution of KCL in differentiation medium was used at 20mM/L, 40mM/L, 
60mM/L and 80mM/L. Using the microscope camera (Nikon, Japan), images of the same 
field were captured prior to stimulation and during different time points of agonist-
induction at 5 minutes, 15 minutes and 25 minutes.   
 
2.9 Statistical analysis 
 
All statistic analyses were carried out using GraphPad Prism 4.00 software (CA, USA). 
Data were presented as mean + Standard error of the mean (SEM). Statistical significance 
was determined using statistical tests such as Student t test and One-way analysis of 
variance (Anova). P-values less than 0.05 were considered statistically significant. 
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CHAPTER 3 
Results 
 
 
3.1 Undifferentiated hESCs express pluripotent markers 
 
It is crucial to maintain and characterize the undifferentiated status of hESCs prior to 
undergoing any further experiments. To this end, the pluripotency of undifferentiated 
hESCs cultures was first determined by carrying out alkaline phosphatase (AP) and 
immunocytochemistry staining on undifferentiated hESCs grown on mouse embryonic 
feeders (MEFs). All hESCs colonies appeared reddish-purple after staining with the AP 
reagent, indicating that these colonies were positive for AP activity (Fig.7) which is one of 
the fundamental characteristics of undifferentiated hESCs. Moreover, a range of human ES 
cell-specific pluripotent surface markers such as SSEA4, TRA-1-60 and TRA-1-81, in 
addition with transcription factors OCT3/4 and SOX2, were also strongly expressed in 
undifferentiated hESCs cultures as demonstrated by immunofluorescence staining with the 
respective specific antibodies (Fig.8A). However, immunocytochemistry staining with the 
differentiated marker SSEA1 appeared negative (Fig.8B). These findings demonstrated that 
hESCs cultured using the current cell culture system is effective in maintaining pluripotent 
and undifferentiated hESCs. Hence, it also shows that these hESCs are suitable for further 
use in vascular cell lineage differentiation.  
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Fig. 7.  AP activity in undifferentiated hESCs. 
Undifferentiated hESCs colonies were grown on MEF monolayer for 5 days and stained 
with AP reagents. Images were taken under a conventional microscope. Bar = 100 µm
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Fig. 8.  Pluripotency status in undifferentiated hESCs culture. 
(A) Undifferentiated hESCs were grown for 4 days on MEFs in the presence of human 
basic FGF-2 and immunostained with pluripotent markers (from Top to Bottom) SSEA4, 
TRA-1-60, TRA-1-81, OCT3/4 and SOX2. (B) Undifferentiated hESCs were also stained 
with SSEA1 (left) and counterstained with DAPI (middle). All images were taken under a 
fluorescent microscope. Bar = 150 µm. 
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3.2 hESCs differentiate towards the endothelial lineage 
 
Pluripotent hESCs have the capability to differentiate into three germ layers, namely the 
ectoderm, endoderm and mesoderm. Based on this theory, undifferentiated hESCs were 
further cultured in EC differentiation medium (EGM-2) to derive ECs. During the 9 days 
period of differentiating hESCs towards the endothelial lineage, expression of EC markers 
was analysed to determine whether the differentiation protocol was successful in deriving 
ECs. A set of EC markers was analysed using real-time PCR (Figs 9-13), western blot 
(Fig.14), immunocytochemistry (Figs 15-20) and flow cytometry (Fig.21).   
 
3.2.1 Endothelial-specific genes were upregulated in differentiating hESCs during 
different differentiation time points  
 
To drive endothelial cell differentiation from hESCs, undifferentiated hESCs were plated 
onto Matrigel
TM
 Basement Membrane Matrix (BD Biosciences, Bedford, MA) coated 
dishes or plates and cultured in EGM-2 medium for the indicated experimental time-points. 
Total RNA and protein were extracted and subjected to RT-PCR and western blot analysis, 
respectively. Majority of the real-time RT-PCR analysis of mRNA levels in EC gene 
marker expression revealed a trend in increasing levels of CD144/VE-cad (Fig.9), vWF 
(Fig.11) and Kdr (Fig.12) as the period of differentiation increased. Gene expressions of 
CD144/VE-cad, vWF and Kdr at day 9 were significantly elevated as compared to 
expression at day 0 control levels (Figs. 9, 11, 12). mRNA level of CD146 expression 
however, was significantly increased at day 3, and declined at days 5, 7 and 9 (Fig.10.)  In 
contrast, expression levels of undifferentiated marker Nanog were significantly decreased 
at days 5, 7, and 9 as compared to day 0 (Fig.13.). Taken togther, these data demonstrated 
an increase in the expression of several EC genes during hESCs differentiation, mostly 
reaching maximum levels at around day 9.  
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Fig. 9. Gene expression of CD144/VE-cad in differentiating hESCs over a period of 9 
days. 
Clumps of undifferentiated hESCs colonies were seeded on matrigel and cultured in EGM-
2 medium for 3, 5, 7 and 9 days. During each respective time-point, RNA was extracted, 
reversed transcribed to cDNA as previously described and subjected to real-time PCR 
analysis. Day 0 (control) samples were obtained from undifferentiated hESCs. Data 
represent mean + SEM of three independent experiments (n=3). Data normalized to 18S 
and presented relative to day 0 expression.* Relative expression of CD144/VE-cad at day 9 
was significantly different from day 0; p< 0.05, One-way analysis of variance (Anova) 
followed by Bonferroni's Multiple Comparison Test.  
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Fig. 10. Gene expression of CD146 in differentiating hESCs over a period of 9 days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression.* Relative expression of CD146 at day 3 
was significantly different from day 0; p< 0.05, Paired t-test followed by one tailed test. 
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Fig. 11. Gene expression of vWF in differentiating hESCs over a period of 9 days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. * Relative expression of vWF at day 9 was 
significantly different from day 0; p< 0.05, Paired t-test followed by one tailed test. 
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Fig. 12. Gene expression of Kdr in differentiating hESCs over a period of 9 days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. * Relative expression of Kdr at days 7 and 9 
were significantly different from day 0; p< 0.05, Paired t-test followed by one tailed test. 
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Fig. 13. Gene expression of Nanog in differentiating hESCs over a period of 9 days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. *** Relative expression of Nanog at days 5, 
7 and 9 were significantly different from day 0; p< 0.001, One-way Anova, followed by 
Bonferroni's Multiple Comparison Test.  
 
3.2.2 Western blot analysis of endothelial-specific marker expression in 
differentiating hESCs during different time points  
 
Since gene expression usually results in the subsequent formation of functional proteins, 
western blotting was carried out to determine the synthesis of each endothelial specific 
gene expression product. The majority of endothelial protein markers were expressed in an 
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marker vWF has a molecular weight of 300kDa and was detected at days 5-9. The protein 
expressions of functional endothelial marker eNOS and two endothelial cell surface 
markers (CD31 and CD146), appeared at day 3 and increased gradually till day 9. 
However, a distinct band with a molecular weight of 130 kDa for CD144/VE-cad appeared 
later only at day 9. Taken together, the data strongly suggest that the endothelial cell 
lineage can be successful differentiated from hESCs. Importantly, all of the above 
mentioned EC markers were undetectable in control day 0 samples, which further confirm 
its undifferentiated state of human ES cells.  
 
Fig. 14. Western blot analysis of hESCs derived ECs over a 9 day differentiation 
period.  
 
Undifferentiated hESCs were differentiated in EGM-2 medium and grown over a period of 
9 days. As previously described, protein samples were extracted from differentiating hESCs 
during days 3, 5, 7 and 9. 40μg of each protein sample was loaded into each well, blotted 
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and probed with endothelial specific antibodies CD31/PECAM-1, CD144/VE-cad, eNOS, 
vWF and CD146 (Top to Bottom). Each immunoblot was again reprobed with GADPH, a 
housekeeping protein to show the total sample loading in each well (Lower panel). Day 0 
samples were obtained from undifferentiated hESCs. (n=3) 
 
3.2.3 Immunocytochemistry staining on day 9 hESCs derived endothelial cells  
 
In this study, data from RT-PCR and western blot analysis have showed upregulation of 
mRNA and protein levels of endothelial cell lineage-specific markers in the mixed 
population of differentiating hESCs under this culture condition. However, the visual 
localisation of these proteins and their expression patterns in individual cells were still 
unclear. To achieve this aim, immunocytochemistry was carried out in day 9 hESCs 
differentiated cells when most of the EC markers were maximally expressed as compared 
to day 0 control (Fig.9-14) with antibodies against endothelial cell lineage-specific markers. 
As expected, CD31/PECAM-1 was found distributed at the intercellular clefts (Fig.15) and 
CD144/VE-cad (Fig.16) as well as CD146 were localised at cell-cell adhesion sites 
(Fig.17). One of the mature EC marker, eNOS which regulates vascular tone, was found 
expressed in the cytoplasm compartment (Fig.18). Kdr was also detected on cell surfaces 
(Fig.19). Another mature marker vWF was found localised as large granules in the 
cytoplasm (Fig.20). In conclusion, day 9 hESCs derived ECs displayed the proper 
organisation of protein endothelial junctions. 
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Fig. 15. Expression of CD31/PECAM-1 in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with CD31/PECAM-1 primary 
antibody followed by polyclonal rabbit anti-goat IgG immunoglobulins TRITC. Anti-
clockwise from upper right. Fluorescent images were captured on CD31/PECAM positive 
cells (upper right), nucleic acid stains (DAPI) in individual cell (upper left) and an 
overlapped image depicting the localisation of both CD31/PECAM-1 and DAPI. Bar = 20 
µm.  
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Fig. 16.  Expression of CD144/VE-Cad in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with CD144/VE-cad primary 
antibody followed by polyclonal goat anti-mouse IgG immunoglobulins FITC. Anti-
clockwise from upper right. Fluorescent images were captured on CD144/VE-cad positive 
cells (upper right), nucleic acid stains (DAPI) in individual cell (upper left) and an 
overlapped image depicting the localisation of both CD144/VE-cad and DAPI. Bar = 20 
µm.  
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Fig. 17. Expression of CD146 in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with CD146 primary antibody 
followed by polyclonal goat anti-mouse IgG immunoglobulins FITC. Anti-clockwise from 
upper right. Fluorescent images were captured on CD146 positive cells (upper right), 
nucleic acid stains (DAPI) in individual cell (upper left) and an overlapped image depicting 
the localisation of both CD146 and DAPI. Bar = 20 µm  
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Fig. 18. Expression of eNOS in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with eNOS primary antibody 
followed by polyclonal goat anti-Rabbit IgG immunoglobulins TRITC. Anti-clockwise from 
upper right. Fluorescent images were captured on eNOS positive cells (upper right), nucleic 
acid stains (DAPI) in individual cell (upper left) and an overlapped image depicting the 
localisation of both eNOS and DAPI. Bar = 20 µm    
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Fig. 19. Expression of Kdr in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with Kdr primary antibody 
followed by polyclonal goat anti-Rabbit IgG immunoglobulins TRITC. Anti-clockwise from 
upper right. Fluorescent images were captured on Kdr positive cells (upper right), nucleic 
acid stains (DAPI) in individual cell (upper left) and an overlapped image depicting the 
localisation of both Kdr and DAPI. Bar = 20 µm. 
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Fig. 20 Expression of vWF in hESCs-derived ECs. 
Day 9 differentiated hESCs grown in EGM2 were probed with vWF primary antibody 
followed by polyclonal goat anti-Rabbit IgG immunoglobulins TRITC. Anti-clockwise from 
upper right. Fluorescent images were captured on vWF positive cells (upper right), nucleic 
acid stains (DAPI) in individual cell (upper left) and an overlapped image depicting the 
localisation of both vWF and DAPI. Bar = 20 µm. 
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3.2.4 Flow cytometry analysis of endothelial-specific proteins during hESCs 
differentiation towards the endothelial lineage and cell sorting 
 
As a heterogeneous population of cells was observed in this EC differentiating culture 
condition, the isolation of pure EC population is a critical requirement for in vivo cell 
therapy.  It is important to further quantify, analyse and characterise the differentiating 
heterogeneous hESC population grown in endothelial differentiating conditions with flow 
cytometry analysis. Moreover, differentiated cells expressing endothelial surface markers 
will be subjected to cell sorting from this mixed population and flow cytometry analysis 
will aid in selecting the best marker and the most suitable differentiation day to proceed 
with cell sorting.  
 
At differentiation day 7, flow cytometry analysis indicated that 16.4% of the cell population 
expressed CD146 (Fig.21A Top). It subsequently increased approximately two-fold at 
34.1% at day 17 (Fig.21A Bottom). Only 12.7% of cells expressed vWF at day 13 
(Fig.21B). Determination of the accuracy and functionality of the antibodies used was 
analysed on a different cell population, human umbilical vascular endothelial cells 
(HUVECS). HUVECS express EC markers and widely used as an EC positive control in 
experiments. In the flow cytometry analysis, 97.3% of HUVECs expressed CD31/PECAM-
1 (Fig.21C), 86% expressed CD146 and more than half of the population expressed vWF at 
69% (Fig.21C). The ability of the antibodies to detect protein markers in HUVECs 
indicated that previous flow cytometry analyses on differentiating hESCs were true 
observations.  
 
Next, the heterogeneous population of differentiating hESCs was subjected to cell sorting 
to obtain pure population of CD146+ cells. The percentage of CD146+ cells obtained 
during cell sorting was 96.5% (Fig.22A & B). These CD146+ sorted cell population was 
further cultured and expanded in vitro.   
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Fig. 21. Flow cytometry analysis of endothelial markers in differentiating hESCs 
towards the endothelial lineage and HUVECS 
Clumps of undifferentiated hESCs were seeded on Matrigel
TM
 coated T75cm
2
 flasks in 
EGM-2 medium and grown for a period of 7, 13 and 17 days respectively. (A) Cells were 
then used for flow cytometry analysis for CD146 marker. (B) Cells were differenatiated at 
day 13 subjected to flow cytometry analysis for vWF expressions. Left.  Histogram of IgG 
isotype negative controls (NC) used in the experiments. Right. Blue histogram depicting the 
flow cytometry analysis of CD146 or vWF expressing cells. Green histogram represents the 
same IgG isotype negative controls (NC) from the left-hand side. (C) HUVECS were also 
subjected to flow analysis to demonstrate the expression of EC protein markers. Anti-
C 
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clockwise Green histogram depicts the percentage of CD31/PECAM-1 positive HUVECS, 
followed by the percentage of CD146 and vWF positive HUVECS. Blue histogram 
represents IgG isotype NC. 
 
 
 
 
 
 
 
 
 
 
Fig. 22 The percentage of CD146 positive cells obtained during cell sorting. 
Clumps of undifferentiated hESCs were seeded on Matrigel
TM
 coated flasks and grown for 
a period of time. (A) Cells were then analysed for CD146 expressions. (B) A FACS 
histogram analysis of the percentage of CD146+ cells which were cell sorted from the 
heterogeneous differentiated hESCs. 
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3.3 Characterisation of CD146+ cells indicate that these cells are capable of 
displaying EC features 
 
As part of the characterization study, endothelial function tests were carried out on in vitro 
derived endothelial cells from hESCs after in vitro expansion to ensure that these cells 
behave like their mature endothelial counterparts. A variety of in vitro endothelial function 
tests include investigating endothelial cell surface marker expression such as vWF, Dil-Ac-
LDL uptake,  lectin binding and the ability to form vascular structures using matrigel 
assays. 
3.3.1  Cell morphology, immunocytochemistry and flow cytometry analyses of 
expanded CD146+ cells in-vitro 
 
CD146+ cells isolated from the heterogeneous differentiated endothelial cell population 
were expanded in vitro. Early microscopic examinations of cell sorted CD146+ cells grown 
in EGM-2 medium revealed that 2 different cell phenotypes were observed (Fig.23A). Both 
cobblestone and spindle-shaped, fibroblast or SMC-like cells were present in passage 4 
CD146+ cell culture. However, as the passage number of the cell culture increased, the 
spindle-shaped, fibroblast or SMC-like cells were absent and only a population of cells 
with cobbled-stone morphology was observed (Fig.23B). Immunocytochemistry analysis 
showed that these cells were positive for EC specific markers such as vWF (Fig.24A), 
eNOS (Fig.24B), CD31/PECAM-1 (Fig.24C) and CD144/VECAD (Fig.24D). Flow 
cytometry was also carried out to analyse EC markers on in vitro expanded CD146+ cells. 
As shown in Fig.25, the percentage of cell postive for CD146, vWF, CD144 and CD31 
cultured in the first passage were found to be at 71.6%, 21%, 11.9% and 5.5% respectively 
(Fig.25) and  which subsequently increased to 75.6%, 29.4%, 15.6% and 6.9% at passage 5.  
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Fig. 23. A bright-field microscopic morphology of CD146+ sorted cells in-vitro culture 
CD146+ cells were cultured on 5µg/ml Collagen I coated flask and in the presence of 
EGM-2 medium. Cells were passaged twice a week and medium was changed every 2 days. 
(A) Left  Cell sorted population of CD146+ cells were expanded in vitro. After 4 passages, 
2 different cell phenotypes were observed in the cell culture. Right A higher magnified 
view of the same population of cells. (B) Left At passage 9, only a population of cells with 
cobbled-stone morphology was observed. Right A higher magnified view. Note the 
columnar arrangement of cells. 
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Fig. 24 Expression of EC markers in CD146+ sorted cells 
Immunocytochemistry staining was carried out in isolated CD146+ passage 10 sorted cells 
and their fluorescent images were captured. (A) Cells were co-stained with CD146 and 
vWF. These CD146+ cells were also stained with other EC markers such as eNOS (B), 
CD31/PECAM-1 (C) and CD144/VECAD (D). To localise nucleic acid, each individual 
cell was also stained with DAPI. 
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Fig. 25. Flow cytometery analysis of CD146+ cells after cell sorting.   
After cell sorting, CD146+ cells were grown in EGM-2 and seeded onto Collagen I coated 
wells. These cells were expanded in vitro and subjected to flow analysis to determine the 
expression of EC protein markers. Here a bar graph depicts the expression levels of EC 
markers after CD146+ cells sorting at passages1 and 5.  
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3.3.2  CD146+ cells display functional EC properties in vitro and in vivo 
 
To further characterize these CD146+ cells, function tests such as Dil-Ac-LDL uptake, 
lectin binding and in vitro/vivo vasculogenesis using matrigel assays were later carried out 
on in-vitro expanded CD146+ cells. As expected, these expanded CD146+ cell population 
were capable of Dil-Ac-LDL uptake, lectin binding (Fig.26), as well as forming vascular 
structures in Matrigel
TM
 in vitro (Fig.27A) and in vivo (Fig.27B). The combination of all 
these tests demonstrated that the CD146+ cell population could function as mature 
endothelial cells in vitro and in vivo. 
 
 
Fig. 26. In vitro expanded CD146+ cells display Dil-Ac-LDL uptake and lectin binding 
Function tests such as Dil-Ac-LDL uptake and lectin binding stainings were carried out on 
in vitro expanded CD146+ cells. Clockwise: Upper Left An overlapped image depicting the 
localisation of lectin, DAPI and Dil-Ac-LDL. Images for individual localisation for DAPI 
(nuclear) upper right, Dil-Ac-LDL lower right and lectin lower left were also captured.  
           Merge DAPI 
Lectin Dil-Ac-LDL 400x 
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Fig. 27. Formation of vascular structures using Matrigel
TM
 assays 
The ability of CD146+ cells to form vascular network in vitro and in vivo, was assessed by 
using Matrigel
TM
. (A) Left  Expanded CD146+ cells were seeded onto a Matrigel
TM
-coated 
surface and 2 hours later, an early formation of a network was observed using bright-field 
microscopy, Right 24 hours since plating, vascular networks were observed. (B)  In vivo 
Matrigel
TM
 plug assay was carried out in SCID mice using CD146+ cells labeled with red 
fluorescent dye (PKH26) and assessed 1 week later. Left From a section of the implanted 
Matrigel
TM
 plug, red fluorescent labeled CD146+ cells were incorporated within a vascular 
structure. Right H&E staining of a section of the implanted Matrigel
TM
 plug which showed 
a complex vascular network which had formed in the presence of the transplanted CD146+ 
cells. 
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3.4 Identification of miRNAs involved in hESCs differentiation towards the 
EC lineage  
 
As previously mentioned, miRNAs play various physiological and pathological roles in the 
cardiovascular system, such as cardiovascular system development and cell differentiation 
112, 146-149, 152
 . We therefore hypothesize that one or more miRNAs may be involved in 
endothelial cell differentiation from hESCs. Potential miRNAs involved during endothelial 
differentiation were selected using miRNA array analysis (Fig.28). Their biological 
functions were further analysed by inhibiting or enhancing their expression and 
determining if these influence the expression of EC levels (Figs. 30-31). 
 
3.4.1 Screening for potential miRNAs during differentiation towards the EC 
lineage 
 
To determine which miRNAs were enriched during the differentiation of hESCs into ECs, 
miRNA array expression profiling (miRXplore
TM
 Microarrays) was carried out on samples 
collected during the 9-day differentiation period by the RNA expression experts from 
Miltenyi Biotec GmbH (Germany). Five potential upregulated miRNAs were selected from 
the miRNA array analysis and further validated using quantitative real-time PCR. These 
miRNAs are miR-150*, miR-1915, (Fig.28A) and miR-200 family members, miR-141, 
miR-205 and miR-200c (Fig.28B). All five miRNAs were selected as they were enriched 
and displayed a time-dependent increase in expression during the differentiation of hESCs 
towards the EC lineage (Fig.28C). Expression of miR-150* at day 9 was increased nearly 
2-fold as compared to day 0 (control) undifferentiated hESCs (Fig.28A Left). Whereas 
expressions of miR-1915 (Fig.28A Right) and the miR-200 family members, miR-141 
(Fig.22B Right) and miR-200c (Fig.28B Middle) were increased nearly 3-fold at day 9 
compared to day 0. A 4.5-fold increase in miR-205 (Fig.28B Right) expression at day 9 was 
the highest observation among the miRNAs.  
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miRNA name Day 3 Day 6 Day 9 
hsa-miR-141 1.61627 1.648101 2.495403 
hsa-miR-205 1.939123 2.332433 3.234446 
hsa-miR-150* 1.986847 2.812245 4.209275 
hsa-miR-200c 2.576935 2.507951 3.607276 
hsa-miR-1915 5.408016 8.339838 18.133837 
Angiogenesis       
hsa-miR-126 ND ND 1.249804 
hsa-miR-210 ND ND 1.241585 
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hsa-miR-130a 0.906145 0.945844 1.271549 
Anti-Angiogenesis       
hsa-miR-221 0.612299 0.58712 0.572099 
Differentiation       
hsa-miR-145 ND ND 1.746961 
 
 
Fig. 28. The expression patterns of a set of five enriched miRNAs chosen from the 
miRNA array analysis. 
Undifferentiated hESCs were differentiated towards the endothelial lineage for 9 days as 
previously described. During differentiation, miRNAs were isolated from each time points 
of days 3, 6, and 9. Day 0 (control) samples were obtained from undifferentiated hESCs. 
All miRNA samples were sent for miRNA array analysis. After which, 5 potential 
upregulated miRNAs were selected from the analysis and the data was collated into 
histograms. (A) Histograms showing the expression patterns of miR-150* Left, miR-1915 
Right. (B) Histograms showing the expression patterns of the miRNA 200 family members 
miR-141 Left and miR-200c Middle and miR-205 Right. The histograms represent an 
average of three independent experiments with standard deviations. Data normalized to 5.8s 
and presented relative to day 0 expression, which was set as 1.0. (C) A summary list of 
miRNAs selected from the miRNA array analysis. (ND=Not detected) 
 
3.4.2 miRNA transfection efficiency 
 
Examination into which of the selected potential miRNAs are involved in hESCs 
differentiation to ECs, was achieved by inhibiting or enhancing their expression and then 
analysing whether these effects would affect EC expression in the differentiated cells. To 
achieve this, transfections with miRNA inhibitors or precursors were carried out in day 6 
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differentiating hESCs using siPORT NeoFX Transfection Agent. An important step prior to 
carrying out transfection assays is to determine the success rate of the transfection 
experiment. This was carried out by transfecting differentiated hESCs with Cy3-labeled 
Anti-miR Negative Control (Ambion, Applied Biosystems) to monitor transfection 
efficiency. It was observed that after 48 hours transfection with Cy3-labeled Anti-miR 
Negative Control, 87.41% (Fig.29A) of the transfected cells were Cy3-labeled and at 72 
hours post transfection, 83.27% of the transfected cells were positively labeled with Cy3 
(Fig.29B).  
 
 
Fig. 29. Determination of transfection efficiency using FACS 
Day 6 differentiated hESCs grown in EC conditions were transfected with Cy3-labeled 
Anti-miR Negative Control (Ambion, Applied Biosystems). These cells were assessed 
A 
B 
87.41% 
83.27% 
Cy3 (TRITC) 
Cy3 (TRITC) 
48 hours 
72 hours 
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using flow cytometry 48 and 72 hours post transfection. (A) A flow cytometry histogram 
showing 48 hours post transfection with Cy3-labelled miRNA inhibitor. (B) A flow 
cytometry histogram showing 72 hours post transfection with Cy3-labelled miRNA 
inhibitor. Green histogram depicts controls which were non-transfected day 6 hESCs.  
3.4.3 Expression of EC markers (RNA and Protein) in miR-150* and 200c 
inhibition and over expression studies 
 
The previous determination of optimal parameters for carrying out miRNA transfection 
assays will facilitate the subsequent inhibition and overexpression assays for the selected 
miRNAs. Real-time PCR results in inhibition studies showed that the expression levels of 
miR-150* and 200c were significantly decreased after 24 hours tranfection as shown in 
Fig.30A i and ii as compared to control. To determine if these miRNAs are related to EC 
differentiation from hESCs, further analyses in the expression levels of specific endothelial 
markers from the same samples were carried out using real-time PCR and western blotting.  
 
In miR-150* inhibition, the mRNA expression levels of EC markers such as vWF, Kdr, 
CD144 and CD146 were significantly downregulated as compared to control (Fig.30Ai). 
As expected, inhibition of miR-200c also significantly downregulated mRNA levels of 
vWF, CD144, Kdr and CD146 (Fig.30Aii) as compared to control. In order to determine if 
the protein levels of the EC markers were also influenced by the inhibition of miR-150* 
and 200c in hESCs differentiation, western blot analysis was carried out. It was 
demonstrated that as compared to control, the protein expression levels of CD146 and 
CD144 were significantly downregulated by the inhibition of miR-150* and 200c 
(Fig.30B).  
Next, overexpression studies with miRNA precursors were carried out to validate the above 
mentioned results achieved in the inhibition studies on miR-150* and 200c. mRNA 
expression levels of miR-150* was significantly increased compared to control (Fig.31Ai). 
Importantly, the overexpression of miR-150* precursor into the cells significantly 
upregulated mRNA levels of specific EC markers such as vWF, Kdr, CD144 and CD146 as 
compared to control (Fig.31Ai). Similar results were also obtained from miR-200c 
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overexpression experiments (Fig.31Aii). Western blot analysis of samples transfected using 
the same treatments in Fig.31A showed that similar results were obtained. Protein levels of 
EC markers such as CD146, CD144 and vWF were significantly upregulated as compared 
to controls in miR-150* overexpression assays (Fig.31B). Whereas in miR-200c 
overexpression assays, protein levels of CD144 and CD146 were upregulated (Fig.31B). 
Taken together, miR-150* and 200c might play a role in hESCs differentiation towards the 
EC lineage.  
A, i 
 
 
 
 
 
 
 
 
 
 
 
A, ii 
 
 
 
 
 
 
 
 
Kdr 
Kdr 
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Fig. 30. miR-150* and 200c inhibition downregulate the expression of EC markers in 
day 6 differentiating hESCs 
(A) Real-time PCR analysis of EC expression markers after miR-150* and miR-200c 
inhibition. i) Day 6 differentiating hESCs were transfected with miR-150* inhibitor and 
Anti-miR Negative Control. EC mRNA expression levels were analysed at 24 hours post 
transfection using real-time PCR as previously described in methods. Each column 
represent mean + SEM of three independent experiments (n=3). Data normalized to 5.8s 
and presented relative to control expression. * p< 0.05 (vesus control), Paired t-test 
followed by two tailed test. ii) Day 6 differentiating hESCs were transfected with miR-200c 
inhibitor and Anti-miR Negative Control. EC mRNA expression levels were analysed at 24 
hours post transfection using real-time PCR as described in methods. Each column 
represent mean + SEM of three independent experiments (n=3). Data normalized to 5.8s 
and presented relative to control expression. * p< 0.05 (versus control), Paired t-test 
followed by two tailed test.  
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(B) Protein analysis of EC expression levels in differentiated hESCs after 24 hours inhibitor 
post transfection. Day 6 differentiating hESCs were transfected with miR-150* and miR-
200c inhibitors as well as Anti-miR Negative Control. After 24 hours post transfection, 
protein samples were extracted and subjected to western blot as previously described. 40μg 
of each protein sample was loaded into each well, blotted and probed with endothelial 
specific antibodies CD146 and CD144/VE-cad. GADPH, a housekeeping protein was 
included to show the total sample loading in each well. 
 
 
 
A, i). 
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Fig. 31 mirRNAs 150* and 200c overexpression upregulate the expression of EC 
markers in day 6 differentiating hESCs 
(A) Real-time PCR analysis of EC expression markers after miR-150* and miR-200c 
overexpression. i) Day 6 differentiating hESCs were transfected with miR-150* precursor 
and Pre-miR miRNA Precursor Negative Control. EC mRNA expression levels were 
analysed at 24 hours post transfection using real-time PCR as previously described in 
methods. Each column represent mean + SEM of three independent experiments (n=3). 
Data normalized to 5.8s and presented relative to control expression. P < 0.05 (versus 
control), paired t test followed by one-tail test. ii) Day 6 differentiating hESCs were 
transfected with miR-200c precursor and Pre-miR miRNA Precursor Negative Control. EC 
mRNA expression levels were analysed at 24 hours post transfection using real-time PCR 
as described in methods. Each column represent mean + SEM of three independent 
experiments (n=3). Data normalized to 5.8s and presented relative to control expression. * 
P < 0.05 (versus control), paired t test followed by one-tail test.  
(B) Protein analysis of EC expression levels in differentiated hESCs after 24 or 48 hours 
overexpression post transfection. Day 6 differentiating hESCs were transfected with miR-
150* and miR-200c precursor as well as Pre-miR miRNA Precursor Negative Control. 
After 24 hours post transfection, protein samples were extracted and subjected to western 
blot as previously described. 40μg of each protein sample was loaded into each well, 
blotted and probed with endothelial specific antibodies CD146 and CD144/VE-cad. 
GADPH was included as internal control to show the total sample loading in each well. 
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3.4.4 miR-1915, 141 and 205 inhibition did not affect the expression of EC 
markers in hESCs differentiation 
 
Inhibition studies were also carried out to determine the functional involvement of the 
remaining three potential miRNAs (miR-1915, 141 and 205), whose expressions were also 
upregulated during hESCs differentiation towards the EC lineage. Unlike miR-150* and 
200c, these miRNAs did not inhibit mRNA expression of EC markers after 24, 48 and 72 
hours transfection (Fig.32 A-C), indicating that these miRNAs play no major role in EC 
differentiation from hESCs. 
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Fig. 32. mirRNAs 1915, 141 and 205 inhibition fail to downregulate the expression of 
EC markers in day 6 differentiating hESCs 
Real-time PCR analysis of EC expression markers after miR-1915, 141 and 205 inhibition. 
(A)  Day 6 differentiating hESCs were transfected with miR-1915 inhibitor and Anti-miR 
Negative Control. EC mRNA expression levels were analysed at 24, 48 and 72 hours post 
transfection using real-time PCR as previously described in methods. Each column 
represent mean + SEM of three independent experiments (n=3). Data normalized to 5.8s 
and presented relative to control expression. (B) Day 6 differentiating hESCs were 
transfected with miR-141 inhibitor and Anti-miR Negative Control. EC mRNA expression 
levels were analysed at 24, 48 and 72 hours post transfection using real-time PCR as 
described in methods. Each column represent mean + SEM of three independent 
experiments (n=3). Data normalized to 5.8s and presented relative to control expression. 
(C) Day 6 differentiating hESCs were transfected with miR-205 inhibitor and Anti-miR 
Negative Control. EC mRNA expression levels were analysed at 24, 48 and 72 hours post 
transfection using real-time PCR as described in methods. Each column represent mean + 
SEM of three independent experiments (n=3). Data normalized to 5.8s and presented 
relative to control expression. 
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3.5 ZEB1/TCF8 is identified as the mRNA target for miR-150* and 200c in 
differentiating hESCs towards the EC lineage 
 
To further investigate the mechanisms by which miR-150* and 200c regulate endothelial 
biology, potential mRNA targets were searched. Predictions of targets for miR-150* and 
200c were carried out using PicTar (http://pictar.mdc-berlin.de), a miRNA target prediction 
algorithm program tool 
159
. Two potential targets, c-Myb and ZEB1/TCF8 were selected 
based on the high degree of sequence complementarity between the 5’ end of the miRNA 
and the 3’UTR mRNA target.  
 
3.5.1 c-Myb and ZEB1/TCF8 were selected as potential mRNA targets for miR-150* 
and 200c  
 
Expression patterns of both c-Myb and ZEB1/TCF8 were further analysed in a 9-day time 
course study using differentiating hESCs. During the 9-day hESCs differentiation process, 
real-time PCR analysis demonstrated that mRNA levels of both c-Myb (Fig.33A Left) and 
ZEB1/TCF8 (Fig.33A Right) were significantly decreased as compared to day 0 control 
(undifferentiated hESCs). In determination of whether there is a direct relationship between 
miR-150* and c-Myb or ZEB1/TCF8, miR-150* was overexpressed in CD146+ cells and 
mRNA levels of mRNA targets were determined (Fig.33B Left). Both mRNA expression of 
c-Myb or ZEB1/TCF8 were decreased in the miR-150* overexpression study. In a similar 
experiment, overexpression of miR-200c in CD146+ cells also resulted in the reduction of 
both mRNA expression levels of c-Myb or ZEB1/TCF8 (Fig.33B Right). However, a 
significant decrease was observed in only ZEB1/TCF8 mRNA expression and not in c-Myb 
expression for both miR-150* and 200c overexpression studies.   
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Fig. 33. Identifying miR150* and 200c’s target/s 
Expression of miR-150* and miR-200c’s potential mRNA targets during hESCs-EC 
differentiation and in miRNA overexpression studies were determined. (A) Clumps of 
undifferentiated hESCs colonies were seeded on matrigel and cultured in EGM-2 medium 
for 3, 5, 7 and 9 days. During each respective time-point, RNA was extracted, reversed 
transcribed to cDNA as previously described and subjected to real-time PCR analysis. Left 
c-Myb mRNA expression. Right ZEB1/TCF8 mRNA expression Day 0 (control) samples 
were obtained from undifferentiated hESCs. Data represent mean + SEM of three 
independent experiments (n=3). Data normalized to 18S and presented relative to day 0 
A 
 
B 
 
 
 
2.50 
7.50 
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expression. * p< 0.05 (vesus control), Paired t-test followed by two tailed test. (B) CD146+ 
cells were transfected with either c-Myb or ZEB1/TCF8 precursors and RNA was 
extracted 48 hours later. Reverse transcription to obtain cDNA was carried out and 
subjected to real-time PCR analysis. Left miR-150* overexpression. Right miR-200c 
overexpression. Data represent mean + SEM of three independent experiments (n=3). Data 
normalized to 5.8s and presented relative to miR control expression.* p< 0.05 (vesus 
control), Paired t-test followed by two tailed test. 
 
3.5.2 ZEB1/TCF8 functions as the mRNA target for both miR-200c and miR-150* in 
hESC-derived endothelial cells 
 
Based on observations from the previous overexpression study (Fig.33B), it is clear that 
ZEB1/TCF8 is the potential mRNA target for miR-150* and 200c.  As shown in Fig.34A, 
The 3’ UTR of human ZEB1/TCF8 contains two highly conserved 7-8-mer binding sites 
that are perfectly complementary to nucleotides (nt) 1-8 of miR-200c. Interestingly, nt 1-8 
of miR-150* also do bind to the 3’ UTR of human ZEB1/TCF8 which contains one highly 
conserved 8-mer binding site (Fig.34A). To further verify if both miR150* and 200c share 
the same mRNA target in vitro, the 3’UTR of ZEB1/TCF8 (Appendix 1) was cloned into a 
luciferase reporter. Luciferase assay was then assessed after overexpressing miR-150* and 
200c. The activity of luciferase from construct that included portion of the ZEB1/TCF8 
3’UTR, was significantly decreased upon overexpression of miR-200c at 48 and 72 hours 
post transfection (Fig.34B). There was also a decrease in the luciferase activity observed in 
miR-150* overexpression assay at both time points (Fig.34B).  
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Fig. 34. ZEB1/TCF8 function as a mRNA target for miR-150* and 200c 
(A)  Complementary sequences of potential miR-150* and 200c that bind to mRNA target, 
human ZEB1/TCF8 3’UTR are depicted in this illustration. (B) 3’UTR of ZEB1/TCF8 was 
cloned into a luciferase reporter. Luciferase assay was then carried out as previously 
described on CD146+ cells after overexpressing miR150* and 200c at 48 and 72 hours 
post-transfection.  
A 
 
B 
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3.6 miRNAs play a role in blood vessel formation in developing chick 
embryos 
 
Since it was previously shown in-vitro that both miR-150* and miR-200c modulate the 
expression of EC markers in differentiating hESCs, it will be interesting to discern if this 
phenomenon also occurs in vivo. Animal models are valuable tools for testing gene 
functions and drug mechanisms in vivo. As the chick embryo is easy to work with and 
readily available, an experiment using developing chick embryos was carried out to analyse 
the functions of miR-150* and miR-200c.  Analysis of HH20 chick embyos after treatment 
with transfection complexes containing miR-150*(Fig.35C) or miR-200c (Fig.35B) 
inhibitor showed a suppressed number of blood vessels formed as compared to control 
treated chick embryos (Fig.35A). This observation implies that miRNAs are involved in the 
formation of blood vessels.  
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Fig. 35 miR-150* and miR-200c play a role in blood vessel formation in vivo. 
HH10 staged chick embryos were treated with transfection complexes containing Anti-miR 
Negative Control, miR-150* or miR-200c inhibitor. The relative area of blood vessels 
formed in these chick embryos were analysed later at HH20 stage. (A) Negative control 
chick embryo (HH20). i) Transfection complexes containing Anti-miR Negative Control 
treatment were administered at the right-hand side of the chick embryo (R). No treatment 
was administered at the left-hand side (L) of the chick embryo. An enlarged image of an 
area of the control treatment was depicted in ii. iii) A bar graph illustrating an analysis on 
the number of observed blood vessels at both sides of the chick embryo using a program in 
photoshop. Each column represent mean + SEM of three independent experiments (n=3). 
(B) miR-200c treated chick embryo (HH20). i) Transfection complexes containing miR-
200c inhibitor were administered at the right-hand side of the chick embryo (R). No 
treatment was administered at the left-hand side (L) of the chick embryo. An enlarged 
image of an area of the control treatment was depicted in ii. iii) A bar graph illustrating an 
analysis on the number of observed blood vessels at both sides of the chick embryo using a 
program in photoshop. Each column represent mean + SEM of three independent 
experiments (n=3). * Relative area of blood vessels with miR-200c inhibition (R) was 
significantly different from non-treated area (L) at HH20; P < 0.05, paired t test followed 
by one-tail test. (C) miR-150* treated chick embryo (HH20). i) Transfection complexes 
containing miR-150* inhibitor were administered at the right-hand side of the chick embryo 
(R). No treatment was administered at the left-hand side (L) of the chick embryo. An 
enlarged image of an area of the control treatment was depicted in ii. iii) A bar graph 
illustrating an analysis on the number of observed blood vessels at both sides of the chick 
embryo using a program in photoshop. Each column represent mean + SEM of three 
independent experiments (n=3). * Relative area of blood vessels with miR-150* inhibition 
(R) was significantly different from non-treated area (L) at HH20; P < 0.05, paired t test 
followed by one-tail test.  (R) Right, (L) Left. 
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3.7 hESCs differentiate towards the smooth muscle cell lineage  
 
In order to fulfill the potential of hESCs in treating cardiovascular diseases, the 
understanding of its roles and functional biology in vasculogenesis is pivotal. Henceforth, 
hESCs differentiation towards the vascular lineage serves as the first step. As shown 
previously, this project has achieved the derivation of ECs from hESCs. The next objective 
is to derive SMCs, another component of the vasculature from pluripotent hESCs. SMC 
differentiation was achieved by culturing undifferentiated hES cell clumps on collagen IV-
coated dishes or plates in SMC differentiation medium as previously described in detail for 
mouse SMC differentiation 
160
. Expression of SMC markers was analysed during 
differentiation to determine whether the differentiation protocol was optimal in deriving 
vascular SMCs. A set of SMC markers was analysed using real-time PCR (Figs 36-39), 
western blot (Fig.40) and immunocytochemistry (Figs 41-43).  
 
3.7.1 Collagen IV can drive hESCs differentiation towards SMCs  
 
To induce SMC differentiation from hES cells, undifferentiated hES cells were plated on 
collagen IV coated dishes or plates and cultured in SMC differentiation medium (DM) for 
the indicated experimental time-points. Total RNA and protein were extracted and 
subjected to real-time RT-PCR and western blot analysis, respectively. The mRNA 
expression of SMA was increased significantly at day 3 and 5 compared to basal control 
levels (Fig.36). SMA mRNA expression appeared to decrease slightly from days 7-9, but 
still displayed a sustained high level during the period of differentiation. Following a 
similar trend, gene expression of Calponin gradually increased from day 0 and its 
expression at day 3 and 5 were significantly increased compared to control levels (Fig.37).  
After which there was a gradual decrease of Calponin expression from days 7-9. SM-MHC 
II mRNA expression was significantly increased compared to control at day 5, which was 
slightly later than SMA and Calponin expressions (Fig.38). However, platelet-derived 
growth factor receptor-beta (PDGFR-) gene expression increased in a time-dependent 
manner, reaching significance levels at days 7 and 9 (Fig.39). Furthermore, based on 
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overall relative expression levels, the PDGFR- gene appeared to be expressed the most 
with its maximal expression of around 60.0 at day 9, while the expression of the other three 
SMC markers peaked at day 3 or day 5 which subsequently decrease slightly but stll 
displayed a sustained high level during the period of differentiation. As the cells 
differentiated further, the expression of PDGFR- gene was increased indicating the 
attainment of an increased functional SMC phenotype. 
 
 
Fig. 36. Gene expression of SMA in differentiating hESCs over a period of 9 days. 
Clumps of undifferentiated hESCs colonies were seeded on collagen IV and cultured in 
SMC differentiation medium for 3, 5, 7 and 9 days. During each respective time-point, 
RNA was extracted, reversed transcribed to cDNA as previously described and subjected to 
real-time PCR analysis. Day 0 (control) samples were obtained from undifferentiated 
hESCs. Data represent mean + SEM of three independent experiments (n=3). Data 
normalized to 18S and presented relative to day 0 expression. *** Relative expression of 
SMA at day 3 was significantly different from day 0; p< 0.001. ** Relative expression of 
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SMA at day 5 was significantly different from day 0; p< 0.01. One-way analysis of 
variance (Anova) followed by Bonferroni's Multiple Comparison Test.  
 
Fig. 37. Gene expression of Calponin in differentiating hESCs over a period of 9 days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. ** Relative expression of Calponin at day 3 
was significantly different from day 0; p< 0.01. * Relative expression of Calponin at day 5 
was significantly different from day 0; p< 0.05. One-way analysis of variance (Anova) 
followed by Bonferroni's Multiple Comparison Test.  
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Fig. 38. Gene expression of SM-MHC II in differentiating hESCs over a period of 9 
days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. * Relative expression of SM-MHC II at day 
5 was significantly different from day 0; p< 0.05. Paired t-test followed by two tailed test. 
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Fig. 39. Gene expression of PDGFR- in differentiating hESCs over a period of 9 
days. 
Data represent mean + SEM of three independent experiments (n=3). Data normalized to 
18S and presented relative to day 0 expression. ** Relative expression of PDGFR- at day 
7 was significantly different from day 0; p< 0.01. *** Relative expression of PDGFR- at 
day 9 was significantly different from day 0; p< 0.001. One-way analysis of variance 
(Anova) followed by Bonferroni's Multiple Comparison Test.  
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3.7.2 Differentiating hESCs express SMC proteins in western blot analysis 
 
Further confirmation of the previous gene expression data was achieved by carrying out 
western blot analysis with antibodies against specific SMC markers on protein samples 
harvested at the indicated time points. As shown in Figure 40, SMA protein appeared at day 
3 and peaked at day 9 (Fig.40 Top). Another mature SMC marker, SM MHC-II, however 
appeared slightly later at day 5 of differentiation which persist at day 7 and further 
increased its expression at day 9 (Fig.40 Bottom). As compared to SMA protein expression, 
it appeared that SM MHC-II protein expression was much lower.  
 
 
 
 
 
 
Fig. 40. Western blot analysis of hESCs differentiation towards the SMC lineage over 
a 9 day period. 
Undifferentiated hESCs were differentiated in α -MEM in the presence of FBS and grown 
over a period of 9 days. As previously described, protein samples were extracted from 
differentiating hESCs during days 3, 5, 7 and 9. 40μg of each protein sample was loaded 
into each well, blotted and probed with SMC specific antibodies SMA and SM-MHC II 
(Upper panel -Top to Bottom). Each immunoblot was reprobed with GADPH, a 
housekeeping protein to show the total sample loading in each well (Lower panel). Day 0 
samples were obtained from undifferentiated hESCs which act as negative control. (n=3) 
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3.7.3 hESC derived SMC-like cells express SMC proteins in immunocytochemistry 
analyses  
 
Immunofluroscence staining and flow cytometry analysis were conducted to further 
identify and quantify the SMC population differentiated from hES cells. Day 9 
differentiated hESCs were used in both analyses to examine the protein expression levels of 
SMC-specific markers since most of the SMC protein markers were maximally expressed 
at that time point as demonstrated by western blots (Fig.40). Calponin which is capable of 
binding to Actin, Calmodulin, Troponin C and Tropomyosin, could observed in day 9 
differentiated hESCs (Fig.41). An appearance of a typical SMC spindle-shaped morphology 
was observed. Likewise, SMA was also observed in the cytoplasm localised as filaments 
(Fig.42A). Intriguingly, another population of cells which might represent intermediate 
SMC was detected as SMA positive, although not displaying a typical SMA staining 
pattern. These cells displayed a lower level of SMA protein expression which was not 
localised in distinct filaments (Fig.42B). A mature and late expressing SMC-specific 
marker SM-MHC II was also observed in the cytoplasm (Fig.43).  
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Fig. 41. Expression of calponin in hESCs-derived SMCs. 
Day 9 differentiated hESCs grown in SMC differentiation medium were probed with 
Calponin primary antibody followed by polyclonal goat anti-Rabbit IgG immunoglobulins 
TRITC. Anti-clockwise from upper right. Fluorescent images were captured on calponin 
positive cells (upper right), nucleic acid stains (DAPI) in individual cell (upper left) and an 
overlapped image depicting the localisation of both calponin and DAPI. Bar = 20 µm.
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Fig. 42. Expression of SMA in hESCs-derived SMCs. 
Day 9 differentiated hESCs grown in SMC differentiation medium were probed with SMA 
primary antibody followed by polyclonal goat anti-mouse IgG immunoglobulins FITC. 
Anti-clockwise from upper right. (A) Fluorescent images were captured on a SMA positive 
cell (upper right), localization of nucleic acid stain (DAPI) (upper left) and an overlapped 
image depicting the localisation of both SMA and DAPI in the cell (middle left). Clockwise 
from middle right. (B) Fluorescent images were captured on a SMA positive cell (middle 
right), localization of nucleic acid stain (DAPI) (lower right) and an overlapped image 
depicting the localisation of both SMA and DAPI in the cell (lower left). Bar = 20 µm
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Fig. 43. Expression of SM-MHC II in hESCs-derived SMCs. 
Day 9 differentiated hESCs grown in SMC differentiation medium were probed with SM-
MHC II primary antibody followed by polyclonal goat anti-Rabbit IgG immunoglobulins 
TRITC. Anti-clockwise from upper right. Fluorescent images were captured on SM-MHC II 
positive cells (upper right), nucleic acid stains (DAPI) in individual cell (upper left) and an 
overlapped image depicting the localisation of both SM-MHC II and DAPI. Bar = 20 µm
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3.7.4 hESC derived SMC-like cells are capable of contraction when assessed using 
contractility assay  
 
As it has been well-established that SMCs are able to contract in response to external 
stimulus such as carbachol and potassium chloride (KCL), a contractibility assay was 
carried out to assess the function of hESC derived SMC-like cells. 40mM/L of agonist KCL 
was found to induce contraction in cells. Upon stimulation with KCL, cells underwent 
contraction as observed by their morphology changes, which showed a contrast from their 
previous normal resting spindle-shape morphology (Fig.44).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 min 5 min 
15 min 25 min 
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Fig. 44. KCL-induced contraction of hESCs derived SMCs. 
Starting clockwise, from top-left hand corner. An image captured before cells were 
stimulated with 40mM/L of KCL agonist. In here, the cells exhibited elongated and 
spindle-shaped morphologies. As the duration of agonist stimulation progressed, there was 
an indication of contraction, with a notable loss of normal resting SMC morphology 
(shown by arrows). Note that the cell denoted by a red arrow had undergone most 
contraction, whereby after 5-25 minutes of stimulation resulted in a near rounded 
morphology, in far contrast to its spindle-shaped appearance before stimulation. Images 
were taken at 10X magnification. 
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CHAPTER 4 
Discussion 
 
 
4.1 Determination of pluripotency in cultured undifferentiated hESCs  
 
hESCs were supported on feeder layers of inactivated MEFs which allowed them to grow 
as undifferentiated colonies 
46
. Prior to seeding, MEFs were inactivated with MMC derived 
from Streptomyces caespitosus that crosslinks the complementary double helix strands of 
the MEFs’ DNA. This prevents the separation of the complementary DNA strand, thus 
resulting in cell cycle arrest 
161, 162
. In addition, hbFGF was added to the hESCs culture 
medium as it is required for maintaining the pluripotent and self-renewal properties of 
hESCs 
163
, similar as leukemia inhibitory factor (LIF) is required for the self-renewal of  
mESCs. 
 
It is vital to determine the pluripotent status of hESCs prior to differentiation as this helps 
to keep in check with the hESC culture system. Hence, the pluripotent and self-renewal 
properties of undifferentiated hESCs in culture was initially assessed by detecting activity 
levels of AP, which resulted in the presence of reddish-purple colonies after staining 
(Fig.7). AP is a hydrolase enzyme which dephosphorylates molecules such as nucleotides, 
proteins, and alkaloids under alkaline conditions. An elevated level of AP is associated with 
undifferentiated and pluripotent stem cells 
164, 165
. Differentiated colonies will appear 
colorless after AP staining, distinguishing the undifferentiated colonies from the 
differentiated ones. It was reported that undifferentiated hESCs also express pluripotent 
surface markers such as SSEA4 which is a glycolipid protein carbohydrate epitope as well 
as keratin sulphate-associated antigens TRA-1-60 and TRA-1-81 
46
. Similarly, 
undifferentiated hESCs in culture have shown the expression of these pluripotent surface 
markers and transcription factors OCT3/4 and SOX2 after immunochemistry staining 
(Fig.8A). Unlike mESCs, undifferentiated hESCs do not express the carbohydrate antigen, 
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SSEA-1 as shown in Fig.8B, which suggest that differences exist in early development 
between mouse and human species 
166, 167
. Hence the display of pluripotent markers further 
supports the validity in maintaining pluripotent and undifferentiated hESCs in the cell 
culture system. 
4.2 Establishment of a EC differentiation model for hESCs and their EC 
expression during differentiation 
 
One of the earliest aims in this project was to establish a model for differentiating hESCs 
towards the EC lineage. Initial attempts to achieve this were tried and tested using various 
concoctions of EC growth factors such as VEGF, BMP or FGF in the presence of serum-
free medium. It was anticipated that differentiating hESCs in serum-free medium was best 
approached as serum contained a variety of undefined factors and might not be ideal for 
future clinical therapeutic application. However, in this project, this type of differentiation 
model proved fruitless in deriving endothelial-like cells. One possibility was that this 
particular Shef 3 hESC line requires the presence of certain undefined factors in serum that 
are not present in serum-free medium which will aid in its vascular differentiation process. 
Hence modifications were made and the existing endothelial differentiation model was 
made up of of EGM-2 which contains 2% serum. In addition, Matrigel was chosen as the 
basement substrate for hESCs differentiation towards EC lineage based on previous reports 
that showed the ability of ECs to form vascular tubes on the 3-dimensional Matrigel 
substrate 
168, 169
. Moreover, the combination of both EGM-2 and Matrigel closely mimicked 
the culture environment for growing ECs. Also instead of utilising the formation of 
embryoid bodies to differentiate hESCs, 200-300 undifferentiated hESC clumps were 
simply seeded onto the Matrigel matrix. This method ensured that every single hESCs 
grown as a monolayer were subjected to equal exposure to the differentiation medium. 
However, this could not be achieved if hESCs were grown as embryoid bodies instead. 
 
Determination in the validity of the hESCs differentiation model towards EC lineage was 
assessed by detecting a set of EC markers during differentiation. Using real-time PCR, the 
expression in the majority of endothelial-specific genes such as CD144/VE-cad (Fig.9), 
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vWF (Fig.11) and Kdr (Fig.12) increased as the number of days lengthened during the 9 
days differentiation period. Gene expression for CD144/VE-cad appeared at day 3 (Fig.9), 
which was slightly earlier as compared to the reported appearance of CD144/VE-cad in day 
4 differentiating human embryoid body 
67
. CD146 gene expression also appeared at day 3 
but subsequently decreased in the later period of differentiation (Fig.10). Gene expressions 
of CD144/VE-cad, vWF and Kdr at day 9 were significantly elevated as compared to 
expression at day 0 control levels (Figs. 9, 11, 12). Furthermore, at day 9, both vWF and 
Kdr gene expression levels were the highest hovering around 4.0, compared to CD144/VE-
cad which was at around 2.0. mRNA level of Nanog, which is a key factor in maintaining 
the pluripotency and undifferentiated state of ESCs, significantly decreased gradually at 
days 5, 7, and 9 as compared to day 0 (Fig.13.). Overall findings indicated that expression 
levels of endothelial-specific genes reached its maximum at days 3 or 9, implying a 
differentiation process towards mature ECs. 
 
Next, protein analysis using western blot, immunocytochemistry and flow cytometry were 
used to further characterize and quantify differentiating hESCs cultured in EC promoting 
conditions. The increase in gene expression of CD144/VE-cad and vWF during 
differentiation correlates with the observation in their increased protein expression in 
western blot analysis (Fig.14). CD144/VE-cad is a cell adherent protein and mediates cell–
cell adhesion (Fig.16) between vascular ECs as part of the adherens junction complex 
170
. 
Western blot analysis showed that protein expression of CD144/VE-cad appeared only at 
day 9 (Fig.14) whereas as previously shown, its gene expression appeared earlier at day 3 
(Fig.9). A probable reason for this discrepancy is that gene expression levels of CD144/VE-
cad from differentiation days 3-7 are quite close (< 0.5 fold increase) compared to basal 
control levels (Fig.9) and this subtle increase is possibly not adequate to detect using 
western blotting. In contrast, a near 1.0-fold increase was observed at day 9 CD144/VE-cad 
gene expression level as compared to basal levels (Fig.9), an expression which was 
sufficient to detect in western blotting (Fig.14).  
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CD146 is a membrane glycoprotein localized at cell-cell endothelial junction 
171
 as 
observed in Fig.17. CD146 protein expression appeared at day 3 and was maximal at day 9 
(Fig.14) whereas its gene expression revealed its maximal expression at day 3 which 
decreased gradually over time (Fig.10). This difference in CD146 gene and protein 
expression patterns could be due to the late translation of its mRNA and hence the late 
expression of its protein product. In addition, flow cytometry analysis revealed that 16.4% 
of the heterogeneous cell population expressed CD146 at day 7 (Fig.21A Top). This 
expression was increased to 34.1% approximately two-fold at day 17 (Fig.21A Bottom).  
 
Previous studies carried out by Levenberg et al. and Kaufman et al, reported that 
undifferentiated hESCs express the VEGF receptor, Kdr on their surfaces unlike their 
mESCs counterparts and increased very slightly during differentiation 
67, 172
. In contrary, 
the undifferentiated Shef 3 cell line which was used in this experiment did not appear to 
express Kdr and its gene expression increased significantly at day 7 as compared to basal 
control day 0 (Fig.12). Immunocytochemistry staining of day 9 differentiated Shef 3 hESCs 
also showed the presence of Kdr (Fig.19) which was otherwise not detected in these 
undifferentiated hESCs (immunostaining data not shown). This absence of Kdr expression 
in undifferentiated hESCs was also reported in a study using BG02 and WA09 hESC lines 
173
. The hESCs lines used in studies carried out by Levenberg et al. and Kaufman et al. 
were H9 and H1 respectively. This showed that differences do exist in different hESC lines 
and further standardization protocols or cell lines may be required for differentiating hESCs 
if applied in future clinical therapeutic settings 
174, 175
.  
 
Several other EC specific markers were also assessed to characterize the differentiating 
hESCs. vWF protein expression was also detected in flow cytometry analysis (Fig.21B) 
and western blotting. vWF protein appeared from day 5 and its levels was sustained till day 
9 in the western blot analysis (Fig.14). This observation was similar to its gene expression 
which appeared at day 5 and with a significance increase of expression at day 9 (Fig.11). 
vWF previously known as Factor VIII related antigen, is synthesized exclusively by ECs 
and megakaryocytes. It is stored in the intracellular granules or constitutively secreted into 
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plasma as observed in Fig.20. Immunostaining analysis also showed the presence of 
CD31/PECAM-1 in differentiated hESCs that is located between EC junction sites (Fig.15). 
In western blot, CD31/PECAM-1 protein levels showed an increasing time-dependent 
expression as the differentiation time period lengthened (Fig. 14). Another endothelial 
specific marker, eNOS or otherwise known as NOS3 in EC, produces nitric oxide which 
functions as a vasodilator and regulates blood flow and pressure. eNOS is found at 
cytoplasmic locations in ECs and its protein was detected from days 3 to 9 of hESCs 
differentiation (Fig.14 & 18).  
 
In general, the overall expression of EC markers during differentiation showed that the 
differentiation method in deriving ECs from undifferentiated hESCs was successful in 
achieving mature vWF-expressing ECs at day 9. Further isolation of cells expressing EC 
markers to obtain a pure EC population was achieved using FACS and their EC function 
assays will be discussed in the following section. 
 
4.3 Characterisation of CD146+ cells using in vitro and in vivo EC tests 
 
Next, the heterogeneous population of differentiating hESCs were subjected to FACS for 
cell sorting to obtain CD146+ cells (Fig.22).  The purity of CD146 + cells after sorting was 
96.5% (Fig.22A & B). When this population of CD146+ cells was expanded in vitro after 
isolation using FACS, two different cell phenotypes were observed (Fig.23A). The first 
morphology resembles round endothelial-like cobblestone-shape while the other has a 
spindle-shaped fibroblast or SMC morphology. It has been reported that the expression of 
CD146 molecule is not only restricted in EC but also in several other non-malignant and 
malignant cell types, including smooth muscle cells 
176
, pericytes 
177
, follicular dendritic 
cells 
178
, lymphocytes 
179
 and melanoma cells 
180
. Since both smooth muscle cells and 
pericytes share similar spindle-shape fibroblast morphology, it is probable that these cells 
were also isolated along with the cobblestone cells during CD146+ cell sorting. However, 
in the later passages of the CD146 cell culture (passage 9), the spindle-shaped fibroblast 
morphology observed in earlier passages disappeared (Fig.23B), leaving only cobblestone-
shaped cells. A likely reason for this phenomenon is that the EGM-2 and collagen-I culture 
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conditions may only favour EC maintenance and growth while the other cell types die off 
as the culture period lengthens. This results in the obtainment of only cobblestone-shaped 
cells as the CD146+ culture gets older. Moreover, flow cytometry analyses for passages 1 
and 5 of CD146+ cell population showed that expression levels of EC markers such as 
CD146, vWF, CD144/VECAD and CD31/PECAM increased in the later passage (Fig 24). 
This implies that the sorted CD146+ cells that displayed EC morphology and markers can 
be expanded successfully in the existing culture conditions. Furthermore, 
immunocytochemistry stainings confirmed that the CD146+ cell population expressed EC 
protein markers like vWF (Fig.25A), eNOS (Fig.25B), CD31/PECAM (Fig.25C) and 
CD144/VECAD (Fig.25D) (Fig.25). Next, further tests such as Matrigel assay to assess EC 
tube formation and Dil-Ac-LDL uptake were carried out to determine the functional 
capability of these cells.  
 
The uptake of Dil-Ac-LDL is one of the classic hallmarks used to characterize endothelial 
cells  
181
. Firstly, Dil-Ac-LDL is taken up by cells via scavenger receptors. Since Ac-LDL 
behaves like oxidised LDL, both are degraded within lysosomes by lysosomal enzymes. 
Later fluorescent lipophilic Dil probes accumulate in the intracellular membrane, labelling 
the cells 
182
. However, smooth  muscle  cells and pericytes do not  possess  the  scavenger  
pathway  for Ac-LDL metabolism 
181
. The CD146+ cell population was capable of Dil-Ac-
LDL uptake as evidenced in Fig.26. But since macrophages also take up acetylated-low 
density lipoprotein 
181
, co-staining with lectin binding was carried out to distinguish 
macrophages and endothelial cells. Anti-Ulex Europaeus-I (UEA-I) lectin reacts 
specifically for UEA-I which interacts with α-L fucosyl residues in oligosaccharides  
present on the membranes  of vascular human endothelial cells 
183
.  Positive stainings of 
CD146+ cell population for Dil-Ac-LDL and lectin (Fig.26) indictate that these cells are of 
endothelial origin and not smooth muscle cells, pericytes or macrophages.  
 
Another EC functional test, in vitro vasculogenesis assay using Matrigel
TM
 matrix was also 
carried out to characterise the function of CD146+ cells. The Matrigel
TM
 matrix (BD 
Biosciences, Bedford, MA) is a soluble basement membrane extract from the Engelbreth-
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Holm-Swarm mouse sarcoma. It gels at room temperature 
184
 and is rich in extracellular 
matrix proteins. The major components of Matrigel
TM
 matrix are laminin, followed by 
collagen IV, heparin sulphate proteoglycans and entactin/nidogen 
184, 185
. Growth factors 
such as TGF-β, insulin-like growth factor, fibroblast growth factor as well as collagenases 
and plasminogen activators are also present 
186
.  
As seen in Fig.27A, CD146+ cells were capable of vasculogenesis in Matrigel
TM
 by 
forming vascular structures 24 hours after seeding onto Matrigel
TM
 in vitro. These cells 
were also capable of forming complex vascular network in vivo in Matrigel
TM
 plugs 
implanted in SCID mice (Fig.27B). After carrying out a battery of EC characterisation tests, 
it can be concluded that the population of CD146+ cells are capable of further expansion in 
vitro after FACS cell sorting and display characteristics and functions of ECs in vitro and in 
vivo.  
4.4 Potential miRNA candidates play a role in hESCs differentiation 
towards the EC lineage 
 
 
miRNA has paved a new window in our understanding of gene expression and is one of the 
most widely applied techniques in biomedical research, especially in the molecular 
investigation of disease pathogenesis. For instance, it has been reported that miR-1 plays an 
important role in heart conductivity since miR-1 levels were positively correlated with 
coronary artery disease and after cardiac infarction. Loss-of-function of miR-1 prevented 
heart arrhythmia, whereas miR-1 overexpression caused heart arrhythmia in normal and 
infarcted hearts 
187
. Both miR-1 gain- and loss-of-function studies affect the conductivity of 
the heart through potassium channels was subsequently demonstrated 
187
. These results 
suggest that miR-1 has a prominent effect on the development of cardiac arrhythmia, an 
irregular electrical activity in the heart. In another study, it was found that the muscle-
specific miR-133 is a negative regulator of cardiac hypertrophy, which is an essential 
adaptive physiological response to mechanical and hormonal stress as well as size of the 
heart 
188
. Taking these studies into consideration, miRNAs are potential therapeutic targets 
for disease treatments. 
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In addition, several in-vitro evidences have indicated the involvement of miRNA in 
regulating endothelial cell behavior such as proliferation, migration and the ability to form 
capillary networks 
147-149, 189, 190
. Dicer, an enzyme essential for the biogenesis of most 
miRNAs is required for embryonic angiogenesis during mouse development 
146
. 
Furthermore, the contribution of miRNA in directing ESCs towards different cell-fates has 
been suggested in studies using Dicer or Drosha deficient ESCs. These Dicer and Drosha 
deficient ESCs were unable to generate mature miRNAs which subsequently impeded their 
differentiation process 
191-193
. In addition, miRNA expression profiling analysis in 
undifferentiated ESCs and differentiating embryoid bodies have identified candidate 
miRNAs involved in the maintenance of the pluripotent ESC state as well as regulating 
early mammalian development 
194-199
. Besides, accumulating evidences have also 
demonstrated the crucial involvement of specific miRNAs in the differentiation of ESCs 
198-
202
.  
In a recent study, Fish et al. showed that miR-126 regulated vascular integrity and 
angiogenesis in mouse and zebrafish models 
152
. However although miR-126 was found 
enriched in vascular progenitors, it does not control early EC lineage commitment in 
mESCs 
152
. The missing miRNA-link in controlling pluripotent embryonic stem cell fate in 
differentiation towards the EC lineage is currently undiscovered. Hence the main objective 
in this project is the determination of which miRNA or miRNAs is/are involved in this 
crucial process.   
 
To determine which potential miRNAs are involved in embryonic EC development, 
miRNA array analysis was carried out in hESCs grown in EC differentiating conditions 
over a 9-day period. From the miRNA array analysis, angiogenic promoting miRNAs such 
as miR-126 
106, 152
 and miR-210 
156
 were initially undetected at days 3 and 6 but surfaced at 
day 9 of differentiation (Fig.28C). In addition, another positive regulator of angiogenesis, 
miR-130a 
156
 was found in an increasing trend over the 9-day differentiation period. 
Moreover, levels of anti-angiogenic miR-221 
149, 156
 appeared to decrease over the 
differentiation time-frame (Fig.28C). miR-145 which has been previously reported to 
facilitate ESC differentiation by repressing the core pluripotency factors OCT4, sex 
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determining region Y-box 2 (SOX2), and Kruppel-like factor 4 (KLF4) 
201
, was induced at 
day 9 as shown in the miRNA array analysis. These observations clearly demonstrate that 
our differentiation process of hESCs towards the EC lineage does coincide with previously 
published miRNA findings.       
 
 
Five potential enriched miRNAs were selected from the miRNA array analysis and further 
validated using quantitative real-time PCR. These miRNAs are miR-150* and miR-1915 
(Fig.28A) and miR-200 family members, miR-141, miR-200c and miR-205 (Fig.28B). 
Further examination into the function of miRNAs on hESCs differentiation to ECs, was 
achieved by carrying out loss-of-function and gain-of-function tests which was transfecting 
day 6 differentiated hESCs with miRNA inhibitors or precursors respectively. Following 
which, analyses into whether their inhibition or overexpression would affect EC expression 
were determined.  
 
Transfection efficiency was monitored using Cy3-labeled Anti-miR Negative Control 
(Ambion, Applied Biosystems) which has a 5' end fluorescent moiety. Transfection 
optimization is required to determine optimal conditions required for maximum gene 
effectiveness. As shown previously, there was a high transfection efficiency of 87.41% 
after 48 hours transfection with Cy3-labeled Anti-miR Negative Control (Fig.29A) and 
which dipped slightly to 83.27% at 72 hours post transfection (Fig.29B). This demonstrated 
that the transfection protocol was optimal and successful in delivering miRNA inhibitors 
into the cells. The siPORT NeoFX Transfection Agent used in this study utilises an 
alternative method of transfection called reverse transfection 
203
. In reverse transfection, 
cells are transfected while still in suspension. This saves an entire day , as cells do not need 
to be plated prior to transfection compared to standard transfection. The lipid-based 
siPORT
TM
 NeoFX
TM
 Transfection Agent uses liposome-mediated transfection whereby 
liposomes deliver nucleic acids into the cells 
204
. Liposome-mediated transfection has 
higher efficiency and greater reproducibility than other transfection methods. In addition, 
siPORT
TM
 NeoFX
TM
 Transfection Agent is a transient transfector giving rise to transient 
transfection. Transient transfection enables higher copy numbers of foreign nucleic acid 
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and hence higher levels of gene expression to be present in the cell for a brief period of 
time. This transient effect can be observed as the effects of miRNA inhibitors and 
precursors gradually diminish over the 24-72hours post transfection time period (Fig.30-32).   
 
Next, to establish which miRNA is involved in hESCs differentiation towards the EC 
lineage, EC markers were assayed during real-time PCR. Since all five miRNAs members 
were selected based on their up-regulated expression during hESCs differentiation to EC, 
the inhibition of these potential candidates should also influence the downregulation of EC 
marker expressions. Inhibition studies were carried out using miRNA inhibitors that inhibit 
endogenous miRNAs. Real-time PCR results in inhibition studies showed that although all 
five of the selected miRNAs were inhibited, only two out of the five selected miRNAs did 
downregulate the mRNA expression of specific EC markers as compared to control levels 
(Fig.30A, 32A-C). At 24 hours post transfection, both miR-150* and 200c were 
significantly decreased and which downregulated the expression of specific EC markers as 
compared to control levels (Fig.30A).  
 
Both mRNA levels of miR-150* and 200c were significantly upregulated by transfecting 
cells with the respective precursors, which are designed to mimic endogenous precursor 
miRNAs (Fig.31A). mRNA levels of specific EC markers such as vWF, Kdr, CD144 and 
CD146 were upregulated as compared to control, after the introduction of miR150* 
precursor (Fig.31Ai) or miR-200c precursor (Fig. 31Aii) into the cells. Further western blot 
analyses using samples transfected with the same treatments in Fig.31A showed that similar 
results were obtained (Fig.31B). Taking these findings together, the inhibition of miR-150* 
and 200c appear to repress EC differentiation from hESCs, whereas their overexpression 
promote hESCs differentiation towards the EC lineage, suggesting both miRNAs play an 
important role in endothelial cell differentiation from hESCs.   
 
To provide further evidence on the function of miR-150* and 200c, experiments in 
inhibiting their expression was carried out in developing chick embryos. It was 
demonstrated that the number of relative blood vessels were significantly decreased in 
HH20 chick embyos after treatment with transfection complexes containing miR-150* 
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(Fig.35C) or miR-200c inhibitor (Fig.35B) as compared to control treated chick embryos 
(Fig.35A). These observations clearly imply that miR-150* and miR-200c do play a role in 
EC differentiation during development as shown in vitro and in vivo. But an intriguing 
question is how these microRNAs carry out their biological functions and which 
mechanisms are involved during the EC differentiation process. These questions will form 
the next set of objectives in the subsequent part of the project.  
 
4.5 microRNAs 150* and 200c target ZEB1/TCF8 during hESCs-EC 
differentiation  
 
Ultimately, the function of a miRNA is defined by the genes it targets and how it affects 
their expression. To understand the mechanisms by which miR-150* and 200c regulate en-
dothelial biology, potential mRNA targets were searched. Predictions of targets for miR-
150* and 200c were carried out using PicTar (http://pictar.mdc-berlin.de), a miRNA target 
prediction algorithm program tool 
159
. An important determinant of miRNA target is the 
high degree of sequence complementarity between the 5’ end of the miRNA (seed sequence) 
and the 3’UTR mRNA target 133, 134. Another factor is the accessibility of mRNA at the 
potential binding site 
205
.  
In this study, target prediction using PicTar revealed that potential mRNA targets for miR-
150* and 200c were c-Myb and ZEB1. Many reports have also shown that a highly 
predicted target for miR-150 is the proto-oncogene c-Myb 
206-208
. Found highly expressed
 
in 
hematopoietic progenitor cells, c-Myb expression declines as these cells differentiate 
209, 210
. 
In regard to this study, where the expression of miR-150 appear to promote the 
differentiation of hESCs towards ECs, it is highly probable that this interaction might also 
be important during EC development. In addition, overexpressing c-Myb increases the 
frequency of hemogenic precursors in ESC-derived ECs population 
211
. Alternatively, this 
might imply that an increase of miR-150* expression during the development of embryonic 
ECs will suppress the expression of its c-Myb target gene and deters differentiation towards 
the hematopoietic lineage.  
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miRNA-200c which is a member of the miR-200 family clustered in chromosome 12, has 
been shown that its overexpression will lead to reduced expression of ZEB1/TCF8 and an 
increased expression of E-cadherin 
212
. Down-regulation of E-cadherin is a crucial event in 
epithelial-to-mesenchymal transition (EMT) whereas TCF8, a two-handed zinc finger (ZF) 
homeodomain transcription factor, mediates cell–matrix adhesion and subsequent 
angiogenesis 
213
. EMT facilitates tissue remodelling during embryonic development and 
has been highlighted in mesoderm formation as well as mesoderm differentiation to diverse 
tissues or organs during embryogenesis 
214, 215
. It also appears that the EMT-activator ZEB1, 
is expressed in less differentiated cell types like embryonic stem cells 
216, 217
. However, the 
expression of ZEB1 decreases as mESCs differentiate under differentiation-inducing 
growth conditions 
217
. Moreover, Wellner et al. also discovered that during mESCs 
differentiation without the presence of leukaemia inhibitory factor (LIF), levels of 
stemness-inhibiting miRNAs, miR-200c was upregulated whilst stem cell factors such as 
KLF4 and Sox2 were decreased 
217
. In another seperate study, it was also found that the 
expression of miR-200c was increased upon differentiation of hESCs 
196
. These studies 
further support our findings that miR-200c which was enriched in our miRNA array 
analysis study, is present in differentiating ESCs. Taking together the current findings and 
previously published studies, these strongly suggest that as hESCs differentiate towards the 
EC lineage, an increase of miR-200c expression contribute to the decline or repression of 
EMT process, which result in the formation of more differentiated, senescence 
218
 and less 
proliferative cells or in this case mature vascular ECs.  
In the next part of the study, expression patterns of both c-Myb and ZEB1/TCF8 were 
further analysed in a 9-day time course study using differentiating hESCs. mRNA levels of 
both c-Myb (Fig.33A Left) and ZEB1/TCF8 (Fig.33A Right) were significantly decreased 
as compared to day 0 control (undifferentiated hESCs). Moreover in miRNA 
overexpression studies, it was shown that mRNA expressions of both c-Myb and 
ZEB1/TCF8 were decreased (Fig.33B). These observations demonstrated that c-Myb and 
ZEB1/TCF8 mRNA expression levels were reciprocally regulated by miRNAs 150* and 
200c. However, a significant decrease was observed in only ZEB1/TCF8 mRNA 
expression but not in c-Myb expression in both miR-150* and 200c overexpression studies.  
Herein, ZEB1/TCF8 was selected as the preferred mRNA candidate target for miR-150* 
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and 200c in this study. Interestingly, like miR200c, miR-150* also happen to share a 
binding site in the 3’UTR of ZEB1/TCF8 (Fig.34A).  
Further validation of the ZEB1/TCF8 target site was carried out by cloning the 3’UTR of 
ZEB1/TCF8 into a luciferase reporter. Luciferase reporter assays were carried out to 
investigate if miR-150* and 200c directly target the 3' UTR of ZEB1/TCF8. A change in 
luciferase activity will determine whether a miRNA can bind to the UTR and regulate the 
expression of the gene 
219
. Upon overexpressing miR-200c in CD146+ cells, luciferase 
activity of 3' UTR of ZEB1/TCF8 was significantly reduced while in miR-150* 
overexpression, the luciferase activity was moderately reduced (Fig.34B). This 
demonstrates that both miR-150* and 200c directly target ZEB1/TCF8 and subsequently 
lead to the differentiation of mature ECs from undifferentiated hESCs.  
At this point of time, no other studies have demonstrated or reported the involvement of 
miRNAs in the development of ECs from hESCs. In this current project, miR-150 and 
miR-200c were discovered to direct hESCs differentiation into ECs, which is of great 
clinical use in the future. Patients with atherosclerosis, and especially with cardiac 
ischemia, treatments such as balloon angioplasty and stenting are frequently used to regain 
blood perfusion for the local myocardium. However, restenosis, a homeostatic response to 
vascular injury, leads to the recurrent occurrence of myocardial ischemia. This is due to the 
loss of the endothelium secondary to the balloon inflation at high pressures and the use of 
foreign metallic stent. Subsequently, SMCs would be activated and switched on, resulting 
in the proliferation and secretion of the extracellular matrix. This would lead to luminar 
narrowing after these interventional procedures were carried out 
94, 220
. It has been shown 
that accelerated reendothelialization by mature ECs effectively inhibits SMC migration, 
proliferation, and neointima formation, and therefore, preventing the development of the 
early stages of restenosis after vascular injury 
221
. Therefore, the application of these 
miRNAs discovered in my current experiment can be used for the generation of patient 
specific ECs and which can also be used to heal the damaged vessel while interventional 
procedures are being performed in the patient. On the other hand, these miRNAs can also 
be delivered directly into the coronary arteries and activate the local EC differentiation 
mechanism so that the vessel damage can be prevented 
222
.    
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As miRNA research is still new and has been conducted for only a few years, there are still 
lots of unknown but exciting and promising findings waiting to be discovered. Most of the 
miRNA studies have revealed a level of molecular control in human diseases that were 
beyond the well-accepted regulatory systems such as regulation by transcription factors and 
signalling proteins 
187, 188, 222
. Furthermore, these studies also have implications that, in a 
cell, a more complex regulatory system, e.g., interactions between miRNAs, cell signaling 
and transcription factors, is involved in many cellular activities and human diseases. 
Therefore, it is essential to study the under-lying interactions between miRNAs and cellular 
regulatory systems and pathways. Hence, this leads to the understanding of gene regulation 
in a more comprehensive manner and opening up new opportunities in manipulating 
miRNAs as diagnostic and therapeutic targets. 
Other than the determination of applicable miRNAs at the molecular level for the 
development of new therapeutic strategies, it still remains obscure as to which strategies 
researchers can use to achieve this goal. Through the understanding of miRNAs is an 
obvious prerequisite for realizing their rousing promise, which calls for an urgent need to 
develop suitable technologies for the purpose. Moreover, the ability to efficiently, stably 
produce and deliver sufficient amounts of miRNAs into the proper cell target, without overt 
toxicity requires fine tuning of the technology before these can be tried clinically. The 
pharmacokinetics, cellular safety, and functional stability of miRNA expression in animals 
needs to be examined, in order to ascertain that the artificial miRNAs are stable, effective, 
and non-toxic in vivo. 
 
4.6 Differentiated SMCs-like cells derived from pluripotent hESCs 
 
Next, VSMCs were derived from pluripotent hESCs as part of the objectives in this project. 
VSMCs play crucial roles in vasculogenesis and human diseases such as atherosclerosis 
and hypertension 
39
. VSMCs are notoriously known for presenting a wide range of different 
phenotypes during different developmental stages 
35
. Even in adult organisms, VSMCs are 
not terminally differentiated unlike other muscle cells and can potentially switch between a 
contractile and a synthetic phenotype 
36
. Hence exploring the molecular mechanisms of 
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early VSMC differentiation will contribute to better understanding of VSMCs and future 
clinical therapies for vascular diseases.  
 
In this study, differentiation of pluripotent hESCs towards the SMC lineage was achieved. 
mRNA expressions of most SMC-specific markers, such as SMA (Fig.36) and Calponin 
(Fig.37), were maximal at day 3 and subsequently decreased slightly over the next 
following days of differentiation. At day 5, SM-MHC II mRNA expression was maximal 
and significantly increased compared to control, which was slightly later than SMA and 
Calponin expressions (Fig.38). However, western blot analyses showed that the specific 
SMC-markers increased in a time-dependent manner. SMA protein expression was 
maximally expressed at day 9 and whereas SM MHC-II protein expression only appeared at 
day 5 and continued to increase over the next few days of differentiation (Fig.40). These 
time differences in gene and protein expression are possibly due to the late translation of 
both SMA and SM MHC-II mRNAs and hence the late expression of its protein product. 
Another possible explanation for the decreased expression levels of some genes at a later 
stage can be due to the negative feed back pathway upon protein translation and 
accumulation. Unlike previous observations, PDGFR- mRNA expression increased in a 
time-dependent manner, reaching maximal and significance levels at day 9 (Fig.39). PDGF 
is a well characterised growth factor which has been known for its significant role in 
angiogenesis 
24
. Furthermore, SMCs also secrete PDGF which acts as a major mitogen and 
chemoattractant 
22, 23
. These results imply that during the differentiation process towards the 
SMC lineage, differentiating cells were attaining increased SMC genes and behaviour as 
well as expressing the PDBFR- gene.  
 
Actin is one of the two major cytoskeletal proteins implicated in cell motility, the other 
being myosin. α-actin being one of the actin isoforms, is found in muscle tissues and a 
major constituent of the contractile apparatus. SMA has been widely used as a SMC 
differentiation marker as it is known to express during differentiation of the SMC during 
development 
223
. Immunostaining carried out in day 9 differentiated hESCs showed the 
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presence of SMA localised in cytoplasmic filaments indicating a contractile SMC 
phenotype (Fig.42A). A less distinctly stained SMA-positive cell was also observed as 
shown in Fig.42B. Note that the SMA was not localised as distinct filaments which could 
imply a possible phenotypic switch to a synthetic morphology and/or represent an 
intermediate SMC differentiation status. Calponin is a marker of the intermediate stages of 
SMC differentiation/maturation 
8
 and is implicated in the regulation of SMC contraction. 
Like SMA, calponin protein expression was found localised in the cytoplasmic filaments in 
day 9 hESC-derived SM-like cells (Fig.41). Another mature SMC protein SM-MHC II was 
also expressed in the cell population (Fig.43). SM-MHC II is a cytoplasmic structural 
protein which contributes to the contractile function in VSMCs. SM-MHC II is one of the 
two isoforms identified, the other being designated MHC-I. Since SM-MHC II is a SMC-
specific marker of late differentiation or maturation stages 
42
 and its appearance together 
with other SMC markers in day 9 hESC-derived SM-like cells imply that the existing 
differentiation model is successful in deriving VSMCs.  
 
An important characteristic of VSMCs is their ability to contract in response to stimulus 
224
. 
To determine whether the hESC-derived SM-like cells function as normal VSMCs, 
contractility test using the agoinst KCL was carried out. Upon stimulation with KCL, cells 
underwent contraction as observed by their morphology changes in contrast with their 
previous normal resting spindle-shape morphology (Fig.44). In general, the expression of 
SMC specific marker genes and proteins as well as the ability to contract like VSMC 
suggest that the differentiated hESCs are most likely to be VSMCs. This also implies that 
an in-vitro differentiation system in deriving VSMCs from hESCs has been successfully 
established without requiring EB formation. However, further steps such as using cell-
sorting will be necessary for obtaining an increased purity and population of SMA and 
Calponin positive cells. Future work will also focus on determining potential miRNA 
candidates which play a role in SMC differentiation from pluripotent hESCs.  
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CHAPTER 5 
Conclusion and future plans 
 
 
 
Differentiation of hESCs towards both vascular ECs and SMCs has been successfully 
achieved in this study. hESC-derived ECs express specific EC markers such as PECAM-
1/CD31, eNOS, CD144/VE-cad and vWF, while hESC-derived SMCs express specific 
SMC markers such as SMA, Calponin, SMMHC II and PDGFR-. Both hESC-derived ECs 
and SMCs also displayed functional characteristics upon functional analysis.  
 
During hESCs differentiation towards the EC lineage, potential miRNAs that play a role 
during endothelial differentiation were selected using miRNA array analysis. Enriched 
miRNAs were identified as miR-150* and miR-200c. The functional roles of miR-150* and 
miR-200c were demonstrated using loss-of-function and gain-of-function gene 
experiments. Importantly, it was demonstrated that miR-150* and miR-200c were involved 
in the in vivo vasculogenesis in developing chick embryos. In addition, luciferase reporter 
assay verified EMT-activator ZEB1/TCF8 as an important mRNA target for miR-150* and 
200c during the differentiation of hESCs toward mature ECs.  
These findings may suggest that as hESCs differentiate towards the EC lineage, an increase 
of miR-200c expression contributes to the decline or repression of EMT process. 
Meanwhile, miR-150* also participates and contributes to the differentiation of hESCs 
which subsequently result in the formation of more differentiated, senescence and less 
proliferative cells or in this case, mature vascular ECs. These findings illustrate that miR-
150* and 200c can regulate the development of ECs from hESCs, providing new targets for 
modulating vascular formation and creating novel clinical therapies in future cardiovascular 
disease applications.   
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Future work will encompass the following: 
1. To further delineate the verification of ZEB1/TCF8 as an important mRNA target 
for miR-150* and 200c using mutation binding sites assays. 
2. To investigate if c-Myb is the mRNA target for miR-150* during EC differentiation 
process from hESCs.  
3. To examine the potential involvement of ZEB1/TCF8 in EC differentiation from 
hESCs using siRNAs. 
4. To identify the potential microRNAs that modulate SMC differentiation from 
human ES cells. 
5. To explore the therapeutic potential of hESC-derived endothelial cells in 
cardiovascular diseases by using various models, such as vessel injury and hindlimb 
ischemia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 155 - 
Publications, Presentations and Abstracts  
 
Presentations and Abstracts 
1. Luo Z, Xiao Q, Wang W, Xu Q, Differentiation of human embryonic stem cells 
towards the endothelial lineage and the role of microRNAs (British Atherosclerosis 
Society Spring Meeting, 13-14 June 2011, Manchester, Poster Presentation)  
2. Luo Z, Xiao Q, Wang W, Xu Q, The derivation of CD146+ cells from human 
embryonic stem cells and their endothelial differentiation (UK National Stem Cell 
Network meeting, 12-14 July 2010, Nottingham, Poster Presentation) 
Publications 
1. Xiao Q, Wang G, Yin X, Luo Z, Margariti A, Zeng L, Mayr M, Ye S, Xu Q, 
Chromobox protein homolog 3 is essential for stem cell differentiation to smooth 
muscles in vitro and in embryonic arteriogenesis, Arterioscler Thromb Vasc Biol. 2011 
Jun 9 
2. Luo Z, Wang G, Wang W, Xiao Q, Xu Q, Signalling pathways that regulate endothelial 
differentiation from stem cells, Front Biosci. 2011 Jan 1:16:472-85 
3. Kane NM, Xiao Q, Baker AH, Luo Z, Xu Q, Emanueli C, Pluripotent stem cell 
differentiation into vascular cells: a novel technology with promises for vascular 
re(generation), Pharmacol Ther. 2011 Jan;129(1):29-49.  
4. Zhang L, Jin M, Margariti A, Wang G, Luo Z, Zampetaki A, Zeng L, Ye S, Xu Q, Zhu 
J and Xiao Q, Sp1-dependent activation of HDAC7 is required for PDGF-BB-induced 
smooth muscle cell differentiation from stem cells, J Biol Chem. 2010 Dec 
3;285(49):38463-72.  
5. Xiao Q, Wang G, Luo Z, Xu Q, The mechanism of stem cell differentiation into 
smooth muscle cells, Thromb Haemost. 2010 Sep;104(3):440-8. 
 - 156 - 
6. Xiao Q, Luo Z, Pepe AE, Margariti A, Zeng L, Xu Q, Embryonic stem cell 
differentiation into smooth muscle cells is mediated by Nox4-produced H2O2, Am J 
Physiol Cell Physiol. 2009 Apr; 296(4):C711-23.  
 
Reference list 
 
1. Wikipedia. Capillary. Available at: 
http://en.wikipedia.org/wiki/File:Illu_capillary.jpg. Accessed 23 June 2009. 
2. Fawcett DW. A Textbook of Histology. New York: Chapman & Hill; 1994. 
3. Li JK-J. Dynamics of the vascular system. Vol Vol. 1: World Scientific Publishing 
Co. Pte. Ltd.; 2004. 
4. Rushmer RF. Structure and Function of the Cardiovascular System. Philadelphia: 
Saunders; 1972. 
5. Jaffe EA. Cell biology of endothelial cells. Hum Pathol. 1987;18(3):234-239. 
6. Pratt BM, Form D, Madri JA. Endothelial cell-extracellular matrix interactions. Ann 
N Y Acad Sci. 1985;460:274-288. 
7. Seyer JM KA. Connective tissues of the subendothelium. 1st ed. Boston:: Little 
Brown; 1992. 
8. Sage H, Pritzl P, Bornstein P. Secretory phenotypes of endothelial cells in culture: 
comparison of aortic, venous, capillary, and corneal endothelium. Arteriosclerosis. 
1981;1(6):427-442. 
9. Sage H, Bornstein P. Endothelial cells from umbilical vein and a 
hemangioendothelioma secrete basement membrane largely to the exclusion of 
interstitial procollagens. Arteriosclerosis. 1982;2(1):27-36. 
10. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK. Two 
different laminin domains mediate the differentiation of human endothelial cells 
into capillary-like structures in vitro. Cell. 1989;58(5):933-943. 
11. Mosher DF, Doyle MJ, Jaffe EA. Synthesis and secretion of thrombospondin by 
cultured human endothelial cells. J Cell Biol. 1982;93(2):343-348. 
12. Jaffe EA, Mosher DF. Synthesis of fibronectin by cultured human endothelial cells. 
J Exp Med. 1978;147(6):1779-1791. 
13. Cantor JO, Keller S, Parshley MS, Darnule TV, Darnule AT, Cerreta JM, Turino 
GM, Mandl I. Synthesis of crosslinked elastin by an endothelial cell culture. 
Biochem Biophys Res Commun. 1980;95(4):1381-1386. 
14. Buonassisi V. Sulfated mucopolysaccharide synthesis and secretion in endothelial 
cell cultures. Exp Cell Res. 1973;76(2):363-368. 
15. Oohira A, Wight TN, Bornstein P. Sulfated proteoglycans synthesized by vascular 
endothelial cells in culture. J Biol Chem. 1983;258(3):2014-2021. 
16. Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular 
endothelium. Thromb Haemost. 1997;77(3):408-423. 
17. Barnes MJ, Bailey AJ, Gordon JL, MacIntyre DE. Platelet aggregaton by basement 
membrane-associated collagens. Thromb Res. 1980;18(3-4):375-388. 
 - 157 - 
18. Kao KJ, Pizzo SV, McKee PA. Platelet receptors for human Factor VIII/von 
Willebrand protein: functional correlation of receptor occupancy and ristocetin-
induced platelet aggregation. Proc Natl Acad Sci U S A. 1979;76(10):5317-5320. 
19. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human 
endothelial cells: processing steps and their intracellular localization. J Cell Biol. 
1984;99(6):2123-2130. 
20. Heldin CH, Wasteson A, Westermark B. Platelet-derived growth factor. Mol Cell 
Endocrinol. 1985;39(3):169-187. 
21. DiCorleto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-
derived growth factor-like protein. Proc Natl Acad Sci U S A. 1983;80(7):1919-
1923. 
22. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin CH. Arterial smooth muscle 
cells in primary culture produce a platelet-derived growth factor-like protein. Proc 
Natl Acad Sci U S A. 1985;82(13):4418-4422. 
23. Grotendorst GR, Seppa HE, Kleinman HK, Martin GR. Attachment of smooth 
muscle cells to collagen and their migration toward platelet-derived growth factor. 
Proc Natl Acad Sci U S A. 1981;78(6):3669-3672. 
24. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates 
endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell 
Biol. 1994;125(4):917-928. 
25. Heldin CH, Westermark B. Platelet-derived growth factors: a family of isoforms 
that bind to two distinct receptors. Br Med Bull. 1989;45(2):453-464. 
26. Clemmons DR. Exposure to platelet-derived growth factor modulates the porcine 
aortic smooth muscle cell response to somatomedin-C. Endocrinology. 
1985;117(1):77-83. 
27. Muller WA, Ratti CM, McDonnell SL, Cohn ZA. A human endothelial cell-
restricted, externally disposed plasmalemmal protein enriched in intercellular 
junctions. J Exp Med. 1989;170(2):399-414. 
28. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-
cell adhesion molecule. J Cell Biol. 1990;110(4):1227-1237. 
29. Sun QH, DeLisser HM, Zukowski MM, Paddock C, Albelda SM, Newman PJ. 
Individually distinct Ig homology domains in PECAM-1 regulate homophilic 
binding and modulate receptor affinity. J Biol Chem. 1996;271(19):11090-11098. 
30. Buckley CD, Doyonnas R, Newton JP, Blystone SD, Brown EJ, Watt SM, Simmons 
DL. Identification of alpha v beta 3 as a heterotypic ligand for CD31/PECAM-1. J 
Cell Sci. 1996;109 ( Pt 2):437-445. 
31. Schimmenti LA, Yan HC, Madri JA, Albelda SM. Platelet endothelial cell adhesion 
molecule, PECAM-1, modulates cell migration. J Cell Physiol. 1992;153(2):417-
428. 
32. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, Davis S, Ruddle NH, 
Engelhardt B, Madri JA. Altered vascular permeability and early onset of 
experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J Clin 
Invest. 2002;109(3):383-392. 
33. DeLisser HM, Christofidou-Solomidou M, Strieter RM, Burdick MD, Robinson CS, 
Wexler RS, Kerr JS, Garlanda C, Merwin JR, Madri JA, Albelda SM. Involvement 
 - 158 - 
of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997;151(3):671-
677. 
34. Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J, Introna M, 
Gulino D, Lampugnani MG, Dejana E. Functional properties of human vascular 
endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. 
Arterioscler Thromb Vasc Biol. 1995;15(8):1229-1239. 
35. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol 
Rev. 1995;75(3):487-517. 
36. Velican C, Velican D. The precursors of coronary atherosclerotic plaques in 
subjects up to 40 years old. Atherosclerosis. 1980;37(1):33-46. 
37. Hao H, Gabbiani G, Bochaton-Piallat ML. Arterial smooth muscle cell 
heterogeneity: implications for atherosclerosis and restenosis development. 
Arterioscler Thromb Vasc Biol. 2003;23(9):1510-1520. 
38. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. 
Physiol Rev. 1979;59(1):1-61. 
39. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth 
muscle cell differentiation in development and disease. Physiol Rev. 
2004;84(3):767-801. 
40. Sobue K, Hayashi K, Nishida W. Expressional regulation of smooth muscle cell-
specific genes in association with phenotypic modulation. Mol Cell Biochem. 
1999;190(1-2):105-118. 
41. Garrels JI, Gibson W. Identification and characterization of multiple forms of actin. 
Cell. 1976;9(4 PT 2):793-805. 
42. Miano JM, Cserjesi P, Ligon KL, Periasamy M, Olson EN. Smooth muscle myosin 
heavy chain exclusively marks the smooth muscle lineage during mouse 
embryogenesis. Circ Res. 1994;75(5):803-812. 
43. Christen T, Bochaton-Piallat ML, Neuville P, Rensen S, Redard M, van Eys G, 
Gabbiani G. Cultured porcine coronary artery smooth muscle cells. A new model 
with advanced differentiation. Circ Res. 1999;85(1):99-107. 
44. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from 
mouse embryos. Nature. 1981;292(5819):154-156. 
45. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in 
medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 
1981;78(12):7634-7638. 
46. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall 
VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 
1998;282(5391):1145-1147. 
47. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-
676. 
48. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, Clark AT, 
Plath K. Generation of human induced pluripotent stem cells from dermal 
fibroblasts. Proc Natl Acad Sci U S A. 2008;105(8):2883-2888. 
49. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, 
Yachechko R, Tchieu J, Jaenisch R, Plath K, Hochedlinger K. Directly 
 - 159 - 
reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue 
contribution. Cell Stem Cell. 2007;1(1):55-70. 
50. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically 
unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol. 
2007;25(10):1177-1181. 
51. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, 
Daley GQ. Reprogramming of human somatic cells to pluripotency with defined 
factors. Nature. 2008;451(7175):141-146. 
52. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. 
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. 
Cell. 2007;131(5):861-872. 
53. Wernig M, Meissner A, Cassady JP, Jaenisch R. c-Myc is dispensable for direct 
reprogramming of mouse fibroblasts. Cell Stem Cell. 2008;2(1):10-12. 
54. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA. 
Induction of pluripotent stem cells by defined factors is greatly improved by small-
molecule compounds. Nat Biotechnol. 2008;26(7):795-797. 
55. Yuan X, Wan H, Zhao X, Zhu S, Zhou Q, Ding S. Brief report: combined chemical 
treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts. 
Stem Cells. 2011;29(3):549-553. 
56. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, 
Brambrink T, Wu LC, Townes TM, Jaenisch R. Treatment of sickle cell anemia 
mouse model with iPS cells generated from autologous skin. Science. 
2007;318(5858):1920-1923. 
57. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, 
Cowan C, Hochedlinger K, Daley GQ. Disease-specific induced pluripotent stem 
cells. Cell. 2008;134(5):877-886. 
58. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced 
pluripotent stem cells. Nature. 2007;448(7151):313-317. 
59. Lee H, Park J, Forget BG, Gaines P. Induced pluripotent stem cells in regenerative 
medicine: an argument for continued research on human embryonic stem cells. 
Regen Med. 2009;4(5):759-769. 
60. Pick M, Stelzer Y, Bar-Nur O, Mayshar Y, Eden A, Benvenisty N. Clone- and 
gene-specific aberrations of parental imprinting in human induced pluripotent stem 
cells. Stem Cells. 2009;27(11):2686-2690. 
61. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem 
cells from fibroblast cultures. Nat Protoc. 2007;2(12):3081-3089. 
62. Feng Q, Lu SJ, Klimanskaya I, Gomes I, Kim D, Chung Y, Honig GR, Kim KS, 
Lanza R. Hemangioblastic derivatives from human induced pluripotent stem cells 
exhibit limited expansion and early senescence. Stem Cells. 2010;28(4):704-712. 
63. Smith KP, Luong MX, Stein GS. Pluripotency: toward a gold standard for human 
ES and iPS cells. J Cell Physiol. 2009;220(1):21-29. 
64. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell 
lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 
2000;18(4):399-404. 
 - 160 - 
65. Levenberg S, Rouwkema J, Macdonald M, Garfein ES, Kohane DS, Darland DC, 
Marini R, van Blitterswijk CA, Mulligan RC, D'Amore PA, Langer R. Engineering 
vascularized skeletal muscle tissue. Nat Biotechnol. 2005;23(7):879-884. 
66. Ferreira LS, Gerecht S, Shieh HF, Watson N, Rupnick MA, Dallabrida SM, 
Vunjak-Novakovic G, Langer R. Vascular progenitor cells isolated from human 
embryonic stem cells give rise to endothelial and smooth muscle like cells and form 
vascular networks in vivo. Circ Res. 2007;101(3):286-294. 
67. Levenberg S, Golub JS, Amit M, Itskovitz-Eldor J, Langer R. Endothelial cells 
derived from human embryonic stem cells. Proc Natl Acad Sci U S A. 
2002;99(7):4391-4396. 
68. Levenberg S. Engineering blood vessels from stem cells: recent advances and 
applications. Curr Opin Biotechnol. 2005;16(5):516-523. 
69. Levenberg S, Zoldan J, Basevitch Y, Langer R. Endothelial potential of human 
embryonic stem cells. Blood. 2007;110(3):806-814. 
70. Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug 
discovery. Nat Rev Drug Discov. 2007;6(8):605-616. 
71. Sartipy P, Bjorquist P, Strehl R, Hyllner J. The application of human embryonic 
stem cell technologies to drug discovery. Drug Discov Today. 2007;12(17-18):688-
699. 
72. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-674. 
73. Matsumoto K, Yoshitomi H, Rossant J, Zaret KS. Liver organogenesis promoted by 
endothelial cells prior to vascular function. Science. 2001;294(5542):559-563. 
74. Vakaet L. Morphogenetic movements and fate maps in the avian blastoderm. New 
York: Alan R. Liss; 1985. 
75. Murray P. The development in vitro of the blood of the early chick embryo. Proc R 
Soc Lond B Biol Sci. 1932;11:497–521. 
76. Sabin F. Studies on the origin of blood vessels and of red corpuscles as seen in the 
living blastoderm of the chick during the second day of incubation. . Contributions 
to Embryology. . 1920;9:213–262. 
77. Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor 
for hematopoietic and endothelial cells. Development. 1998;125(4):725-732. 
78. Chung YS, Zhang WJ, Arentson E, Kingsley PD, Palis J, Choi K. Lineage analysis 
of the hemangioblast as defined by FLK1 and SCL expression. Development. 
2002;129(23):5511-5520. 
79. Nishikawa SI, Nishikawa S, Hirashima M, Matsuyoshi N, Kodama H. Progressive 
lineage analysis by cell sorting and culture identifies FLK1+VE-cadherin+ cells at a 
diverging point of endothelial and hemopoietic lineages. Development. 
1998;125(9):1747-1757. 
80. Huber TL, Kouskoff V, Fehling HJ, Palis J, Keller G. Haemangioblast commitment 
is initiated in the primitive streak of the mouse embryo. Nature. 
2004;432(7017):625-630. 
81. Oberlin E, Tavian M, Blazsek I, Peault B. Blood-forming potential of vascular 
endothelium in the human embryo. Development. 2002;129(17):4147-4157. 
82. Zambidis ET, Peault B, Park TS, Bunz F, Civin CI. Hematopoietic differentiation of 
human embryonic stem cells progresses through sequential hematoendothelial, 
 - 161 - 
primitive, and definitive stages resembling human yolk sac development                               
Blood. 2005;106(3):860-870. 
83. Adair TH MJ. Angiogenesis: Morgan & Claypool Life Sciences; 2010. 
84. Wang L, Li L, Shojaei F, Levac K, Cerdan C, Menendez P, Martin T, Rouleau A, 
Bhatia M. Endothelial and hematopoietic cell fate of human embryonic stem cells 
originates from primitive endothelium with hemangioblastic properties. Immunity. 
2004;21(1):31-41. 
85. Kennedy M, D'Souza SL, Lynch-Kattman M, Schwantz S, Keller G. Development 
of the hemangioblast defines the onset of hematopoiesis in human ES cell 
differentiation cultures. Blood. 2007;109(7):2679-2687. 
86. Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A, Bhatia M. 
Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic 
stem cells. Blood. 2003;102(3):906-915. 
87. Gimbrone MA, Jr., Cotran RS, Folkman J. Endothelial regeneration: studies with 
human endothelial cells in culture. Ser Haematol. 1973;6(4):453-455. 
88. Doetschman TC, Eistetter H, Katz M, Schmidt W, Kemler R. The in vitro 
development of blastocyst-derived embryonic stem cell lines: formation of visceral 
yolk sac, blood islands and myocardium. J Embryol Exp Morphol. 1985;87:27-45. 
89. Vittet D, Prandini MH, Berthier R, Schweitzer A, Martin-Sisteron H, Uzan G, 
Dejana E. Embryonic stem cells differentiate in vitro to endothelial cells through 
successive maturation steps. Blood. 1996;88(9):3424-3431. 
90. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, 
Nakao K. Flk1-positive cells derived from embryonic stem cells serve as vascular 
progenitors. Nature. 2000;408(6808):92-96. 
91. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F, Xie X, Patel M, Gambhir SS, Robbins 
RC, Cooke JP. Differentiation, survival, and function of embryonic stem cell 
derived endothelial cells for ischemic heart disease. Circulation. 2007;116(11 
Suppl):I46-54. 
92. Suzuki H, Watabe T, Kato M, Miyazawa K, Miyazono K. Roles of vascular 
endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic 
stem cell-derived vascular progenitor cells into endothelial cells. Blood. 
2005;105(6):2372-2379. 
93. Cho SW, Moon SH, Lee SH, Kang SW, Kim J, Lim JM, Kim HS, Kim BS, Chung 
HM. Improvement of postnatal neovascularization by human embryonic stem cell 
derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. 
Circulation. 2007;116(21):2409-2419. 
94. Xiao Q, Zeng L, Zhang Z, Margariti A, Ali ZA, Channon KM, Xu Q, Hu Y. Sca-1+ 
progenitors derived from embryonic stem cells differentiate into endothelial cells 
capable of vascular repair after arterial injury. Arterioscler Thromb Vasc Biol. 
2006;26(10):2244-2251. 
95. Zampetaki A, Zeng L, Xiao Q, Margariti A, Hu Y, Xu Q. Lacking cytokine 
production in ES cells and ES-cell-derived vascular cells stimulated by TNF-alpha 
is rescued by HDAC inhibitor trichostatin A. Am J Physiol Cell Physiol. 
2007;293(4):C1226-1238. 
96. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The 
histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater 
 - 162 - 
antitumor effect in combination with the vascular endothelial growth factor receptor 
tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004;64(18):6626-6634. 
97. Li Z, Suzuki Y, Huang M, Cao F, Xie X, Connolly AJ, Yang PC, Wu JC. 
Comparison of reporter gene and iron particle labeling for tracking fate of human 
embryonic stem cells and differentiated endothelial cells in living subjects. Stem 
Cells. 2008;26(4):864-873. 
98. Kim J, Moon SH, Lee SH, Lee DR, Koh GY, Chung HM. Effective isolation and 
culture of endothelial cells in embryoid body differentiated from human embryonic 
stem cells. Stem Cells Dev. 2007;16(2):269-280. 
99. Levenberg S, Ferreira LS, Chen-Konak L, Kraehenbuehl TP, Langer R. Isolation, 
differentiation and characterization of vascular cells derived from human embryonic 
stem cells. Nat Protoc. 2010;5(6):1115-1126. 
100. Moon SH, Kim JS, Park SJ, Lee HJ, Do JT, Chung HM. A system for treating 
ischemic disease using human embryonic stem cell-derived endothelial cells 
without direct incorporation. Biomaterials. 2011;32(27):6445-6455. 
101. Wang ZZ, Au P, Chen T, Shao Y, Daheron LM, Bai H, Arzigian M, Fukumura D, 
Jain RK, Scadden DT. Endothelial cells derived from human embryonic stem cells 
form durable blood vessels in vivo. Nat Biotechnol. 2007;25(3):317-318. 
102. Yamahara K, Sone M, Itoh H, Yamashita JK, Yurugi-Kobayashi T, Homma K, 
Chao TH, Miyashita K, Park K, Oyamada N, Sawada N, Taura D, Fukunaga Y, 
Tamura N, Nakao K. Augmentation of neovascularization [corrected] in hindlimb 
ischemia by combined transplantation of human embryonic stem cells-derived 
endothelial and mural cells. PLoS One. 2008;3(2):e1666. 
103. Gerecht-Nir S, Ziskind A, Cohen S, Itskovitz-Eldor J. Human embryonic stem cells 
as an in vitro model for human vascular development and the induction of vascular 
differentiation. Lab Invest. 2003;83(12):1811-1820. 
104. Oyamada N, Itoh H, Sone M, Yamahara K, Miyashita K, Park K, Taura D, Inuzuka 
M, Sonoyama T, Tsujimoto H, Fukunaga Y, Tamura N, Nakao K. Transplantation 
of vascular cells derived from human embryonic stem cells contributes to vascular 
regeneration after stroke in mice. J Transl Med. 2008;6:54. 
105. Bai H, Gao Y, Arzigian M, Wojchowski DM, Wu WS, Wang ZZ. BMP4 regulates 
vascular progenitor development in human embryonic stem cells through a Smad-
dependent pathway. J Cell Biochem. 2010;109(2):363-374. 
106. Kane NM, Meloni M, Spencer HL, Craig MA, Strehl R, Milligan G, Houslay MD, 
Mountford JC, Emanueli C, Baker AH. Derivation of endothelial cells from human 
embryonic stem cells by directed differentiation: analysis of microRNA and 
angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2010;30(7):1389-
1397. 
107. Chen T, Bai H, Shao Y, Arzigian M, Janzen V, Attar E, Xie Y, Scadden DT, Wang 
ZZ. Stromal cell-derived factor-1/CXCR4 signaling modifies the capillary-like 
organization of human embryonic stem cell-derived endothelium in vitro. Stem 
Cells. 2007;25(2):392-401. 
108. Sone M, Itoh H, Yamahara K, Yamashita JK, Yurugi-Kobayashi T, Nonoguchi A, 
Suzuki Y, Chao TH, Sawada N, Fukunaga Y, Miyashita K, Park K, Oyamada N, 
Taura D, Tamura N, Kondo Y, Nito S, Suemori H, Nakatsuji N, Nishikawa S, 
Nakao K. Pathway for differentiation of human embryonic stem cells to vascular 
 - 163 - 
cell components and their potential for vascular regeneration. Arterioscler Thromb 
Vasc Biol. 2007;27(10):2127-2134. 
109. Thorgeirsson G, Robertson AL, Jr. The vascular endothelium-pathobiologic 
significance. Am J Pathol. 1978;93(3):803-848. 
110. Garlanda C, Dejana E. Heterogeneity of endothelial cells. Specific markers. 
Arterioscler Thromb Vasc Biol. 1997;17(7):1193-1202. 
111. Aird WC. Endothelial cell heterogeneity. Crit Care Med. 2003;31(4 Suppl):S221-
230. 
112. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific 
microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436(7048):214-
220. 
113. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, 
Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle 
proliferation and differentiation. Nat Genet. 2006;38(2):228-233. 
114. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage 
differentiation. Science. 2004;303(5654):83-86. 
115. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E. 
Phylogenetic shadowing and computational identification of human microRNA 
genes. Cell. 2005;120(1):21-24. 
116. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. 
117. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, 
Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental 
timing in Caenorhabditis elegans. Nature. 2000;403(6772):901-906. 
118. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are 
transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051-4060. 
119. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, 
Kim VN. The nuclear RNase III Drosha initiates microRNA processing. Nature. 
2003;425(6956):415-419. 
120. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex 
in primary microRNA processing. Genes Dev. 2004;18(24):3016-3027. 
121. Ruby JG, Jan CH, Bartel DP. Intronic microRNA precursors that bypass Drosha 
processing. Nature. 2007;448(7149):83-86. 
122. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of 
microRNA precursors. Science. 2004;303(5654):95-98. 
123. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A 
cellular function for the RNA-interference enzyme Dicer in the maturation of the 
let-7 small temporal RNA. Science. 2001;293(5531):834-838. 
124. Gregory RI, Chendrimada TP, Cooch N, Shiekhattar R. Human RISC couples 
microRNA biogenesis and posttranscriptional gene silencing. Cell. 
2005;123(4):631-640. 
125. Chiang HR, Schoenfeld LW, Ruby JG, Auyeung VC, Spies N, Baek D, Johnston 
WK, Russ C, Luo S, Babiarz JE, Blelloch R, Schroth GP, Nusbaum C, Bartel DP. 
Mammalian microRNAs: experimental evaluation of novel and previously 
annotated genes. Genes Dev.24(10):992-1009. 
 - 164 - 
126. Ghildiyal M, Xu J, Seitz H, Weng Z, Zamore PD. Sorting of Drosophila small 
silencing RNAs partitions microRNA* strands into the RNA interference pathway. 
RNA. 2010;16(1):43-56. 
127. Okamura K, Liu N, Lai EC. Distinct mechanisms for microRNA strand selection by 
Drosophila Argonautes. Mol Cell. 2009;36(3):431-444. 
128. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the 
assembly of the RNAi enzyme complex. Cell. 2003;115(2):199-208. 
129. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit 
strand bias. Cell. 2003;115(2):209-216. 
130. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA 
biogenesis, function and decay. Nat Rev Genet.11(9):597-610. 
131. Davis E, Caiment F, Tordoir X, Cavaille J, Ferguson-Smith A, Cockett N, Georges 
M, Charlier C. RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 
locus. Curr Biol. 2005;15(8):743-749. 
132. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. 
Science. 2004;304(5670):594-596. 
133. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by 
adenosines, indicates that thousands of human genes are microRNA targets. Cell. 
2005;120(1):15-20. 
134. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target 
recognition. PLoS Biol. 2005;3(3):e85. 
135. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAs to Nanog, Oct4 
and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 
2008;455(7216):1124-1128. 
136. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by 
microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A. 
2007;104(23):9667-9672. 
137. Maziere P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 
2007;12(11-12):452-458. 
138. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by 
miRNAs: how many mechanisms? Trends Cell Biol. 2007;17(3):118-126. 
139. Liu J. Control of protein synthesis and mRNA degradation by microRNAs. Curr 
Opin Cell Biol. 2008;20(2):214-221. 
140. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes 
coding for small expressed RNAs. Science. 2001;294(5543):853-858. 
141. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. 
Science. 2001;294(5543):862-864. 
142. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with 
probable regulatory roles in Caenorhabditis elegans. Science. 2001;294(5543):858-
862. 
143. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol. 
2006;342:129-138. 
144. Ambros V, Bartel B, Bartel DP, Burge CB, Carrington JC, Chen X, Dreyfuss G, 
Eddy SR, Griffiths-Jones S, Marshall M, Matzke M, Ruvkun G, Tuschl T. A 
uniform system for microRNA annotation. RNA. 2003;9(3):277-279. 
 - 165 - 
145. Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res. 
2009;104(4):442-454. 
146. Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G. Dicer is required for 
embryonic angiogenesis during mouse development. J Biol Chem. 
2005;280(10):9330-9335. 
147. Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC. Dicer dependent 
microRNAs regulate gene expression and functions in human endothelial cells. Circ 
Res. 2007;100(8):1164-1173. 
148. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for 
endothelial microRNA expression and angiogenesis. Circ Res. 2007;101(1):59-68. 
149. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, 
Hammond S, Rainaldi G. MicroRNAs modulate the angiogenic properties of 
HUVECs. Blood. 2006;108(9):3068-3071. 
150. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield 
J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher 
AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of 
ischemic tissues in mice. Science. 2009;324(5935):1710-1713. 
151. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML, Colige A, 
Rakic JM, Noel A, Martial JA, Struman I. MicroRNA-21 exhibits antiangiogenic 
function by targeting RhoB expression in endothelial cells. PLoS One. 
2011;6(2):e16979. 
152. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau 
BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and 
vascular integrity. Dev Cell. 2008;15(2):272-284. 
153. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 
regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl 
Acad Sci U S A. 2008;105(5):1516-1521. 
154. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, 
Kamphorst AO, Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, 
Foa R, Schliwka J, Fuchs U, Novosel A, Muller RU, Schermer B, Bissels U, Inman 
J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti D, Trompeter HI, 
Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G, 
Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, 
Brownstein MJ, Bosio A, Borkhardt A, Russo JJ, Sander C, Zavolan M, Tuschl T. 
A mammalian microRNA expression atlas based on small RNA library sequencing. 
Cell. 2007;129(7):1401-1414. 
155. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, Richardson JA, 
Bassel-Duby R, Olson EN. The endothelial-specific microRNA miR-126 governs 
vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261-271. 
156. Wu F, Yang Z, Li G. Role of specific microRNAs for endothelial function and 
angiogenesis. Biochem Biophys Res Commun. 2009;386(4):549-553. 
157. Horan PK, Slezak SE. Stable cell membrane labelling. Nature. 
1989;340(6229):167-168. 
158. Hamburger V, Hamilton HL. A series of normal stages in the development of the 
chick embryo. 1951. Dev Dyn. 1992;195(4):231-272. 
 - 166 - 
159. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da 
Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial microRNA target 
predictions. Nat Genet. 2005;37(5):495-500. 
160. Xiao Q, Zeng L, Zhang Z, Hu Y, Xu Q. Stem cell-derived Sca-1+ progenitors 
differentiate into smooth muscle cells, which is mediated by collagen IV-integrin 
alpha1/beta1/alphav and PDGF receptor pathways. Am J Physiol Cell Physiol. 
2007;292(1):C342-352. 
161. Szybalski W, Iyer VN. Crosslinking of DNA by Enzymatically or Chemically 
Activated Mitomycins and Porfiromycins, Bifunctionally "Alkylating" Antibiotics. 
Fed Proc. 1964;23:946-957. 
162. Ueda K, Komano T. Sequence-specific DNA damage induced by reduced 
mitomycin C and 7-N-(p-hydroxyphenyl)mitomycin C. Nucleic Acids Res. 
1984;12(17):6673-6683. 
163. Ding V, Choo AB, Oh SK. Deciphering the importance of three key media 
components in human embryonic stem cell cultures. Biotechnol Lett. 
2006;28(7):491-495. 
164. O'Connor MD, Kardel MD, Iosfina I, Youssef D, Lu M, Li MM, Vercauteren S, 
Nagy A, Eaves CJ. Alkaline phosphatase-positive colony formation is a sensitive, 
specific, and quantitative indicator of undifferentiated human embryonic stem cells. 
Stem Cells. 2008;26(5):1109-1116. 
165. Pease S, Braghetta P, Gearing D, Grail D, Williams RL. Isolation of embryonic 
stem (ES) cells in media supplemented with recombinant leukemia inhibitory factor 
(LIF). Dev Biol. 1990;141(2):344-352. 
166. Solter D, Knowles BB. Monoclonal antibody defining a stage-specific mouse 
embryonic antigen (SSEA-1). Proc Natl Acad Sci U S A. 1978;75(11):5565-5569. 
167. Solter D, Knowles BB. Developmental stage-specific antigens during mouse 
embryogenesis. Curr Top Dev Biol. 1979;13 Pt 1:139-165. 
168. Grant DS, Kinsella JL, Kibbey MC, LaFlamme S, Burbelo PD, Goldstein AL, 
Kleinman HK. Matrigel induces thymosin beta 4 gene in differentiating endothelial 
cells. J Cell Sci. 1995;108 ( Pt 12):3685-3694. 
169. Crabtree B, Subramanian V. Behavior of endothelial cells on Matrigel and 
development of a method for a rapid and reproducible in vitro angiogenesis assay. 
In Vitro Cell Dev Biol Anim. 2007;43(2):87-94. 
170. Salomon D, Ayalon O, Patel-King R, Hynes RO, Geiger B. Extrajunctional 
distribution of N-cadherin in cultured human endothelial cells. J Cell Sci. 1992;102 
( Pt 1):7-17. 
171. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, Le Bivic A, Sampol J, 
Dignat-George F. Identification of CD146 as a component of the endothelial 
junction involved in the control of cell-cell cohesion. Blood. 2001;98(13):3677-
3684. 
172. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic 
colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci 
U S A. 2001;98(19):10716-10721. 
173. Boyd NL, Dhara SK, Rekaya R, Godbey EA, Hasneen K, Rao RR, West FD, 3rd, 
Gerwe BA, Stice SL. BMP4 promotes formation of primitive vascular networks in 
 - 167 - 
human embryonic stem cell-derived embryoid bodies. Exp Biol Med (Maywood). 
2007;232(6):833-843. 
174. Andrews PW, Benvenisty N, McKay R, Pera MF, Rossant J, Semb H, Stacey GN. 
The International Stem Cell Initiative: toward benchmarks for human embryonic 
stem cell research. Nat Biotechnol. 2005;23(7):795-797. 
175. Adewumi O, Aflatoonian B, Ahrlund-Richter L, Amit M, Andrews PW, Beighton 
G, Bello PA, Benvenisty N, Berry LS, Bevan S, Blum B, Brooking J, Chen KG, 
Choo AB, Churchill GA, Corbel M, Damjanov I, Draper JS, Dvorak P, 
Emanuelsson K, Fleck RA, Ford A, Gertow K, Gertsenstein M, Gokhale PJ, 
Hamilton RS, Hampl A, Healy LE, Hovatta O, Hyllner J, Imreh MP, Itskovitz-Eldor 
J, Jackson J, Johnson JL, Jones M, Kee K, King BL, Knowles BB, Lako M, Lebrin 
F, Mallon BS, Manning D, Mayshar Y, McKay RD, Michalska AE, Mikkola M, 
Mileikovsky M, Minger SL, Moore HD, Mummery CL, Nagy A, Nakatsuji N, 
O'Brien CM, Oh SK, Olsson C, Otonkoski T, Park KY, Passier R, Patel H, Patel M, 
Pedersen R, Pera MF, Piekarczyk MS, Pera RA, Reubinoff BE, Robins AJ, Rossant 
J, Rugg-Gunn P, Schulz TC, Semb H, Sherrer ES, Siemen H, Stacey GN, Stojkovic 
M, Suemori H, Szatkiewicz J, Turetsky T, Tuuri T, van den Brink S, Vintersten K, 
Vuoristo S, Ward D, Weaver TA, Young LA, Zhang W. Characterization of human 
embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol. 
2007;25(7):803-816. 
176. Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol. 
1999;189(1):4-11. 
177. Montemurro T, Andriolo G, Montelatici E, Weissmann G, Crisan M, Colnaghi MR, 
Rebulla P, Mosca F, Peault B, Lazzari L. Differentiation and migration properties of 
human foetal umbilical cord perivascular cells: potential for lung repair. J Cell Mol 
Med. 2011;15(4):796-808. 
178. Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, Lesaule G, 
Sampol J. S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel 
human endothelial antigen. Tissue Antigens. 1996;48(5):531-539. 
179. Pickl WF, Majdic O, Fischer GF, Petzelbauer P, Fae I, Waclavicek M, Stockl J, 
Scheinecker C, Vidicki T, Aschauer H, Johnson JP, Knapp W. MUC18/MCAM 
(CD146), an activation antigen of human T lymphocytes. J Immunol. 
1997;158(5):2107-2115. 
180. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression 
in human melanoma, shows sequence similarity to the neural cell adhesion 
molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A. 
1989;86(24):9891-9895. 
181. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of 
endothelial cells based on their increased uptake of acetylated-low density 
lipoprotein. J Cell Biol. 1984;99(6):2034-2040. 
182. Pitas RE, Innerarity TL, Weinstein JN, Mahley RW. Acetoacetylated lipoproteins 
used to distinguish fibroblasts from macrophages in vitro by fluorescence 
microscopy. Arteriosclerosis. 1981;1(3):177-185. 
183. Holthofer H, Virtanen I, Kariniemi AL, Hormia M, Linder E, Miettinen A. Ulex 
europaeus I lectin as a marker for vascular endothelium in human tissues. Lab 
Invest. 1982;47(1):60-66. 
 - 168 - 
184. Kleinman HK, McGarvey ML, Hassell JR, Star VL, Cannon FB, Laurie GW, 
Martin GR. Basement membrane complexes with biological activity. Biochemistry. 
1986;25(2):312-318. 
185. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR. 
Isolation and characterization of type IV procollagen, laminin, and heparan sulfate 
proteoglycan from the EHS sarcoma. Biochemistry. 1982;21(24):6188-6193. 
186. Vukicevic S, Kleinman HK, Luyten FP, Roberts AB, Roche NS, Reddi AH. 
Identification of multiple active growth factors in basement membrane Matrigel 
suggests caution in interpretation of cellular activity related to extracellular matrix 
components. Exp Cell Res. 1992;202(1):1-8. 
187. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen 
G, Wang Z. The muscle-specific microRNA miR-1 regulates cardiac 
arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13(4):486-
491. 
188. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini 
P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn 
GW, 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, 
Condorelli G. MicroRNA-133 controls cardiac hypertrophy. Nat Med. 
2007;13(5):613-618. 
189. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) 
that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 
2008;111(3):1217-1226. 
190. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, 
tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl 
Acad Sci U S A. 2007;104(51):20350-20355. 
191. Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, 
Livingston DM, Rajewsky K. Dicer-deficient mouse embryonic stem cells are 
defective in differentiation and centromeric silencing. Genes Dev. 2005;19(4):489-
501. 
192. Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. Characterization of 
Dicer-deficient murine embryonic stem cells. Proc Natl Acad Sci U S A. 
2005;102(34):12135-12140. 
193. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R. DGCR8 is essential for 
microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat 
Genet. 2007;39(3):380-385. 
194. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. 
Dev Cell. 2003;5(2):351-358. 
195. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu AL, 
Zhao Y, McDonald H, Zeng T, Hirst M, Eaves CJ, Marra MA. Application of 
massively parallel sequencing to microRNA profiling and discovery in human 
embryonic stem cells. Genome Res. 2008;18(4):610-621. 
196. Bar M, Wyman SK, Fritz BR, Qi J, Garg KS, Parkin RK, Kroh EM, Bendoraite A, 
Mitchell PS, Nelson AM, Ruzzo WL, Ware C, Radich JP, Gentleman R, Ruohola-
Baker H, Tewari M. MicroRNA discovery and profiling in human embryonic stem 
cells by deep sequencing of small RNA libraries. Stem Cells. 2008;26(10):2496-
2505. 
 - 169 - 
197. Tripathi R, Saini HK, Rad R, Abreu-Goodger C, van Dongen S, Enright AJ. 
Messenger RNA and microRNA profiling during early mouse EB formation. Gene 
Expr Patterns. 
198. Knelangen JM, van der Hoek MB, Kong WC, Owens JA, Fischer B, Santos AN. 
MicroRNA expression profile during adipogenic differentiation in mouse 
embryonic stem cells. Physiol Genomics. 2011;43(10):611-620. 
199. Wilson KD, Hu S, Venkatasubrahmanyam S, Fu JD, Sun N, Abilez OJ, Baugh JJ, 
Jia F, Ghosh Z, Li RA, Butte AJ, Wu JC. Dynamic microRNA expression programs 
during cardiac differentiation of human embryonic stem cells: role for miR-499. 
Circ Cardiovasc Genet. 2010;3(5):426-435. 
200. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, Lee TH, 
Miano JM, Ivey KN, Srivastava D. miR-145 and miR-143 regulate smooth muscle 
cell fate and plasticity. Nature. 2009. 
201. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 
regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic 
stem cells. Cell. 2009;137(4):647-658. 
202. Krichevsky AM, Sonntag KC, Isacson O, Kosik KS. Specific microRNAs modulate 
embryonic stem cell-derived neurogenesis. Stem Cells. 2006;24(4):857-864. 
203. Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs. Nature. 
2001;411(6833):107-110. 
204. Fraley R, Subramani S, Berg P, Papahadjopoulos D. Introduction of liposome-
encapsulated SV40 DNA into cells. J Biol Chem. 1980;255(21):10431-10435. 
205. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in 
microRNA target recognition. Nat Genet. 2007;39(10):1278-1284. 
206. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender 
TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting the 
transcription factor c-Myb. Cell. 2007;131(1):146-159. 
207. Lin YC, Kuo MW, Yu J, Kuo HH, Lin RJ, Lo WL, Yu AL. c-Myb is an 
evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important 
for embryonic development. Mol Biol Evol. 2008;25(10):2189-2198. 
208. Oh IH, Reddy EP. The myb gene family in cell growth, differentiation and 
apoptosis. Oncogene. 1999;18(19):3017-3033. 
209. Westin EH, Gallo RC, Arya SK, Eva A, Souza LM, Baluda MA, Aaronson SA, 
Wong-Staal F. Differential expression of the amv gene in human hematopoietic 
cells. Proc Natl Acad Sci U S A. 1982;79(7):2194-2198. 
210. Gonda TJ, Metcalf D. Expression of myb, myc and fos proto-oncogenes during the 
differentiation of a murine myeloid leukaemia. Nature. 1984;310(5974):249-251. 
211. Dai G, Sakamoto H, Shimoda Y, Fujimoto T, Nishikawa S, Ogawa M. Over-
expression of c-Myb increases the frequency of hemogenic precursors in the 
endothelial cell population. Genes Cells. 2006;11(8):859-870. 
212. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA 
hsa-miR-200c leads to reduced expression of transcription factor 8 and increased 
expression of E-cadherin. Cancer Res. 2007;67(17):7972-7976. 
213. Inuzuka T, Tsuda M, Kawaguchi H, Ohba Y. Transcription factor 8 activates R-Ras 
to regulate angiogenesis. Biochem Biophys Res Commun. 2009;379(2):510-513. 
 - 170 - 
214. Perez-Pomares JM, Munoz-Chapuli R. Epithelial-mesenchymal transitions: a 
mesodermal cell strategy for evolutive innovation in Metazoans. Anat Rec. 
2002;268(3):343-351. 
215. Wyatt L, Wadham C, Crocker LA, Lardelli M, Khew-Goodall Y. The protein 
tyrosine phosphatase Pez regulates TGFbeta, epithelial-mesenchymal transition, and 
organ development. J Cell Biol. 2007;178(7):1223-1235. 
216. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. 
An embryonic stem cell-like gene expression signature in poorly differentiated 
aggressive human tumors. Nat Genet. 2008;40(5):499-507. 
217. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, 
Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, 
Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T. The EMT-
activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting 
microRNAs. Nat Cell Biol. 2009;11(12):1487-1495. 
218. Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G, 
Antonini A, Martelli F, Capogrossi MC. miR-200c is upregulated by oxidative 
stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. 
Cell Death Differ. 2011. 
219. van Rooij E. The art of microRNA research. Circ Res. 2011;108(2):219-234. 
220. Zeng L, Xiao Q, Margariti A, Zhang Z, Zampetaki A, Patel S, Capogrossi MC, Hu 
Y, Xu Q. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation 
toward endothelial cells. J Cell Biol. 2006;174(7):1059-1069. 
221. Nowak G, Karrar A, Holmen C, Nava S, Uzunel M, Hultenby K, Sumitran-
Holgersson S. Expression of vascular endothelial growth factor receptor-2 or Tie-2 
on peripheral blood cells defines functionally competent cell populations capable of 
reendothelialization. Circulation. 2004;110(24):3699-3707. 
222. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. 
Cardiovasc Res. 2008;78(3):413-421. 
223. Hungerford JE, Owens GK, Argraves WS, Little CD. Development of the aortic 
vessel wall as defined by vascular smooth muscle and extracellular matrix markers. 
Dev Biol. 1996;178(2):375-392. 
224. Lesh RE, Somlyo AP, Owens GK, Somlyo AV. Reversible permeabilization. A 
novel technique for the intracellular introduction of antisense oligodeoxynucleotides 
into intact smooth muscle. Circ Res. 1995;77(2):220-230. 
 
 
 
 
 - 171 - 
Appendix 1 
NCBI Reference Sequence: NM_030751.5 
 
      5’  taa 
     3481 tc gtttttctag aaggaaaata aattctaatt gataatgaat 
     3481 ttcgttcaat attatccttg cttttcatgg aaacacagta acctgtatgc tgtgattcct 
     3541 gttcactact gtgtaaagta aaaactaaaa aaatacaaaa tacaaaacac acacacacac 
     3601 acacacacac acacacacac acacacaaaa taaatccggg tgtgcctgaa cctcagacct 
     3661 agtaattttt catgcagttt tcaaagttag gaacaagttt gtaacatgca gcagattaga 
     3721 aaaccttaat gactcagaga gcaacaatac aagaggttaa aggaagctga ttaattagat 
     3781 atgcatctgg cattgtttta tcttatcagt attatcactc ttatgttggt ttattcttaa 
     3841 gctgtacaat tgggagaaat tttataattt tttattggta aacatatgct aaatccgctt 
     3901 cagtatttta ttatgttttt taaaatgtga gaacttctgc actacaaaat tcccttcaca 
     3961 gagaagtata atgtagttcc aacccgtgct aactaccttt tataaattca gtctagaagg 
     4021 tagtaatttc taatatttag atgtcttagt agagcgtatt atcatttaaa gtgtattgtt 
     4081 agccttaaga aagcagctga tagaagaact gaagtttctt actcacgtgg tttaaaatgg 
     4141 agttcaaaag attgccattg agttctgatt gcagggacta acaatgttaa tctgataagg 
     4201 acagcaaaat catcagaatc agtgtttgtg attgtgtttg aatatgtggt aacatatgaa 
     4261 ggatatgaca tgaagctttg tatctccttt ggccttaagc aagacctgtg tgctgtaagt 
     4321 gccatttctc agtattttca aggctctaac ccgccttcat ccaatgtgtg gcctacaata 
     4381 actagcattt gttgatttgt ctcttgtatc aaaattccca aataaaactt aaaaccactg 
     4441 actctgtcag agaaactgaa acactgggac atttcatcct tcaattcctc ggtattgatt 
     4501 ttatgttgat tgattttcag aatttctcta cagaaacgaa agggaaattt tctaatctgc 
     4561 tttatccatg tacttgcatt tcagacatgg acatgctatt gttatttggc tcataactgt 
     4621 ttccaaatgt tagttattat ggacccaatt tattaacaac attagctgat ttttacctat 
     4681 cagtattatt ttatttcttt tagtttatag atctgtgcaa catttttgta ctgtatgtct 
     4741 tcaaacctgg cagtattaat acccttctta ctgacatatg tacttttagt tttagaaaac 
     4801 ttttatattt atgtgtctta tttttatatt tctttattta ttacacagtg tagtgtataa 
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Appendix 1: Sequence of the 3’ UTR of human ZEB1/TCF8. Area shaded in yellow 
depicts the location of 3’ UTR of human ZEB1/TCF8. Sequences in red are binding 
sites for miR-200c while the sequence in green is complementary to the 5’ miR-
150*. 
 
 
 
 
 
 
4861 tactgtagtt tgtattaata caataatata ttttagtatg aaaatttgga aagttgataa 
4921 gatttaaagt agagatgcaa ttggttctcc tgcattgaga tttgatttaacagtgttatg 
4981 ttaacattta tacttgcctt ggactgtaga acagaactta aatgggaatg tattagtttt 
5041 acaactacaa tcaagtcatt ttacctttac ccagttttta atataaaact taaattttga 
5101 aattcactgt gtgactaata gcatgatgct ctgcagtttt attaagaaat cagcctaacc 
5161 atacaactct catttcctta gtaagccaaa ttaggattaa cttctataaa cagtgttggg 
5221 aacaatgttt aacattttgt gccaatttgt tcctgtattc atgtatgtaa gttacagatc 
5281 tgactcttca tttttaagtt ccttgttaca tcatggtcat tttctagttt tttaccagac 
5341 tcccatctca caataaaatg catcaacaag cctgaactgc tgtcattctt ttcatcatta 
5401 tcagtatttt ctttggaaaa ctgtgaaatg gggtacattg tcatcctgca tttgattcat 
5461 cttgagctga atttgggtaa cactaaatgt tttagacatt ctccactaaa ttatggattt 
5521 tcttgtggct aaatgtttct ggagaggtca gagttgacaa aacctcttca caggttgctc 
5581 cttcttcctg aaatccttaa tcctccgcat ttcatgcttc aggtcatttc agggaagcct 
5641 gggtttagat gcctttctga ctctcagctc ctgcacttct gtcatcatac ctctgatact 
5701 attatttata ttccttcccc actaggaaca ggaaccacat ttgtcatagt cactctcaca 
5761 ttcctcactg cctaacaggg tgcctggcat aagttgggac aacagatatt tgttgaataa 
5821 aaatataatt tgcatgttta tggagctcag ctatgttctc actttttttg cttctaattc 
5881 cagaatatat gttaaatgat ctaataattt gattattttc ttataagtct tattaaacac 
5941 tagtcataat agacacaata aattatgcct tctttttcta ttgccttaaa aaaaaaaa 3’ 
 
